var title_f30_58_31648="Erosive hand osteoarthritis";
var content_f30_58_31648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F81740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F81740&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erosive osteoarthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 296px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain radiograph of the hand shows erosive osteoarthritis. There is normal bone mineralization with extensive erosive changes involving the distal interphalangeal joint spaces (arrows). These changes are associated with soft tissue swelling and with large lateral osteophyte formation. The proximal interphalangeal and metacarpophalangeal joints and the intercarpal joint spaces are relatively spared.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31648=[""].join("\n");
var outline_f30_58_31648=null;
var title_f30_58_31649="Radical vulvectomy completed";
var content_f30_58_31649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F74101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F74101&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Radical vulvectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wound has been closed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of C. William Helm, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31649=[""].join("\n");
var outline_f30_58_31649=null;
var title_f30_58_31650="Patient information: Early puberty (The Basics)";
var content_f30_58_31650=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16739\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"         Female reproductive anatomy",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"          Male reproductive anatomy",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/12/1218\">",
"         Patient information: Acne (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/12/3266\">",
"         Patient information: My child is short (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?30/1/30738\">",
"         Patient information: Normal sexual development (puberty) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/21/1363\">",
"         Patient information: Teen sexuality (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/8/35973\">",
"         Patient information: Adolescent sexuality (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Early puberty (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/early-puberty-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H23378695\">",
"      <span class=\"h1\">",
"       What is early puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty is a term for the changes in the body that happen as a child becomes an adult. Early puberty is when a child&rsquo;s body starts changing at a much younger age than normal.",
"     </p>",
"     <p>",
"      Puberty usually starts between ages 9 to 12 in girls and ages 10 to 13 in boys. Puberty is early if it starts before age 8 in girls and age 9 in boys.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378710\">",
"      <span class=\"h1\">",
"       What causes early puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Puberty is caused by hormones in the body. Normally, these hormones come from the brain as well as organs called the ovaries (in girls) and testicles (in boys) (",
"      <a class=\"graphic graphic_figure graphicRef80271 \" href=\"mobipreview.htm?14/52/15171\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef68075 \" href=\"mobipreview.htm?21/43/22194\">",
"       figure 2",
"      </a>",
"      ). Different things can cause puberty to start early.",
"     </p>",
"     <p>",
"      Sometimes when puberty starts early, it is because a child&rsquo;s body might just be ready to start puberty earlier than other children. This can be normal and not caused by a medical problem.",
"     </p>",
"     <p>",
"      Other times when puberty starts early, it is because of abnormally high levels of hormones in the body. This can be caused by:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A problem in the body, such as an abnormal growth in the brain, ovaries, or testicles",
"       </li>",
"       <li>",
"        Skin products for adults that have certain hormones in them &ndash; If a child touches these products, the hormones can rub off onto him or her.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378725\">",
"      <span class=\"h1\">",
"       What body changes happen in early puberty?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The body changes in early puberty are the same as those in normal puberty. They just happen at a much younger age.",
"     </p>",
"     <p>",
"      The changes that happen during puberty in girls are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The breasts grow bigger. In many girls, this is the first sign of puberty. If your child is overweight, her breasts might look like they are growing. That&rsquo;s because breasts can look big from being overweight. This is different than starting puberty. Your doctor can help you tell if your child is starting puberty.",
"       </li>",
"       <li>",
"        Hair grows in the genital area (pubic hair), under the arms, and on the legs. In some girls, pubic hair is the first sign of puberty.",
"       </li>",
"       <li>",
"        They start having monthly periods.",
"       </li>",
"       <li>",
"        They can have white or clear vaginal discharge. Vaginal discharge is the term doctors use to describe the small amount of fluid that comes out of the vagina.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The changes that happen during puberty in boys are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        The testicles get bigger. This is usually the first change that happens.",
"       </li>",
"       <li>",
"        The penis gets longer and wider.",
"       </li>",
"       <li>",
"        Hair grows in the genital area (pubic hair), on the face, and under the arms.",
"       </li>",
"       <li>",
"        The voice changes.",
"       </li>",
"       <li>",
"        They can ejaculate a small amount of sperm at night while they sleep. This is sometimes called a &ldquo;wet dream.&rdquo;",
"       </li>",
"       <li>",
"        Their breasts can get slightly bigger. This usually goes away over time.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378740\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Maybe. The doctor or nurse will want to know why your child started puberty early. He or she will talk with you and your child, and do an exam. He or she might also do:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Blood tests",
"       </li>",
"       <li>",
"        X-rays of 1 of your child&rsquo;s hands and wrists &ndash; These X-rays can show how fast your child is growing.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on these results, the doctor might do a CT scan, ultrasound, or other imaging test of your child&rsquo;s brain or belly. Imaging tests create pictures of the inside of the body.",
"     </p>",
"     <p>",
"      The doctor or nurse will also do repeat exams over time to follow your child&rsquo;s growth and development.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378755\">",
"      <span class=\"h1\">",
"       How is early puberty treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatment depends on the cause of the early puberty, your child&rsquo;s age, and how fast his or her body is changing.",
"     </p>",
"     <p>",
"      One main goal of treatment is to make sure your child grows to a normal adult height. When children go through puberty earlier than normal, they are often shorter than normal as adults.",
"     </p>",
"     <p>",
"      For some children, doctors do not recommend treating early puberty. Children might not have treatment if they are going through puberty slowly, or if the puberty started but then stopped on its own. For example, some girls grow breasts very early, but then go through the rest of puberty at the normal time.",
"     </p>",
"     <p>",
"      For other children, doctors do recommend treatment. Some treatments stop puberty for a few years. Doctors can sometimes stop puberty with medicines. After a certain amount of time, your child will stop taking the medicine. Then normal puberty can happen.",
"     </p>",
"     <p>",
"      Other treatments help with the problem that is causing the early puberty. These treatments might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Taking medicine to lower abnormally high amounts of hormones in the body",
"       </li>",
"       <li>",
"        Having surgery to remove an abnormal growth",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378770\">",
"      <span class=\"h1\">",
"       What else can I do to help my child?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can help your child feel good about him or herself. Point out your child&rsquo;s strengths instead of focusing on his or her body changes. Some children who go through early puberty can have a hard time fitting in. They might be teased or treated differently, because their bodies look different than other children their age.",
"     </p>",
"     <p>",
"      If your child is having problems at home or school, talk to the doctor or nurse about ways to get help.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H23378785\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=see_link\">",
"       Patient information: Normal sexual development (puberty) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=see_link\">",
"       Patient information: Teen sexuality (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=see_link\">",
"       Patient information: Acne (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/12/3266?source=see_link\">",
"       Patient information: My child is short (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=see_link\">",
"       Patient information: Adolescent sexuality (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?30/58/31650?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16739 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31650=[""].join("\n");
var outline_f30_58_31650=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378695\">",
"      What is early puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378710\">",
"      What causes early puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378725\">",
"      What body changes happen in early puberty?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378740\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378755\">",
"      How is early puberty treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378770\">",
"      What else can I do to help my child?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23378785\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16739\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/52/15171\">",
"      Female reproductive anatomy",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/43/22194\">",
"       Male reproductive anatomy",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/12/1218?source=related_link\">",
"      Patient information: Acne (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?35/8/35973?source=related_link\">",
"      Patient information: Adolescent sexuality (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/12/3266?source=related_link\">",
"      Patient information: My child is short (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?30/1/30738?source=related_link\">",
"      Patient information: Normal sexual development (puberty) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/21/1363?source=related_link\">",
"      Patient information: Teen sexuality (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_58_31651="PMN development and kinetics";
var content_f30_58_31651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F75855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F75855&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Neutrophil development and kinetics",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 341px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of polymorphonuclear neutrophil (PMN) development and kinetics expressed as the flux time myeloid precursors spend at each stage of maturation in the bone marrow. Note the larger pool size and longer period PMNs spend in the marrow compared to the smaller pool size (in red) and shorter period PMNs spend in the blood before entering the tissue pool (in blue) where they undergo apoptosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Bainton, DF. Developmental biology of neutrophils and esinophils. In: Inflammation Basic Principles and Clinical Correlates, 2d ed, Raven Press, New York, 1992.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31651=[""].join("\n");
var outline_f30_58_31651=null;
var title_f30_58_31652="Nizatidine: Patient drug information";
var content_f30_58_31652=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Nizatidine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/16/29958?source=see_link\">",
"     see \"Nizatidine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38885?source=see_link\">",
"     see \"Nizatidine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F202316\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Axid&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F202317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Nizatidine&reg;;",
"     </li>",
"     <li>",
"      Axid&reg;;",
"     </li>",
"     <li>",
"      Gen-Nizatidine;",
"     </li>",
"     <li>",
"      Novo-Nizatidine;",
"     </li>",
"     <li>",
"      Nu-Nizatidine;",
"     </li>",
"     <li>",
"      PMS-Nizatidine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop heartburn and sour stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691849",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat gastroesophageal reflux disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702615",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to nizatidine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020660\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020663\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure or a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695856",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take at bedtime if you are taking once a day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10914 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7E15F350EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31652=[""].join("\n");
var outline_f30_58_31652=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202316\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F202317\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020654\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020656\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020655\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020660\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020661\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020663\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020658\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020659\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020664\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020665\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?29/16/29958?source=related_link\">",
"      Nizatidine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/62/38885?source=related_link\">",
"      Nizatidine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_58_31653="Ocular causes of anisocoria";
var content_f30_58_31653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F81796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F81796&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Pupillary abnormalities related to ocular causes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 382px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF+AgMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD3P4ieO/8AhDriwiGm/bftSu2fP8vbtI/2TnrXM2vxje4Py+HiF9Tef/YVS/aCtJbvUdCWLqElzzjulec29rcStHFESgU8+9eDjMbWpVpRjLReS7Hr4bC0Z0lKS1PVX+L8qtj/AIR7jOM/bf8A7XU8XxbD9dFP4XWf/ZK4L7BD5YSZnaUDoKdaWtshKzqdi+nNcrzHE/zfgjT6pQ/l/FnoqfFFSpZ9IZR2/wBIzn/x2oZPizEmf+JQxx2Fx/8AYV59JcQLMscCM6d8DpTCB5jP5LBOvIpPMcT0l+C/yD6nR7fiz0KD4sGZgq6G4J6Zuf8A7CtuDx2ZEDSaaIgTjm4/+xryCG7eSQrDEvJ7VNqF3dLGElYKQMgHiqWY4jrL8F/kJ4Sl0j+Z65qfjlLG3EpsRJnoBPjP/jtV7T4gC4Ukabt9vtGf/Za8h0+7F4224c7ui5NayM8BG1gcfrUvMsT0l+C/yEsLR6r8z0kePyZ/KOmYPr9o/wDsa2I/Ejvb+aLNcennf/Y14ze6gUYZXafUdaqt4xTTRiaVWHT52qo5lX6y/Bf5CeFpLp+Z7TF4reQkLYDjrifP/stQXPjKSFiv9mbsf9N//sa8htvHVtOTsuo1J67TUU/jbTrQl5LlZGPXLU3mGJvZS/Bf5C+rUeq/Fnrj+O2UZ/ss/wDf/wD+xqD/AIWKmcHTGB7Dzxz/AOO14HrnxK3Sk20ZcAdTwBXM3Xj2/lJlZEWMdMGrWKxrWkvwX+QnQodvzPp+T4lRR8NpxB75n6f+O1BH8U7d5Nn9nY9/tH/2NfJt98RLuTKxoV9yayx4o1JjuFwV7jFaqePe8rfJf5C9jQ6I+4bHxnFdSBTbpHkZXdOPm+nFU9Z+IMOmTeW1mrn/AK+Mf+y18S3HivWCpAuiKqL4t1NzmW5csPU1qnjXH4/wX+Rm6dJPWJ9sR/FOyKsZLMIR2M//ANjVQfF+y8xlfT9uOh+0df8Ax2vjQeK9SbI887DxUbavcOv/AB8Se+TzUr671n+C/wAgcKPSP4n2QfjPp6PiSxCj1+05/wDZaR/jRYYPl6eHx/084/8AZa+NDfTOQfOdvqavW2oSDgkj8acp4tL4/wAF/kSoUv5fxZ9dp8Y1liaSHQmeMHBYXY4/8cqSX4tzom5fDbsM4OLwcf8AjlfMek67c26oqTssYzxxxnrXYaZq7SoqwTMWJ6dsVxVMVjovSa+5f5HLKlVb91Rt/wBvbHtw+LUxUEeHWyen+mj+eymQfF2adJCnh1t6EgqbwdR/wCvKp5pZojJHM8bIc4AHP1qZYbiSMTW0zRzd1xw3rkVzvMsavtL7kaU8LXd+ZR/8mPRrj4y3VsAbjwtKik9ftoP/ALJU9r8YhchSuh4B9bv/AOwrz2G9MyiK8jPBAZW5qVtMtom8yEskbH67f/rURzXFNay19F/kdlLCLl/epX8rnd6j8YJ7SEyx+G2mUdQt5g/l5dY0H7QUUjxg+HHUM4Rv9N5XJx08uucltZomUIVkT1HBrJufDMdxfW83llJBIpLKOvPpW1LNK97Sl+C/yLeFpLp+Z2XxD+Ptz4S8Z6pocegQ3SWbqgma6KlsordNpx1rnP8AhqC8/wChWt//AANP/wARXmnx/wD+SweJf+u0f/opK8+r6e58vOtNSaTPoz/hqC8/6Fa3/wDA0/8AxFH/AA1Bef8AQrW//gaf/iK+c6KVyfb1O59Gf8NQXn/Qr2//AIGt/wDEUf8ADUF5/wBCtb/+Bp/+Ir5zpKLsPb1O59Hf8NQXn/Qr2/8A4Gn/AOIpD+1Bef8AQrW//ga3/wARXzlS4ouHt6nc+jP+GoLz/oVrf/wNP/xFL/w1Bef9Cvb/APga3/xFfOWKOKLsPb1O59G/8NQXn/Qr2/8A4Gn/AOIpP+GoLz/oVrf/AMDT/wDEV86qhLAA9aRlIJz2o5vMftau9z6L/wCGoLz/AKFe3/8AA1v/AIij/hqC8/6Fe3/8DT/8RXznikp3F7ep3Po3/hqC8/6Fe3/8DW/+IoH7UF4f+ZWt/wDwNb/4ivnVUZicdqtLYTYyykD1qHOxpCVaezPoJf2nrwnA8L2//ga3/wARTm/abvgcf8Itb/8Aga3/AMRXgkNi5Pyrye9DW0gI3AjPFZOs7nRGFS2rPe1/abvT18L24/7fD/8AEU//AIaZvM8+GLfH/X4f/iK8FWzfCkqT+NPfT3JBYNUfWG3Y1VKolqe8n9pe8/h8MQY/6/D/APEVEf2nLwHnwvb/APgYf/iK8NNttTnriqMluBcLu4Ga1pupJ2IrNwVz6DT9pe+Zv+RWgx6/bG/+IpW/aXvlbB8Lwf8AgYf/AIivLLOGCSBYwq57mpn8MpcHdGWwMcA0TVaLNIqLV+Y9Wt/2jr2b/mWYB/2+H/4iq93+0rf28uw+FoCPX7Yf/iK87h8NPDlwcr6VheJ9OZBkocYrGNSsp2a0N50Y+z92Wp60f2nr0DJ8KwAf9fjf/EU0/tQXn/Qr2/8A4Gt/8RXgzwmeyLBWOz3rMYEHFdEZt77nl1ZVIaqV0fRn/DUF5/0K9v8A+Brf/EUf8NQXn/QrW/8A4Gn/AOIr5zoNXdmXt6nc+jf+GoLz/oV7f/wNP/xFdZ8Lfjlc+N/GdpocuhQ2aTpI/nLclyNqFum0elfI1eq/syf8lg0r/rjcf+impplU603JJs+1qKKKo9A8i+OUSyaloe+QoNkoz+K1xeo2w0lIXlYsJB8jDjNeh/GLTBf3OlP5mx41kwD0OSteX61DdwS28OqShbdTiKXqgz6ntXzWOX7+f9dD2cLL91Ev6WxkYNKrMx5GehrVYWMulSmaVVk3YCrxUdtZOYURrhXjAGDGOv4029tbSFC2wk9K4krGzlfYz7a/h0qdCirMT19qNZ1kTqEdoY9/OxfvEVSu541ZI1jChWyeK4zxZcbL+G5hIBXgj1rWlDm0RnOpqbt94gWyKi0GJBwTXN6tr9xcXBJk3MevNYE9/wDa5BJuK+oqtf3sMEO2DLTH7zHoK66eHjExlOTNmXWZbYAxzfverEn7tOi8cXsfB2OOxOa4ee5bB3MTnnrRZyxNJumkxt5Ga0lh4voJSfc7rUfFl3HZF5dqyvwuK5GXUJp5Ge6kZy3PJzis6+vTdy5H3F4UVDHMW+VuMVUMOorYp6iy3LozGAkZPQGprOchTIWGR61WK5IwfrV/QbaK61SGKdTtZscDrWs+VRbZVKDlJRKt3eT3PHRRyMVUkNwyhXYlR2zxXsg8O2cUYEcK4I+8Rnj3piaXYy2NwJrSIFcrwMZxXBDMqe0YnfUy2UU5SZ420IdOeo70kTeUdrkn0r1yLQNLkjBjtkDYrG8TaFBBbF44VHHUCu1YqL0Z5UaibsefTSAc8D3FVJo1cgg4brS3P+sYYO0Gq+4s+M13QjZXQ5asFYo3NPVyzfLUZyOozSgleVOK0tcnYtIxVQT0q5BKBiqEW4jpkVMDzxnFYSjcLGzBOD3wK3NLvTbuHRjn0rkYnO3NaEFychRmuSpRuGyPWNIvYrhOH2uw5ya6XS5m27AeRwCO9eRaRqDxSA56V6Rot9HNErr8zY5ArycRRszWEzpLiyS4wGcmX+9049KsWnz4t5AWXGAD/KorRsqHYblIwQeuavSwieJSg2yrzletcPLZnUpXIljMTiLHup9R/jVy0OZYhjo4BU9ue1Zw3y4DyKJFOVG3G78au2T+Zcwhcgq4BB6rzRGVpFSjdHin7QH/ACWDxL/12j/9FJXn2a9B+P8A/wAlg8S/9do//RSV58a+6Z8RU+NiDP4VJHGz8IpJpgHuKtW1wICSFzUybS90dNRb996Ef2WYdY2/Kg28gyShH1qzJqMrJhcD8aqtO7gbnNZp1HujacaC+FtjGQrnOBTQD3p5DN1FNCnBx2rVMwa10QKCcVfsrLziNwNVoEyw659hXS2OPLXbwOAc1L952TOqhRt7zVyKPTQyL5aAH1NV7nSnJYBRuxXReWEVcg7fWlZNrMcdec040YrW51SbatY4iWwuEOBGSPapodOk4Z1+XHGa6h4mYNxgdOahRDgKR8g4x71fKu5zRoLmukZYiMXEaA59q0okZYgWTJIH0qORkiIBHRgMj3rYVQbVQRgetdFOMGtB2kn2KgKbSGQA1mXcyQybQoIB6mtWVAu7JHTjNY2pSJJLvK89MUSjDqTKdSKvc0bPUrMIC4G7PpT5tWhKME2nHTiubeMEgKeBzkVp6TpwnRmkYcdBSpYam3zIUsbWfuosvNHOGwuM9BVb7CbhyPLJHtW7BZREbhjI7itWwtFEORjO7mutUIpXRzurOTtM53Ti1tgMCO1dnodnqd7bmXT7WWWNTgsozWVfacDlhx346V1/gLxwfDNrJZy2omjJ37gcHNawoXi2tyZ4hwkovYeItQhQi4sZwoIzmMisDxIq3KOohZSeMFea9gs/H1jfopls3UuMkbgRVXWLuzunV7e1U56kgVhOi3urG8cRHoz55g09rHcZoT5bAg8Zrl9agWC7PlDEbdOa+m5NAtLq3bzbYMGPI9a8+8feCdMa1kmtI54LmNCdpOVOK461Jr3jSynHlR4qM5pTTnADkdxwaaax3OJqz1CvVP2ZP+SwaV/1xuP/AEU1eVivVf2ZP+SwaX/1xn/9FNTRdL40fa1FFFWeqcP8Rot9xYE8AI+T+K1yEgDq0cih0YY2sMg/UV13xIP76xBzja/8xXFu+PvHgV81j/48v66Hq4f+EjMS1j0qZ5bYMkTDmHPyj3AqCTfdfP8A8s/XOKkvZyWZFGT0GeaoXl4ltbmMKVY8n0rjgud2NJe6tDF8QTrbsWJyO1eba9etLKWzxmt/xJqXmsVB+tcZqEu8Hnk16dOmonO7y3K0s4jJ2VRllyckmklcEY7iqkrgD3rojEpIdM5cHv24qs+4HrinLJtJORih2DjO4EGtUrGnKmRxufXB9KkU/Nn1qEp3Wnqmc7atpAlbQsptAHc1reFpfJ1u0ZunmDmsNdwYB81f05zb3sUnJ2MDWFWN4NG9KympHvP+qDoDgt8xBHX2qm+JJL1FVf3o3KSfUdR+RqzaTGe2t5RsEkkQYcZz/nmkeAvcxSohaIoFJ9OelfHQbhJpn08rSic7ZSP5CkAN2OO1W9RjWWwYP0I71VtV8ia6gHBWRhj8anuy5tthRl4PUda97WSTPiqsOWo0eK67D5F86Y43Gs+JQDnNdP4lsibxzHg+tYUkDKMYIb0xXs0al4I0iu5TcZ6ZpUQ5HpVyGzaT5iDjGSQOlHlFeMc+la862K5bkSMVO3mpGPyA0jRjAIB596i+YjP4GluJ6aDllIPzHAqxDIc7h0qqY2J54qeIEDB6VMkrGTRsWU5BBJGDXdeFNREU0aluD1rzn5o9mCORmt/Rbloyp7g9a4a1JSQtj3SznLBShLZ6A1tqMopAw/YVxPhO/W5hCuBkDgj1rsLF8tl2yx9a8erCzOinIleAByxbJPXIp9rEZryExkRurgAgZzz39qsSKmz5cEnuelSWkflTQvESrFgCOo61zqKujpUtDwP9oDP/AAuHxJ/12j/9FJXn2DXoPx//AOSweJf+u0f/AKKSvPs19wz4uq/fYCk5zS05FLMB6mk3ZERV3YfHHu4/Gp1txwF/Wta105jGG28VILMAZKgc8VwTxKb0PYp4CVk2ZRhwwHFM8k9iK3/sKsCQMkVGbEBvufpWSxCOj6k+pmQKIXQvxk1t2yAR7lYZH8Jqnc2oYBjgAc1o6dbq0iKxznmplXaV0bUKDUuRouJLugIbr1FS3Z2ac8rFcAfjRPaCOPglVJxk0mp2craLMyAkhcGksY7o6JYdJP0M5NQjkQEDdu4pPNLOAo+X1qnpEAeJEHUHLe1a/wBkCzSFRmNFJz2Na1MR7zRjSpe4pMoNGGVW425zzUmoyvHbQIhILtwBV0QI0BZcGLbkAUzV7YmxtZVIJzkAdRW9Gu00mZVqC5W0Yk0jsQrEntUZgYcsCT1x61oLAXbOOcAnjvT7i38tUDHDYzzXS5tuxy+ySTb2MXGz5Bj5jyfatCylMKAscr0qEW5IZiuSc8+lKY2VIyvzZ4ruoz6Hm1KdtUbFvcYJbI296vabqio/3spnBrlCZs7FJ46mp7ZGGOCRmvQjJNHDJyTO+e8hkjIVwcjpisWdZWnJQHH0qnZuUlGXwCQM46VrahcK04EOCgUDI71tCyehFS81dj7G/mgU4f5RwMV0uk+IGIClsZ9e9c1aQefKoi5YjpjiriWhRQ24BxnitZ2ZFO61R6ro+pmRFCEZHWptUgivbeRJVBDdSRXC6NfvCi7jtPTHrXTxXryxBVyQeprz8RQuj0aFZ31Pnnxzob6NrEobiKVyyYHGK5o5zX0l4r8Lwa3pwE6ZZTlWA5FeD+JtDn0bUHidG8sdHxxXlzg4OzNK0FJ88djFr1b9mT/kr+lf9cZ//RTV5VXqn7Mn/JYNK/64z/8AopqlGNL40fa9FFFWeqcN8Rzi5sPXa/8AMVwGoOVUg4rvPia2yWxYjor/AMxXm1wwncZfgHmvl8yf7+S/rY9jCr90hludyse+eK5vxTd+TGRn5q6e72RQEjGccV5r4ruizld2fxq8NS01MqjblocnqNzvkbPesW5PU5q7e4JODkiqTgODntXaOJnueGz+dVmjZj8ozVhyu/GaarKj/NggVonYtK5AVCKe59PSo0iJJIx+Jqa5l8184AqASMG52gfrWiu0VaxPHCVlCtyjcbh0FTSNBEQY+ZP0qhJIzNg5K56GnRSYyHTKnofShxb1Y+ZbMteZGwLHc0noBgVes7q3UqzwAsPcnP15rOTK/MFDL3HcUsZHmr/d7ColFNApNHt/gy+gm0a0cRsWClQCOAfTOc1tGQrdxwhU8s/vU6nB7j+RrlPh2QNDRHHLSkoxOBjHI9jXXOkbSRP8pZWPzD0xXx+K9ytJLzPp6HvUoyZg2zx3WuXqu8cDqxwzDgkDkUmoKCf3UpdcdQMc1kQSltev9xAbzT0HWtoDlt3Ixmvdou1NI+TxS/fyfmeUeOVaO675rmEMmPvuM9q9A8c2hldSFAAPBriJY1R8njHUV6WHmuSxC12GJuVSVkZSeuD1pounUMrHdnjkc0sjjoo4FV2YF9ucE963SvuVzWJIrqWCRZFbafcVEXOc/wAOfpTXU9CcgcetTKgC5I/Or0Qr3IzIwYANk1LCzc5/Wo1QGTJFLKRkbc4Heh66BbTUv25DdSNwrTtZlVhtPA61go/IwTmrtozZrmqQ6knp/g2+2TKGPBr1az2yojntz9K8L8NTlbhDgc17T4YummhCHnA715WJgEHZm5NEzwkKctjI560+wEk1zD5rlQGA2IeTz3NWbNQRggYq7bRLHcx7QAjMOnevOcHzI641Fynzj+0B/wAlg8S/9do//RSV56a9D+P/APyWDxL/ANdo/wD0Ulee19sz46r8bEqe15kT681AOtT24Yyoq9zWdT4WVR+NHp2jxK2noHUE44NR3+lPcklMK/YiptIXZBFHjBQDJzWw8OSHTIb8xXysqvJPQ+6hDmgrnHW4kgvVtrmMrJggL2b3FXEh3JyMkZGPetS5tUu/luY/mB4cHkfSqOo6fdQALAWywznGcj0NbKopvXcy9lKHmhp09LizaNUETMQD7GqOi20paSKRcOjcMfQGuo0JEOLfUVKzOQQp/iA7g1ZvrDZci4gAEA4IxS9rZOL6lexTtNFFI4L5TDHywOGGOhFXrsRxWJhH3sYI9eKtwWIi1gOo2KYN7H/aqpNGZ9TbdkRZ/CsZO7sbRjZHPCySKGRwoUSELwKcfLgtmRyNhUp+da13cW32qVVmjFpbqXkcnr7CvPtT8SLdPNHFCUi6Ic9BXZQpTr62OHFYilh1aTNPwxMVnuLCfLDkIT2zV54ZsxwMMg52n0rmdB1MeeRcsBJkENXfWvkywpdowK52sCfWu+pzUp69Tlw8o1qejILW0iS32nDE96wb7MuspBnEQ4JPrXXpaeXKic4Y5rBv4N1wDCo855CcjsBXZhLSd2ZY2LUUkR3lmIUKJ6Zqo1tggjAxxity7hMSbZCWlKjC1DbozmQuoVV6E967aaaVzhqpN2Zhm1weACehqeKAHB7dDWmlp5kRuDnqQB2IoEK4BPA7e9d1NpnBUp21KUcIJUAfe6VchtwJQG/Kp4YiEG1Ru7Zq1DGiY3E7vzrtg7HBONyWAFJXWP5d+OnatgWgmSd0dEWJRgt1JPYVkISoDYwexIrd8PeQ32lrwnb5ZKjHVu1W7vUmL6EEdnNHCk7EbCSBmuy8KW6MsTykBSeE/vVl6RapdDN2zfZoV3EDufQV1uiLbWBhITzLiRshSflQdvxrCporG9PXU6FtJTyyeBgZIxwK8w+K/h2GfRbiQlVZQWGBzXtNsvmoCfmz/DXP+NNNtGsZY5Y3lJQ5wf0ryq95HqUUtnsfDzjBZRnAOK9T/Zj/AOSwaV/1xn/9FNXEeMbCOw1qeOJGjQkkKfSu3/Zk/wCSv6V/1xn/APRTVzx8zkUeWrbzPteiiitD0Tzz4rth7DPQq/8ANa8+VQU+UfWvQPixE0kmn7eyv/Na88liaNVYSEAelfLZgv8AapfL8j2cN/ARS1uZYrcgHO0V5Nrk5luH5IxXo2vO5jbcCOOleV6sxMzYzgmuvD7aGEviMa4L5bFU5ZCsZ3H8KuysQOazbpxyAK6rFogdgDk8n0qM8ncR7VFIxGRjr3qNNwHDnFaqOhSZNlVbAYZ9DUrqrqMqv1qsxLDjt3NKAO4JB67TyKdjRSJhb5OQalW3zGQVYDP3j3qOMIQNkgOOoPFWnmZYghJ2ms5Ng0noMjXY4B5T0NTSRqhHQq3f0qndMAF2glepw/NTQuGZSrZT+VS07XEl0PY/hvb7/ChMv3GkYA46ehHpWvcyNbx7pgMo2Sc4yPWsrTNUj03w/ZRIvztEG2E5U+5z0rndWvZrtsyyHAPyqPugegH9a+YdCeIrylbS59BLEU8JRjzsItSt7jxNetCw2GTiuqj2OMRsCT6GuV8N6fa/amLJudySWY8nNdvHpaqo+z5Uj3r21RUUkj5SriVWm5HCePoPLtc/xDvXmUjtM2+TnHQCvYfG9u32F2kUnHYivKprdVGWJGfTpXRh2o3RrCzWhnM+7ACfjTRATzzXq3gr4N+J/FWmR6haW0MNnIMxSTvt3j1A61xPi3Qr7w5rd1pN9Gq3Nu21wpyPXOa6VVTdkWkmtzDIWNck/Me1N3ZBZicd/SldWx8wx2pgUsR1IH5VoiW+ghbjIoC8EVJIV2kKvNRpnoeBTQS7DkG3B7j1q5BK24AkVSQMSevNXYYztB6YqJ+Zm0zpdAl2TLlsnNezeDbkKE3EfSvD9IZhMh/OvW/C7ndCQcZ4rzMVorijvY9UtyAeTgHnNXYH/exKowNwrNtiDCh7YrRtwDNFjOdwNeZL4kbxVkfN/wAf/wDksHiX/rrH/wCikrz6vQvj/wD8lh8S/wDXaP8A9FJXntfYM+Tq/GxPxrc8M2huLsMADsweaxlA4z6123gS0bzfMfAVj361x42p7Okzuy2j7WsjrrWzcSMQFCsO9XHV4VH93p9auTQEwhoMLKB8voT70wWs9xbAXCrFcMcYQ8V8r8XvM+2SUdEMtHJIbylOOxHUVcSESTiWVdgYbQD0FU9LsdQW4ZbtozGBgBPvVv2qSEGO5h8xeibeo96bVnZMpO6uyrbaMt1p80M4Zo0k/dyj7yg+hpY7Xy7aSxmfMnVH9QK6URJYW4KuPJA+YNXknxK8VyWt6INOkVJcHJQ52g/1rqoUKlbRbHJiMRTw6c5HUaxren6Iry30ytK6BAi8mvPdd8dCezlg02Bo3fgyt1A9q4We4kuJC80ju55JY1HkmvZpZbTg+aWrPm8RnNWa5YaIkeeSQfNI5B6gnrUQpaDXopJbHjym5bijrXSeGNRYI9iXP7x1K5PQ5rmhT4XKPlSQwOQRUzgpKxrh67oy5kfQVvErJG7DISE5PvisHw/p/l7bmduRl8HnGTXN+E/FkgiFjqLhYCMb812VykdzCltZyZRsEshz8v1rClRnRbg9mfQvEU8QlOL26eYy1tXvHmuyM7m2ge1UfEti7WixwNyOw4zXXKsdhZpCgHmMOCOw96o3FupXcc/j/Su2jJqSfToYYiCcHHr1MezjxZQQvwwAyMVHLAoHC9DgZq9IoMgwCqjjJqOeUFlWMKcHtXZSXvaHDVaULFMQgNkcMasQQ4bd97AxVgRDJIXoP1qZPl3CMDbjrXdDc8yrG2xBBBlyRg9iDWvbQ7VyQM4xUFvGNxyCB2960reLO08Y7DNdHQ5Wrst2CEYUEqOtbtjjzEkZiNh9OtZtnAF+Zjz2rTtgFHJ5J/Ss5PQ0jvqeg6RKJI/k6jrTNcjD2MgwDwTVHRJ0WJMk9MGtO9lSS3eMYII615VSOp6dOTsfH/xktPs+upIFPzg5rR/Zjx/wuDS8f88p/wD0U1a/x7swvlTIpADEfhWR+zH/AMlg0sf9MZ//AEU1cdrMVVfvU/Q+16KKKs7DhPiUCZrHH91/5ivP7y3AznkYzn+lehfEnImsGAzhX4/EVxN6mYAMfMwr5nHL/aJfL8j18P8AwUcX4gXbasxz049q8l1M5mfJOM17D4njMdkVI+YDBryDVF/fnjg120NIGL1kY8yjaR3rOm2gH19a154i3TFZ1xCdpz1rVs1SZlyIcc1XA5wM1cmU5+UdKjEbEjHGa1jLQtRK8kO3GX6+1Swbh8u8flzUhjBxvclh2UUjDr5WR3yRT5r6FcnUkSJXJEpB98YNS6hFEIrdfMbaVyctUSLOygq6ZPYig2p5aaSM/hUqSW7E43ITCiRkxnc3rmpLNj5iAZzkCkeFQpdcH8KmtjyoC45HU0Sd0K2p6XqMwMUEagbYYlQLjgHHNY9xJgCr+ov5USM64IABx0HA/Osl5BLgL3PeuLCU1yXM81nKVXleyR0Phc7rgV39vyV3MQfavPvCvyT5JHFdytwoUcbvoa6JxszzoIwfiLHssWcHJ6HJrypYQ+C5OOo716f4+uVfS2LFQSPu968shlaNgxBwD+FYpPWx3U9EfcfwWQL8LtAGP+WJ/wDQjXy/+0raeV8VNScjAljjcflj+lfSnwa8Q6NP8OdISHUbQPFFtljMoDRtk5BB6da+cf2jdVs9T+I129nNHNHHEkZdCCCR1GfxrrbSgrPUnDxftJXWn/BPHmhX1GcdKCWkAXCqB/dzzVhgNwwAR71G+8ZIXk+lNSudLikNKBYzuU+xqFDhtoX9KnZ/l5OTjp6VGkg3gE4qlsJ2HR/6zOME1aQNgVWVvm44x3q5AQy479c1EjOTsa2kgeauR+FereGgfLgxwwYfSvLdHGZl4OK9t8IacZ9H8xEzIhBB9K8/Er3SE/eO2sVDWvUDA61eth+9iIIxkdO/NVbJAIED/lV22Ci4Tb/fHHpXly3Ruj5w+P8A/wAlg8S/9do//RSV57XoP7QB/wCLweJf+u0f/opK8+HSvsWfJVfjZLAhdgPU17J8PbBEsQ/RvcV5f4dsxc6lBEf4mGTnpXumlWgtLdFVgoxgYUc14ObVtoI+myPDtJ1GSXEDmL5OMZ5xVD/SQzHySMcrnqa1UZiJArkE8KcVXlj1BYA7SiZs4wByRXjR10PoJsdYvJdEKUMTt3B5rrLO1GxWhG7HDZPSud0a1cPKbvaS4+RR/DXTSXlpoeky3l04SFFz05NaJa2RMnZXZh+OLuO2sp4wwjkSEuHPavmK8LSTySO5ZmJya9O+Ifj6y8QWUkNjDKsjjaWJ4wK8wEe7rkV9dRjCnBJdEfF46cqs31u7lfBPH9aOhx3qwY+PWomHPpWu+x58otbjaB704DJ54NKE/vcUWYuXS4zpSoMsOO9SbB3walVSTz07U9tWVGFx8II/GvRPh7qiIZIbjocck+lefR5B5FbmifLOGK7Qa9GFJVadmZ067w9VSieyQKsoMr/cY5qw0ZlXJwNo4yKg0dIX0+K43/uFXGPU1fMcskW7aEj9681+67H0kbTV+5yOuytCrCJMZ7mpdAsttkXkGWPzHPrWveWKzxkhd7dmI4FLZReRD5RXc3biuxV1ycq3OL6q3W5pbFZotqEgdeTTYTuDbEIzwQamuriKKQJI/wAx4wBnmhMZPHGK6qLlbU5cRGKejFhQ7wOwrVs4lPAI49KoQj5c4yDwprX09RkAjBHvXb0PKa1NG3j+ZVUVdtrVpCcL908ZpNMtmuZdiEA+prqorCOKNRjk8HBrnqTsb0qfNqZFr5kIIA47Zq1NcvCjbjlallQI20DB9zWfqfMLkgYxgivPxTaXMj0cLZvlZ4r8bLs3VkN4bO/AFY37Mf8AyWHS+MYhn/8ARTVf+LwH2FfXf3qj+zJ/yV/S/wDrlcf+imrgptvcvFpRqxsfa1FFFbmpyfjeMSTWeewb+Yrl7iyBnic48vvXW+MTtktW64DcfiK5m8D7WKZKnn6V89jkvbS+X5Hq4f8Aho4XxxBtMgwPmGa8V1WP98cjoa978QoLqwLPhnHGa8Q1yMJcOAAOT1rejLmjchKzMFgMHI4rOuFPPStJ/lOFHX0qjOx54XFaNM2izOkTgZ4NVZE8xSAcGrFxJuYjcDVJpGVyFxj1qoJmvOthm2dSMKuOnFIYp2OdwA9KmRmyCx+vakJy25W2j3NaXYrIFUqPmmC9jtHNNMf90/Qsc05lTIyRTkdN3TcP50Xe5L7CRWhcZ3ZfsTV61sihDyNgg5z6/SnwQlhn7o71ZSMBgIwSp9TWE6jehDu37p3uq6ab/SrZ4i2/yweBkHA71wV7BdWc2yVHUg55/wAa9a8PRsdJsyGy7ABjjoK05tGF7FNAqgiRedwGQe1eZhsXKjJweqPRxmDhXip7Ox5f4Tllaf5iee1d/b7icAbhjr3FQ6P4TmspOYgNhwWxWt9lZd44yPwr1KlRPVHhKnyuzOL8ezAWYTGSR1rzRmkLYCqee1eg+PehjCgsD6/5zXBwAkucg/hjFTB2Vzpir6IBcmAEfNGSOcHGap3MXmYYuT361YfDvjP51VljZDmLA9Qa1ha+htKT2exWNvIo4ZvUDNNSV1bG0tVkXLAANx7mkWRWYkYOfStrvqiGl0Ef7u5j17VWaI7tw4qxhuufzpwQFTkfjSTsJq6GxKWxn0rRtkGMYOagiTA+UYrQtsAgcnPtWcpXM2ja0OEtInHU17/4Vt3sdAUnKtIABz614t4Vg826XdkjPevdLaTdYW1tEQxAB57Yrz8VLQKavIvacJQrbwDjnJNadmB5yY+8WHNVlQpFgDt1FWLTPmxAjuOa8p3Ulc6Uro+bP2gP+Sw+JMf89o//AEUlcDDG7thELEegrvv2gP8AksHiX/rtH/6KSuIsrmS3b9020nrX2U27Ox8qknVtI7LwLoF7JqEdy0DiEH7xHFervMlsi+bOH7KqfMc/hXmPg3WLm6u4oJ53MQ/gBr1W0+zWttthiJkPIz3Jr5jHyvU99an2OX01GkvZsDNBBB50+I1PIDnbzWTHrrXCzfZWDbflKouQPx70X2h3WqXxuL4jyVOFiXoTWvp1hBYQCONFjLHlcc1ypQjvudj5m/I0dAtZxDG9zkzEdAf4ao/Fh7iHwlMtqgdGGHyM4FdBpk/lTiORcEL8uDkmsz4oCWTwZfeSCDsyQPStaXxp+ZjiH7jS7HzBKp6A4FB46nFBYZ54qNmUjqM19VPex8aurJAcdaQxhsdM0zcCMH8KcJNu3acMDSi9RNp6Ma0eDgn5vQilWIEAmpJ5mml3yEFzxTCwGecDPNXKbT0EqcbbAVVcbR+NOB+bqaaWGOuaQNuIA60KbZLikTr171u6RksMnFYSrgZNbGjsDJgHOeOa9rD/AALQ86q/ebR6lot3ttra3jKlBzmushPnkBjuGPwrzzw1Og8sSK3UgECu9idNiCIjCjkDqa87GRUZaH0OXNzhdk1wVUbVX5RWRdG6lz9nIQd2q3eagsKhXG6VvuoOv5VmJBe6mzMcRIvRFPQ+tZUNHzM6cQ7rlX3Fg2ttHDGR80xGWc9c0gi4AAzVlrZbeJQxLsOCaYWyfl6CvRpTv1POrU0ltYWIEDaAePXtWlaMVfA7dfes8OFBw3OMHHWrtowBUd8d67o7HkzVpM6DR5ltrkMwOPTt+NdpbuJLUynr1FefwOGAHY8cVvWN8UgCyfMB0GawrQvqjSjUsac5yxYrke9Zd8Q0bBm+XHSrn2xGiPQEDNY2qTqbaVtwyf0rgxOkTuwzvI8e+LEe/T8Ku47skelZv7Mh/wCLwaWP+mU//opq0PHOoW9swa4AYYI2nmqf7NrI/wAZ9OZAArR3GB/2yasHThGnGcXqwxEpSxPK1tY+0qKKKR1HL+MgzS2qqeqt/MVhtkWoOMNjGK6HxV/x8Wnrhv5isa5hzEcEjvXz+M/jy/roerQ/hI43WLdiJNvcZrxnxbaNDdPkdea921O2k85BkbDxivNfHOnfuzJt5HWlhewqmjPJpSVOOmaz7kHHJrYuoQGIqjJGm0q3Qd677dgTsY7Q7lLLg+9UnUq5BArchkggPzqeemR1qleiF5S8YY1F2pWsbpK10Z0q78YIBHdhmq7Kd+Vw7+p6VYkQ5PbNNEYjGe9bRdhPXchEckpzIwA9F4q3bW6g8vnHQdhTEj5yw61OdiL82OKmUm9ECitzStnV4x/dFS28fnTZGQucCs2F2ZTjIU/pWxocZmvIbcEncQK5Jrkuy4wu7I9k8MW4stBhlkDl/KwuTnOTwBXpfgPRormSMzor5XndyTivPo0EYsLbccBhwTnoOteieGNXGnyptKGNVy2Rz+FeXQlH2l5dz0sVCbpcseiPRJdD0xoipsYMey4rxHxnawx6tOtopjiBwF9PWvT/ABF4ugg0uGWzljf7QPvI4JTjvXj+v37XMrysclv4hX0NfkaXKfMwjJfEeY+N03NgHGPWuG8/axRlAf8AnXXeK7nfKQRnmuLvezHqK5Y66HdFWVyO5Bcgq2CPwqq5PIY8j1qdZQwG7r702VAUPc9j6VrHTRltX1RAF+UnvUGGBOCoFTqpYYxx7U0rzggYHpWqZPQYATjJzUqgEAGmxqSfYVbWH5Q3X2pSkQxtspD89DWvaouV4PvVa2hAbHFb2m23mSIAAeayk7mUmdd4Nsd0obbivWNGtXd0k/gC4HrXJ+D7AJGox6c4r0W2g2R/K3zLwAK83EPmZdLQmI49OKfYbQyMrFwWHeqM7TIm1uB0B9al06GN5kOHALDOGwPyrz3K8zsjG0dT5z/aA/5LB4l/67R/+ikrgEGW9q7/APaA/wCSweJf+u0f/opK4FCM19nPY+Ol/Efqdd4Fgkk1WNwCqrkmvarJreKAyStuC4JBxmvFfBlywuPLVjg8gDufrXrFgm9QvIU8HnODXy+Y39tdn2WVpKhZFrTby5v72Z5kZbNQxjUHBY9q1Ld98Qd0xJn5VpsNmIykaHll/hplxLHZhUcquzqGrhbv0PRNfToS03nABGxgsepq1r9o2oaDfW8WDLJEUXPes+2uTJAtwcoO24fyFblqWnj3FfkYfjirTadyJK61Pj/ULaa0upre4XbLGxVgfWqbZGTxXo3xk8NJo2tC7tizQ3bFmz2avOG5OAK+roTVaCn3PiMZB0ajgwL0gPJPekpO9b8qRwuTY/cetIXJ70n86QU7IfMyRSMd6mUgnpVU1LCxyFqZK2qNKcr6Mtq3GP51raUf3q54BrJiwDg11XgvTV1TVorZn+UnJx1xXsUJ2p80tjllTc6nJHc9J8FpZ/2QgkQF87t5HIPpW7FEqsfLPIOaqWyLpsMaEAIPlzjnA9asPG7Rb4XDo3IFeJUqc03K+h9bRpckFHsQ3QYOXZATjGQOcVLZiZ7Um3Vt+cHPFVLggK29mDZzj6VrW92JbRXjUqCPWt07QVjGesjV8H6E+s6kUulPkjl69XtfDelWsPlxWUO33XNee+A9chs9UMdyNgmG0NXqwkRkDKylfUGtqratbY4UtXfc81+IXha0tLM32nxCN93zgdMV5+j4fIzXpnxH8RWgsXsIJA85OGA5xXlscnJHGM16OCcnD3jzcYkp6G7at8oIOSK0bWQhfm27R6VhWshLKoII9q0Vc7cHoDxiumSuc0XY00kK7yx+ToOayNTkAhkDdgTVzziFwo4A6EVz+sXH7mUkjcv61w4uKUDtwsrzPHPidO32qJR/FzWv+zJ/yWHSv+uM/wD6KauP8bXZudQAJztyK7D9mT/kr+lf9cZ//RTV5VPY3xE28Qfa9FFFanUc74pUGa1JOOG/mKpMEaLHBFX/ABUMtb9M4P8AMVlBAdp/lXgYx2ry/roerh9aSKOoQKY8Jy3bNcd4lsBPA+R97tXbagDCnPzJ3rn9TIaNgOV7VjTmoSLnByieA67p/wBnncEd+K5ySEEncpFeo+LrDcGkVfevO72P95tHFepGV1dHPotzGu7VWToM+tZkqtgADgVtXEcmDuOcdDVSaD6880crSNYy7GP5eTk4NMk4IIA3djirs0ICtnioQmMBhUXsarsQK3y7nPIpqxvO+4/cHepwA54PAofglQee/pRcu1ySOVEB4AHaum8BW5m162UjJLbjkdK5qGENj1HQ13Hw5jYaqX27iq8GuXEzUabZ04eHNUSPVrOILILhjvkIEaD0Gefxq1fXZtbK7kZgrLGR16HtVaOcXEiogARH3NjuB/8AXqn4pnU6FK6r88rLGBntmvAoybmkz26sUouRk2t862oXccNiq1/elUYnkYqsvCAH8Kp6nLstWJ6Dr9K+k5rqx8jKN5HIazMZrtlzgnp7Vg3eGO1hluxA61fnmAujIc4z3qrcKk0hKEn1pRVmdFrqxlNlW5HB61bDB4SvUjpUcse5ieeKIRg5bueOa2buiU+VjfKKqWjYg/lUMQfJD7ic55FaxCGPK5BPeqixsDkKcA0ozuhzjZ6EKRnceOKv2yD5e2Pamxpk46n2q/DDge/rQ2YydiS3iDAHH411nhmxLyq204FZGl2jSuqqOK9S8MaUYoULL1IHSsasuVGd7s6Xw3bmGBPl/Gumt4iRkE1Qs0UBY16j0rZt2VEB5IPJ4rzZyvodEY21M7UFAK9T6Yqa0URCItlRuBPqTmrKhmBkwpVugqLZiWJcdGHH41yOPvXN+bSx81ftAf8AJYPEv/XaP/0UlefgdOa9A/aA/wCSweJf+u0f/opK8/HJAFfaSPjZfxGbvhcH+04QCeWA2g1734ctwqbmiO3rivFPh/aC41uLIUqnJzwK9oM/2O0LWzQMvRsHJ/Cvmsys6qR9fk6aoXJNb1/TdPk+yfaf9NbpGgLNis2zSbUYEe7DJITyCeSO1VtP0SG4v21KVHMzHh27VvwwrHIock44B9TXDNwsuU9OPNf3i7pcbKzBiDGBjbnoa6K1uF8lUjGCBisK2jAiaQ8bzghe9WI5UjG5zsWMZJPH51nctoj8Z+HbbxLpD294g3Lyjr1B9q+WdY0+XTdQnt5Y3jMblQGHUetfVula1FqcHmQAGIOU3Hpx3Nc34r8K6b4ndmu0IkjGFmU4IPsO9ergsZ7B8s9jx8wy/wCtLmhpJHzQMY60neux8d+CZvC5hkWZri3l/jMe3afeuPHp3r36dWNWPPF6HydfDzoTcKiswPFFKc4pAfatDESpIT8/PIpoBrU8P6PdazfpbWu0Oed0hwPzpM0pRcpJLcbboZJFSNSWY4Ar1z4c6DLZRyXU+QxXAXbgqapeEfBltFqANw/mSRgFxwQpz2NeiQDE7wtJsR/lDCjEYxcnsofM9bA5a1P2tXfoVBJHdwiJiBKOnv7H1psRntpNiBSuOY+34elVZEFnqIAX5434I9+9bN7AtyqzwuY5APvAcGuS6jbsz1tXd9UZd7F5yMYxkMp3rnlfwqr4Ym+02MkKvlomPU84o+1hNRAkBjnKkCT+Ej3qrp8kcWqMbdBDI4w4HRveuynfkaOOpJe0Ul6M0ppGJyrcg9D2pH1i/WMRRXlwqE/dEpAovF2bymcH0rKk3AKWOD0rtoSTRyYqNnexZkunllZpHLMTjOeamWXLZLYBNZBkJcg7qtJIwQMo+UHGT1/CvWpR0PBxD965sxTYf5WIFaUFwxA+bK1g20pEnOTn3q/bz7BxuGf0ptGUXc0rm82oBnGeSRXG+IdQb7JcHeBgGtLULtzEQCSDnmuA8W6mYLSZRnDDGR2rzcc/dsejg7Jts871Gb7RdPJuzknrXpf7Mn/JYNK/643H/opq8rY5JJzk16p+zH/yWDSv+uNx/wCimrzUrCjLmqJ+Z9r0UUVZ6Ry/jG4WCe0D/wASt/MVirdhgNuMCo/ivdG3utMw2CVf+a1y1jqIcbWYg/WvnsbJe3kv62PZwsb0kzqprnzcl+QB0qmYBNC2eSBkADmoYJo2kXdwO1WjKE+dB8w4Yeorm31Zq9rI4rXdNYqxCnYeua8w17SzFIz44PQ177cWqXagoQF6/X2rifFGjpJGxCdeBiu7DScdOhy1Vrc8WljGNh6H1qpNbgPjB47Vv6tYGCZlYEc9ay5cqnzN0rtJTMZ1VC26P6VFDah2LHuelaMiq3Xk11Gm+FI5fCU+rR3G66SZVNsBztP8Q/w9KieiNVI4C6txHOUA2gHpVcqFJwpznmtC5iDXDM5Jfd972pJUBmHzBM45PT61DjqWpXKIwDnDflXofwvBN2yOfkOcH3rmtWt7RbmCKxk8yEQLub+8/wDF1AxitTwrqH9k3TK5k2PwSgzg444+tc2KpuVNxW52YSoo1FJ7HrKFbSKRyAzEdRjjBrE8RyM8KIM7HdWBIxnjmuYi8cAswngLE8HHap9S8XLLZp9nhVuCj7/4QfT3zXm4bCThUTkj0cViISptQZbBwhU9Ox9awvEE+INiZLHsKg/4SV0iDS2zYPcdKx7/AFlrm4jkjTaQeM9K9nl0PnlFp6mLMJGfIBKHkcVIuPkKjOeufWrs7RRokyvhoioKdS5PU+gAqIxQ5mKuxGcxkdPfNFro0vZlS6haMsHG1hxtqgySK/3SMdAa2LhGlgUkgvHx7mqjKSo35z/epx0JlK7AI7wkvxxx7n0p1uMKFbv1zU1kpcSxbQQwypY9CKmjQNHyD5g6ccVXKjNzFitdxHlgHJ4q9aW7tjjmm2KN5gJAVh0xXSaVZtPIOOpycVEny7kvVmr4V0/Mq7lJP0r1CygWO3jVMr9axtAsFtlU8FgucV0VqPMbJLbh+WK82tWvoaU4dS/YpGvIGcHAz1q6ZE8rg4HSs15PsyZBCnPAHOar/b853AbiciuOU0tzpUbml5/loBnjsKbG+Z48nncP51kC8XDEtnHGfWn2N4JLmPLDhxgfjWUW5SBqx4J+0B/yWDxL/wBdo/8A0Ulef57dK9A+P/8AyWDxL/12j/8ARSV591YV9uz4yfxv1Op8EXDRaoiAt+8+Xiva4ILf7NGI7dcL1+Y/n1rxLwNGG1q2zkDd+Ve86dCpiPzx/gvX9K+ZzNL2lkfYZO37G7HwSAIEXPqPQ0oy75YZcHJ56VCAqkMuM57Z4pFncS+WrB5QMtgV5Vj2C/cyiGyk+bDkZGO1YTTSX0Qgbftb7/8AtCrF1d7nRWwMD5lz0+tR2iMxHlN8jNt4PYU1oKxs6FDFYW8sCoFg6nBrRjRVAd22wj5unAFZoY4jhjUM7Z3fT1rA1jUri81b+wbVyiFR50nJwPQelaRTkRJqKNjUzba/cJB9nSa2Q5YuPlY9sZrlPFvw/sNQmEqlbTau3Eaiu4i8uARWkLIgjAAOMk/jioPEbbLUkEMTjJH/AOqtIV5UtYMznRhVVqiueH618ONQs8NaSxzRk4HmEKaypvB2pW0Ty3AQIh+fnOBXsHiHUY7Kwtbm9gdnlcRonTb7mma9b/a7q008ptgkxI8vXcB2rvhmNey5tjzZ5RhW24qzPNYvCW66015NotrgckgjPtivSdM0i2tkeK1g+zW64TGc7j3Oagntjc6+pJAtbDaBkZDsa6oIl3PPa27KZEiJKnnDGn9YqVLXZtTwtOk3yrUzvCjxXMl4ITkbyDgZHHSrWoTCd/JGUmixk9DkHrWX4AUadb3Fs2SzSsGz6g1o63mPV4LkYzOm0gdDiuy1qvKRGTdNORDfL9u3xFilzFjqOXqXTdUWGH7Pdfu5l4IfsKq3MYnmWaJts0YyCD94elQ3Esd1PFK8e8xnYxPUexroVpKzIekroq+KpWgP2iCBniI5YD5frRptm7abG6nEpbdkjJrR1W3iubcAyPHuHAXsPpWVBcXUcWyTaFBwrL3FdlKfNTSjucdWmlVcpbF0zYRxk4PBrOupSSfL+760XEjEMOxHBFUwzYIf69eDXfh4dTz8VV6DyeCd9WIQxiXvz1J+7VGNvmO5cL6561Zhc7clSWBBABwAa9elseBWldmvEQAmBtB61MsoUD8vwqhG+EXeQwznPpUV3eCIZUFsg5I7VbMosg1mcqDtyNo7V5T4nvjcXZjDEqvWuq8Q6myRsQwPHIzXnk0plkZiOSa8LFzcp2PTj7lP1I69U/ZkH/F4NK/643H/AKKavK69V/Zk/wCSwaV/1xuP/RTVyoml8aPtaiiirPVPIfjwG+0aS0b7XEcmOevK15db6tcWzFZkPHcV3v7R90be+0HA6xzfzSvJbnUfMCsznIFfL5h/vEvl+R9NgKV8PF/1udraeKEUKjttJ7NXS2Grxy4G4Zx+deexarpP2NYXCs7EZYrk8entTRPElztsZ5NnYGuTmlE1lSv0PTbm4lUebAQxHVc9aRLiK/TBGGHXd61xh1O7s9glZJAwyCh6fWn/ANsKzbgTG3Xp1rSGIcGcs6N1qS+J/D6zqXjA3e1eZ6xpzwOVZTx3xXp8evQyfJLIDzzz0qlqVlb36M0RV/fNenSxcZaHFOi4ank/lALk8PXTajMbZ7LT7IlU8qN5nYbW3nOevQYIqHUdK+yXAMsXmRg5KnjI9KZ4vvtKuIrFNCsnszCh+0M5yZGOMDGSABzXVzKRHNYxdajsBMyWKTeYrsHdmBVh2wMcVkyxMSNi/jVuGZlLbwvrmpVkWUYAxVJplJ9hQCNMRNg3xvv3+xqjNJIj7uuSPcGtq2j2o3zgKR8wz2qlI6qVEgXAPpUpXNeZpGdtmeTEY5Y8AA1q2um3reZCbSVS3VmUgKR3J7daW2uQzuoZVAbgnqv09K9B8MarNKl4by8RVnZVlupJCxUAqeVHJBwAapRu7Bzabnl94swXySMqGI6YP5VFFaTKvmmB/KXksOQK+mrX/hA9V0K5mf8A4R5L9lZnnecsRJk8kMM149rd2ro+n219AbCNi+yGMBM54PqR7nOK1qUuVXZkpuT1OCa3mkChIydx4yeppn2SSKMN8oYkjaTyK05slhzn0APWqUu5Cc/e9TWSjZFOQlum1w7NuGOcdaka2Vzkq2OwJpYDlTyMjrxmp08yRtseSalx1FdFfKxvlQQ2Mcdqs26tJjAIpYbNpHHseQa6nRtKiBDzNj8KznOMVqZbsp6RpklxIAqZrvNK02C3jG4gMDz6iksYYbdQRhCBwR1NSm5ggY5IEmM8sOK8rEYi+iOmFM37eZEAUqVXsO5FXluFjjLElV6Ba4u58VWNicSSh2x1rn7zx1EpYoWfngtxxXFac9kdMabeyPRbi9ZmycYA44rKvdSQHaJBjqW6V5neeNbi4HyNt+lc5fa3cyMT5pOevOauOCqTeuhvGjJnq2oeJrO3UgyhiKxLfxkzX9skB25lUZz715nLeFyNxPPqafpdyf7Vsx285P8A0IV3UsAo2uW6KtqdV8f/APksPiX/AK7R/wDopK8+6kV6F8f/APkr/iX/AK7R/wDopK8/QZYeuK+kbtqfATV5s7n4c2jC8W4fYU/2ucV7DY3UbZCGHIPYAV5b8OljQAuxjf25yK9T07y1Ut5nB54GP618njpOVZn2+XQUaKsN1e+hs4Gl2qZMfKoGck1k2sk0GnSSvtN3cnOM5EfoBVrUXEkplKKCp+RyM8VTtYjd3nmzsz7RgEjiuS/Q7XfcZp2nPbxM8srSSu+5i306VsWnl28bAICy8gDtTVk2uzIoLdACOKraxfwaPaI8uGuZuEjPUmpvKbLsoI1La5ZS7x4eVxgEnpVaztBYysqnfcyMXkkI7ntT7NGstMNxdFEd/wC90FVluiUl2HczHg+1Gq0ErPUbpmoW0mpXKIS+xsEsOp9BWtf3InmSFVUgDqKxvDtpFFPKzkDvuB71s2jb7gyZ+UNwcU3y390a2uzl/HkbvYWaLsbyZVdieuM9K19UVjb/AGkbSzRhEAGNuetZfipTe6zaQQSFog3mO2Ont9K6OaANpy7juULgL7mtteWKMUlzNszbGFYFjto1z5mGBPUnuTTfCLP/AMJBf3Ukh2s5Uj/ZHHFWdQcafLAy7f3QCEHpg1BpKfZ7o4bCFM4xkDNehSglB+ZzVNZrsh6wpZa3qcoJEUrgpn6VneM9ViitLFlVvtAmBRV/iHetPxLMbeCOZUDADErdOPp61i3NpHqmkyQTYDqQyseqntiu6jZ8s5dDmrXUXThuaKwTwG3kZMJN8wH93vikZI03TKOJuqE96twbo9PgR5CzIABn6VnXmGYvExZWwAo7HvWkbyY9kia8cCIgHlcYHrWc5Cx7RhQeQRUsshYMTt3EfjVG7WV4CVUBguRzXZQh0OWtLRtEcsgAALHeDgZ/iqsZCc5XOex61ni6ZkEcvyupz1qUSFpM4AYjqT1r26VOx83ia6ZZONrsNynpjtVu1DFYxkjGCQT1qoCFU8c+h9afG3yEvGCQOMnv+Vd8NDzZ6l+Mkj59wwcH0rH1i/MZcFicg5BHSkvbh1zvCgDpgjNcd4g1Bi7qjgUq9RQjcmnqzI1u7eeUqW+XPSsqlZizEk5pM187Um5O53MK9V/Zk/5K/pX/AFxn/wDRTV5X2r1P9mT/AJLBpX/XGf8A9FNUoul8aPteiiiqPVPA/wBp2GaW80BoAWKxzZHrylc78KvAcHiLTL271q1umjmlFnavFuxDJsZjK2P4Qdg54y1df+0VhtR0BDJtyk3y5xu5SvNb24uLmCxt1k8iKybzIFi4WNyQSwHqSB+VfP4mpGGJk5q6/wCAfTYTnlhIwg7efzZw95a3Vhfz2tyjJPbyNHIp7MpwR+Yq1ZXcsb8HBHf0rpL9Hlnlvb26W8up23SSkc59TWNPp7CQlCCScDHOa8+UlLoempqS94uw6izkPI+cD+KpYdQEjFWkAU1jT6fJG5R/vDtmqjS+TIY2Vs1HJzbB7OLOvvprBliECAlRz6mnRlYUVkk2BuyP/SuViMrjMeT61MHlUDLHH1pbO5k8NF6G/eXEsiEeYrA8fOP61zWpWdwwYrHGwPo1aNtdFFYSRqxP3ST0qTzlePqwbP3QOK1jWlHqcs8BBnIjSdVufM+yWbylBk7WFYzvqEUh3Ws6lTjAQ16Ol75DMIcrkYPvVG9kid/MWPb/AHsHrXVTxzW6Od5Zd6M4eHVrmOfbslXIweCKsJePPLt8m4HBI2ISSR2rrYggc4GN3TPNW7KVoZQVAyDwfetHj9fhM3lk/wCYzNT0i7sYrS6XS5JrZ4Uk8yKORWl3D+IHPIIIyOODTNK1eO3g/f6PrLwFyCYLgxhjjoRtPT1ro2vrkKVR2iUjGFYjj0/WqRuXXIIzTlmCveKKWWyetzqvDevWC+E9Rt/+EMaWaUfuZ5ZCxY9OfTGe1eUzx64Jpnt9MugY1MjNGjcJ659K7ODWJoY3jicorfeXsao3l3LNKZJZCzYwCTT/ALRk4qLQnlsn1schpxvriUtKHtEwcSyxttzjgcDPNUWN+1swWN3lL4Eewlj7iuruLgt8uM4qj5sqyb0yGHQ+lNYyT6FrKr7yMCCW9jO2ZWiUnDDIB/Kr17dwW05WynluICB88ihDnvwCafcRtc3BaQFm6sSe9KbMDAwD7Y4rR4i+5qsqgizpuvW8UM3m27eZs+Q54De9Xbrxw32dYLO0igOBvkY7mY/XtWBPZoCSEOfaqhsHkOVSptTnqzVYKENkbJ8T3smS1ywB67aqtrE0jkeYx+pqmmkTM3HAqwNHmQF25ApONBGkaUYivfOW5OfrUHmF2PINSm05AOAfrVuLTwY9xIwO9LmhE1skZ/lyHlRxUEgfIUL8x7V0UdrKYj9nTGOpYZFZs1pdRyMVWKTn3Un+dOFVNkuVjONs+Nzn8qtaNEzavZqV/wCWyc/iKtwosrCK5j2Oez/0rU0rTIjqdoyxkYlTBViO4qvbqL94mUtDR+P/APyV/wAS/wDXaP8A9FJXofgHwT4b1f4deGRcaVazazrFpqRR389XklhkbyyJFPlxgAc7hzxjvnzz4/n/AIvB4l/66x/+ikrlLfxNr1tpQ0y21vVItM2sv2SO7kWHDEkjYDjBJJPHevYPz3mUakro3vB9wILmGRm5UYA9q9Rt9SLwMqMDvHDbBx+leGaZdPE4CkfU16R4Z1DfHtZ8r+oNfOY+g78x9PluKUoKKOugu1ClXJIA6bf/AK1SRKQuVIGTuxjFVoWQfMAxHTjFWIQXILbwP515DR7UZX3Jrkoi5IYlhk84zVOPTF1DXY7+6+aGFAsS+9WIWLF1ZHY54PpV5UVLfhW9fempuL0LspblXxSn2x7WGIssUbbmX1NQ2cR8pi2N5eohL9ouCASyirdsRHyVOc9KOZ2swUVuOluPIgdRgM3RcDipLOUiBigw23jPNZt+FizJNncSSmat2x26WXwwduMUJX2FdXF0SDzBdXEmNwUn8q2bfM9pE7Y5Ac544HNZNmphUomVRl5z39a1PMaSAJGMDbtx6V1xhYycrnNXl1/aN3KOiuw69qvabJujLtkEHaR24OKozRB9ScxofLQhRtHcdav2ZXOV+ZWGWX0Oa9LTlsjlSd7sb4gBuNNng3fMGyCOc1maVJvt2VyCyD5v8K0dRZjcfdIQjtWKUe21VJCNsb8EDue1dNFXjymFXSamawkyVZjyp6VVeUwPvTJXPcdqLl84Yde5rNkkZMxFs8dQelb0oc2xlUnYnnl+cHjjv6+1VpbgbFBOT0wKrSThoHRuCpzn2qnGxzkjjk816lGhpqeXXxFhNRt/NQsi4cc4zVe1kDKMbh6d6sMzhdykEninbUSRSg6CvaoJWsfOYl3k2iwhEjENnpg54zUVxtjAUnHoQfT8ajlkKKGcj6dxWBqupMikBxz0Fat8quznvd2QusXnkjggk8jnNcbdyl2JJySamvLppWJZsknoKok5I4rxcZiXUfL0OylBRV2J3peaSiuE0CvVf2ZP+Sv6V/1xuP8A0U1eVV6r+zJ/yV/Sv+uM/wD6Kami6Xxo+16KKKs9U8B/aV8c6H4W1jRbXXPCf9vNLBJLHJ/aUlr5Q3AEYVTnOBzXkCfGrwggAX4ZkADH/IwTf/EVvftvf8jV4a/68pP/AEOvmqolShJ3kkzSNWpFWUmvme9j44eEwCP+FZ8Hr/xPpf8A43TY/jZ4QiOU+GWD1/5D03/xuvBqKn2FL+VfcP29X+Z/ez3qX43eEpWzJ8Mgx9f7dl/+N1CPjL4MDFv+FXruPc67L/8AG68Loo9hS/lX3D+sVf5397Pdo/jR4NjBCfDBQD1/4nsv/wAboPxn8GkYPwvQ/wDcdl/+N14TS0ewpfyr7g+s1v5397PdB8ZvBgJx8Lxz/wBR6b/43T0+NPg9CCvwxAI/6j03/wAbrwyOMv0BNWIUySp6jtUujSX2V9xrCpXl9t/ez2p/jR4Of73wwX/wfS//ABuom+MHgphg/C4Ef9h+b/4ivH4GWCb51G0+orpvC7vtkkihib3ZQaiUKUVdwX3I1j7aTt7R39Wd0vxg8FLjb8L8Y6f8VBN/8RTx8ZfBqtkfDAZ/7D03/wAbrEub1dctCINGiilhGxiP+Wh+lJ4f1BfDltdpqmjXEsD9IXXEYPqeKSVF/ZX4Dkq0Vf2j+9m//wALp8If9ExH/g+l/wDjdRn4x+DCcn4XjJ/6j83/AMbriw+pagLi3GmSSW9w2YVjhxtz2BxXQ6V4F11FjtrzQZfImXCyMuMH3PaiUaSXwL7hR9q9qj+9/wCZoj4weCh0+Fw/8H83/wARSt8YfBT/AHvheD/3H5v/AIisy7+EPiuyVjbWDyFv4FAcEVBD4F1a1ihOsaBdQLG4MkogJ+XueKfLStdQX3AvbN2dR/e/8zXHxb8Ef9EsX/wfzf8AxFH/AAtzwR2+Fq/+D+b/AOIqXxJ4X023vrKfTEe70q4UCcCHlfcelcvrvgiWWWU+E0uri3b78TRnI+nrUx9k94JfIqUa6+Go382dEvxb8DqSR8LF56/8T+b/AOIpT8XfA/8A0Sxf/B9N/wDEV5n5Gq6WHtrqMQgHaY7iP/EVkTwSvOVEa5J/g6GtVTpP7KMZVKyV+d3+Z7F/wtzwP1/4VYn/AIPpv/jdA+LvgfBx8LE/8H03/wAbryGTSL+OLzXtZRH/AHtpx+dVreNGmVZdwXOGKjkU/ZUn9lfcjN1a/WT+9ntA+L3ggdPhaB9Nfm/+Ipn/AAtrwNkk/C4n2/4SGf8A+IrzR9AMV9JaySyROUDxb48b89M1HeaTdaJMv9r2cqxyqdjjofp60vZ0r2UV9xXNXtdydvVnp6/FjwIGyPhWufU6/N/8RUq/GDwSoZR8LVweo/t6b/43XkFjfi2dh5KTQFuY5BwR9eo/Cr9jrMEMLWzQKImOQSoJX1HuKr2NN7xX3E+2qfzv72epR/GLwXGCE+FwAP8A1H5v/jdRv8XvBDHLfC1c/wDYem/+IrzXUrzTpLaS3jIZid8TqoAjz1Xpz25rn5YisaORw+cHI7daPYU/5V9xLrVV9t/eeyy/FfwJKP3nwsDf9zBP/wDEVc034t+Cje20cXwx8tjIqq39vzHacjn7nNeE9qtaT/yFbL/rsn/oQp+yp/yr7he3q/zP7z7E+I174Gh8casviDwhbXd6HXfdNfSK0p2LyVAwOMD8K5c6p8Ntw/4oC3EZGd7alKB9OlZPxqsjP8Utekkc7FkTA/7ZrXKabbC4ffdSMbeEnaD/AEry6uKqQlJKW3kj0aWAozim4as7S31/wDPerDbfDKJkJwJDqko/TbXX2UvgtJ1it/A0SE8sRqMvyj8q8zsUMt1GsSBC3Kgdh616DY2BtbMs/wDrZP09BXDXx1bo/wAF/kd9HLcOn8P5m5aap4YkvxaweDxjqW/tCTj9K3Vbw4ig/wDCN7R2/wBNkrA0HTDZxyT3YxNIc4/2a0LpxKwigA2nnNcssXWT1t9y/wAjd4WjeyT+9/5lxJvDxkITw0c+v26SrcUfh+Y4bw7gHr/pshqjDEkCDJB9TTZ75IFIUY469qn65V8vuX+RnKhTbtFP73/mX20rwnbgkeHlXPX/AEyT/GqpTwkZcDw8CR3+2SCsG41AzMA8gUEZHfn0rINw5lyWwfX1pfXavS33L/II4KFryb+9/wCZ2Wop4SO1pfDYlKdM3sgxVJb/AMMNhB4VOwf9P8lc490M/MSR7mq82pxxqcYFdEcRXfVfcv8AIiVCgu9/V/5naPN4Txu/4RzJ/wCv2WmHUPCyDB8O4z2+3yV5zPreM4PH1rIv/EYQZ3c10xrVX2+5f5HNKlT7P73/AJnqv9oeEITkeGsHuft8lVX1vwXb52+Gue/+ny14zd+JWbOGPPTmqX9ryTDO4/nWvtK2/wCi/wAiI0oN6fm/8z2afxT4LUAHwsW7f8hCWqc3izwW5BfwduI7nUpf8K8ckv2YkDk05Z5JFHOD9aftqq6/gv8AIbwsH0/Fnrh8YeCsY/4QwEZ6f2lL/hUX/CWeBgxJ8EjPc/2lL/hXkzOw7mozIxUkmmsTV6P8EH1Kn1X5nrb+KPAhJx4IU5651KUf0p8eveB3Hy+BU46f8TOX/CvHxOc96ljvWQ5Unim8ViFtL8ifqVHrE9b/AOEg8FdB4Dj4/wCopL/hVK58X+ELd9o+HisvqNWl/wDia87i1MnhuatwzpJwxz7Gp+vYmO8gWBwr3gjuoPFnga5IE3gJEzwd2qSn/wBlq5DqXw5nYCbwRAhI4J1CU/0rze5tEf54/lNRo0iko33feonjcVLaf4ImWWYaXwq39eZ64NP+HroJF8CW5jP8Qv5acmm/Dpjj/hB4B/2/S153pOs3Fjhc+bBnmNv6V1dpNb6jAJLaYAnqndTXHLG4yL+P8F/kbwybDN3bfpp/kbx0f4edvA9uR6/bpaa2k/DsRlh4ItiQcYF/LWcglWLBAY9uetUblfMmDKrRyeoHB+opLMcV1l+C/wAjeOTYaD1V/wCvI6SHRPh64JbwLGoAzxeSmus8FaB4V0nxLp9zo/hWGwu5AypcpdO5QFTng8HIrzqy1S6SNUeMHYcHHeu28Aai974oshJ8qgkquc/wmt6GPxEqkYylo2uiMK+XYaEHKELWR7PRRRX0p4R8gftvf8jV4a/68pP/AEOvmqvpX9t7/kavDX/XlJ/6HXzVQAUUUUAFFFOCnGccUBYApPAq3ZWhnm2GpdJtxczBCQD711GmeFr+6uJpLSLK2yeY7Z4xWU6ltDso0E0pMzodMMSkp6cGseQH7cBGpVlODnvXdaDajzLGe8njbzAzGBfmb0Ax6mvSvCHwhtbxIr+9m829vHLRwAcIvvWcJO+ptV5WlymD4N+H9nq+hWv265ga/vQzJF3RR3NRaF8Nr6y8bQ6RZ3r/ADKXkYp8qivetF+HV1a65b6i00NusEflJGi9q9AstNs7F2n2obhvvSkYNS13M51kndbnlugfC5tNjkRkS4J5WbO1lPritc+D9UuPLtdVazm08MOGXMhHueldF4o+IHh3wzEX1PUIUYDhFO5j+AryvWP2jNDRz9is7mbaflJGzNCpqWyuYuvN7ntVholpbpCq20KRRj5Qq1ryQW5Ta0asvYYr5Uv/ANpLVZiRp+k28a9mkYsa3/C/j/xj4ytpZYHWCGNcsEQIT+NdCpT3sc8p+Z9DiS2txjIQelVbnVLPaVd0IP8ACSDXh50bxJNIZp9ReQkgeXvPFMn8NXFtdLbS3UssshySWJx7Zo9i9rijUW9j1hU0SN2KRwR7jkgEdfpUZm0tGPkiIMf7gArzGPwNcmZf9KZlbkM5P5Vp2fhieE7GCgqfvZPNYVKTWsWdEK2utzp9U0TT9XiZbm1t5VPaVA3FUNO+GmiWjZt9Ks2J5BIBx+dMhsLi1lQOjtx039q6rRZonx5xkgQHaDw3NRHDT3KljbaIgPhK0S3aK5toCjLgpsGCPpXz/wDEH4PQ2OoSXFjbSS6e+T5kOd0PsR3x2P519P8AkJM27zXdB0Jp/wDZgk6OwB9uKfspQ1ihLFqT9/U+B/ENjqWkXUY+1G9tFTy1YqdyLnoc8gjt+lO1GTVNT06GKeeK+tcYVlb5oz7jqDX3LeeErCdZPPsLWcMMMHjHNeNeM/gla/aHu9HsmTB3CNDyvsPUex/OjmenOjWNaLuovc+W3sfskphuVjkV/lWVH4U+/wD9eqt9p89lM0VyhRwAwyOGB6EH0r2q4sLDTxPa+JvDxG4kCeHKH8VNcHrFjOkw/se686yjyI453BZFPVee3tW6nciVJPY4XHNBq1ewyw3DeZCIj6L0/Cqueea1OZqwVa0n/kK2X/XZP/QhUE3l78xBguOh7VPpP/IVsv8Arsn/AKEKBH0v8Yp4rn4na1byjy0idNzheWPlqcVxl35sgigt4xGHxtQdT7mus+K6zP8AFzX2SLzAjxhV6c+WtO8H6eIzLd3o8y5ZuWI4HsK+bxclCcn5n02Ei5QivIu+EtBFjH9qu8tMw43HoK6ywtvtdwHnBECc/U1BaRvezBYw3lD7zEY/Ct9wlrBsKBcDAB615jbk+ZnbK0VyIdql1C0CCM/vMbfwrLW5SLOCC1VLrzDIGboadbRqsheQfTms5ycnYpRVONrmkrsYg8g57Cs3VbtXgKlzuHQCodR1AJlUYVzV5eHcfmJx15q1DoZKy1LZuFjOC2c+tUrjUljyQaw76+YsdpPNZskrMck10wppGUpORq3mqOxJDfhWZc3z4zk1UkY5Ge1RsQeDmtkkhKncgnvHbqTVCdjMpzmtUxp5eCoBzwaheJcEDrWsaiWxLomIto5HzEkA1YSCQ/KOFrRiVVyO49amkaKMKVcMzDJA7exqnWb0BUox1KCW4UjAJPrUjxMD8vWrMeJJOSRGT1A5q06QrIFRmZfXGCazc2aRijN+zsB87dRUTQDb94/gK3bmOyzN5M8hC42CSLBcY56E4/OqlxCip8roxz0Gf8KSmxtIyFiUk8sT9Klkhg3YiMuO+7Gc1fW0Jj3jpnHHWoXicKcZB9SKrnuTyIoNsXuwP0p6SbW+V81M0Adcnk+tVHiKkg1qmpbmUqZr2t4SQrcg1dmthdRjY2w+tc5HuVsr0rZ0y8HCPUShbYxd0y0ljJCoBO4ipoJZLWRZIHaKYdGFbFoRMu3rUs2llxuQZ/CsJG0KjNDRPEqzRm2v4kWdv4xwH/8Ar1q3dk6RCeJsxtztPUVw93ZgDay8+tXdJ8R3enKLe8Pn23bfyVrmlT6o64VGW7+GYEyxSSAH+Ifwn3rpPhRqL/8ACbaTb3MY815HAf1+Q9Kd51hLpkc8MybpBkhSDj61L8OFQ+PtJeNRnzGDAdjsbkVphv4sL91+ZniUnSk12Z9GUUUV9efJHyB+29/yNXhr/ryk/wDQ6+aq+lf23v8AkavDX/XlJ/6HXzVQAUtOSMvnHQdTU0EDM4ypK56gUm7FRg5MksrGW5PyLkDrWsumzNaOpgCqhGXxzXQ+FX8vzLTagTG9WK8+4zXoHh/RbjUtOlgtbFVt2OJbyYHv12jua5qlVpno06MYxOe8B/D631XRJNWmm8iNWOwnrgf4mtGP4d+I7KzaKTUTD9vb5bRDmR17A+nFe16D4H0mKztzOZZfKA8qL7qJjvt7n3NdVBpul6f5t9chA4X5ppTyq+majn1uyJNLSJ5v4H+GVtodusVlbLPrMse2W+n+ZIM9do9a9S0rT9O8IaaJLm5QMq7WnlYAn6V5Z4x+NVnp9w9j4bjWeQHZ5pHy59h3rm9NsNc8YXhu/Ed/M0PDLEDgY9hSTcndGcr212PVdZ+KVpsaHRIXvLjopAO2uNLeLvE1wov9QXToHbATlc11Wj6Hp2mwJJYwxgdCUOWNT32krewNJBKexVW7Gm37NXmzBWk7ROX1H4XaNcWc66vctc3pQiOVm24J75rlfEHwWsrTwcptS8mqoCyvGNxl9AR6fSvaGht9SslCufPjADJnB4qn4j8P3GuT6SbW8aye1kDMAxHmL3BwamOY00knLUp4ad9jwTwR8NrTUPD07ayj214H+RmbaTjqAteqeF9KfQtEhsrG1Mk07bTKvRY/XPfpXVeKvCd3f2UT6YQJ7ZjgnqQRg/Wrnga3a00Ew3a+XHHKRGXPUd8DsM54rbE5iqdNNLcmnhuZttmOI7yyt5o7RPPu8b0Vj19a3Esze6aryIkV6EDEDnB+tGtCCKOSaJmURjc7hAdmffNUU1wabpa3N44aJiFD9N2eg5rgqY2SacUdMMKpI27azVbS28wkSDr9atwaf5srMAGTGDn19ao2N9FIgkclWfoDzitW31K3VxEbmPzCcYz3rKjjJN6oVbDW0K8lmbUEnMiMMAHqv0rOW1b5nCrhTkP0NdNcxmaPG4gjuKxL1LoSr5du3lng4r1MNWctDhrU7K43TtRkKmBcLtbpXT2kySxLtwfX2Ncq9sEPmOu2fGD6GptPu3guOTmM966WubVGKaW51uARSMgIPGaZDMJEBBFTVFikcx4l8NWOsxBLu3SQeuOR+NePeK/g1p0k0klmgQEcKex+tfQrKCOlUrq3DdMfjSshqco7M+F/FPw51GykkCLLsB/3hXmd/ZzWVw8U6FWU9xivvnxBo255MngfNkLXkHxI8D296Gn+zKzEc4XBrSCT2LlVv8R8t1b0n/kK2X/XZP8A0IV0+r+C7q3u5BEuyL+ENWFb2U9lrVnHcIVPnJj0PzCqcGtQUk9j62+KEUFp4x1i5wBLIy4PqdiiqHhvTp5dNghkDDqx9yTmr/xLga++Jc9qFZo9yu/oMKtbdvE8QAgyPpxj2r47FP8Aey9X+Z9fQdqUPRfkPgspdOUK52LjI96hnka4m3sd6jpkYxV+SymvNMe8MmI1YKdzfeNQ+UIlJrHkkt+o/aJ631K5VNnzisbVLhYhhevpU+oXmAwQ/hXNX9xzmRuO+OtWoX0JcrashnkaaRgp59TWJeTIZTHE27AyWHTNM1LU3lzFCgjTPbqfrVGMlIJnYjpgH3raNOxk5uRFK/Vj1zUeC464psRGG3HNEPy55OM1UtDaCuPdAFBx+NROq4GSKfcuRGGwfpUe3dGGxjPbFSnc0sRuFPBBqKRCBlc49asrgq6nlsYFIY9pUAEjvTvYVimkZZvmY01oDyQTgVpLGrHptNIygN8gJFPn1JcSGJWKAAcChwRIWwcCrsQAJqUxMy9tvrU82pPQzgjPllz1pkyyeoPfHpVx8IpAOPeqLEtK5yemKqLCQ+GSRRuVioHoavNqcjwiGe3glAHDkENVNAqxEfxelG3zCCpJx1zTTsJq4OIZCSuYpM8L2qAxfK2RntkGmsxaTbgHHep4+UHY+nrV7Ep3ZTMO3PXBohUK4INav2OZ4zmFhkZB7VmvG0cvzcVcJX0M6kdDqtFmBjXnkV2Gmy7lAOK860edRNsJC5/Wuz0uYx7dx5qKkDnTszW1PSo50LKOa5HUtMZA2Qa72GUhAeDGRz7U+bTlu4WZVB4rlbsdcJHldndT6dIdoLRH7ymvTvhI6XHivTLiMbkLsoI7HYeDXG67pbQMcL19qvfBwSw/ErR0V2VGkfcueD8jdq0w9pVYvzX5lVv4UvRn1fRRRX1h8ofIH7b3/I1eGv8Aryk/9Dr5sUZIHrX0n+29/wAjV4a/68pP/Q68B0GwS7MzyEful3bT/FSbsVCPM7IZBaCYKlujNID8zZ4I9hXW+HLDfdR2ghXewyd3GKp6VYzWsTTxAHHbrz6CvR/BXhibV7NL29jHmyjzQ7Nt2AHgcdzXJVqXWh61KmqZv+GNFt7Fr65vZI1tIEVVjVATJL12j3+lejeB9OSDS0e5RmuZGMjFznbnoAPas6303SNNsoZpFijEY3bmfJUnqee9cR4s+JzKxs9BZVjXhpR3+lcrm0W6bqao9K8WeNdN8NQsu5ZbkDIQHp9a8D8a+O9X8UuYzO0VoWwI0JCn/GuO8S6/cX0zLJKXYnkk9TWpp0cSafYpgO4bzHIHSrUWkpzI5FeyOn8AaBa3GpQxzKzu43B2HU17lbaCLCxZ4hI+BzGG6e4rhvh1axGynnYmaINzGPvJ7qa9LsZZWsZEh82XP3S3Jx6Vk63K/MwqRc9DndOvmt9VVLOImDOZBnJGa6j7O6XglsWBR8FoyOVpND8Pi3d7v5TK5BbI5P1rf1PTd9r59mfKuQp2spxivPxuIdeLhBmtGEack2RQaQrXy3UaGNWX96D6+taFvNYNeeSsv+koN+wnBI9ea8L+IHxmbwsklhZX0WoamFH+rYPHG3fcR39q8H8c/ErxD4v1SO8vLo2vlx+WkdoxjUDv0OSTUYPLqmIXPNW83/kLEVVT93mv6H134y+M/hHwvcva3d+Z7lQcw2o80g+hI4B+teCeKf2jNbvb28XQ7K2tLCVNkYmXfInq2QcZrwlmLEknJPOTSV79PA04/H7z8zgdZ/Z0Olm8c+J5re4gk13UDDcHMqeccN9ayZtX1GYDzb+7cBtwDTMcH169aoUZrqUIrZGbnJ9Tq7D4g+KbPaseuXxRRt2tJu49Oa9C8CfGERmG18Uwm4ZMLHegkuADxu/xrxKprSZ7e4SWPG5DkZGRSdGE9LFxrTj1PvfQfF66xcQy6TOt3pwCqzo33X64561r6jpl5JrC6hZX7wwFPniLcZ9q+Q/hB4vuPDWqxy3NzI2kyyZuIAM7mx19se1fXXh28fV9l9a3EUlnJGB5Sncje/1rlnSeGnfoaNqrG63LxMt1ZxXaRM0mNrAdsHGaYQrhgv8ArF6g9vetW/Qi0WKAm3wuQVHArNs4vPKSMwLE4IFdlOV43POmrM0tIk+VVYjnpW0pytYKWzRnIIAU5rZt2yoz6VN7stEx96idc1KaafpQBlX9sjqfX2rjdes12ssikg8A4rv5gMcjmsu9hDAnApxbi9CJeZ4lruhQk5cD2ryLxXoCy6jA8ZGY50I9vmFfS+sWSZcrGvPXivJfGemRNewyRja4lXIU4/iFdlOfMrMxtyyuj0XxVZlfHWr3Un8TKqn0Gxao6hf+XCsaD5m4Hqa2fiBOltr187nuD/46K47TzLdT+dcdf4c9hXwOJu60/V/mff4ZL2MG+yN/T3kS2WKSRjHu37e271o1G5+UjJoYLHH2xisy4kDB88KOvvV002jGckncyb+4YA7QeK5vWZjGMOCHIzgmtLVbwqcpgbRXG6teEhmZs/jXZTpHLOoQtPzuUfjUl7MIbOAPyZCWrIjmd1AQdT0qe7kaWRUb+BQAK0lCxVN3ZZjcOw4wMc1PGFLDHQ9KpwkYUY5PWrTAqoCjkYrknud0SW4AmKADBxzTp4yIVGeMdRSRNuCkgBs1Ow3DGOQMcdxWV7GhRAwQHPy+tSlAAMYwKk8jcxBHzY4poBR9vGB1zVc19hNAhG7DdDSzEKM7e+Kh2tk5HHUVYVAYx1P1pPTUkqJNiTCjrTpZp9jIrsoHbNOWLEowOSKWZMq2T7VehnbQr4IQE8n61UlcebkVoum2HJHy4qjHEGYkVpF7ky6D9xKD1pBIY1bGeRTgnykHoOlRzZCYFNbib0ILZCXb5vm61p24DMEf5QeMnnmqMKhTl+WPSra4AA6nrVSZMVoaEd7cWcxMN0+VXaQrnBHpV25j0/ULCMxqY7gjBYnGG9MY71zk33cjpn8qSK5cSxkOVdWDAjuR0pKOt4kyHTW9zZTfvY2QoeciuysZVa1in7EZp0+sw6/o0WnX0UFvehxi5/vg/wB6sSIzWUU1qMtGjEbxyv4Vqpcy1ORqzPQNOmUopJ3I1dHpTAHZwR2rzXw/fFX8t2PXvXdaVcruBXrXJWgawl0Ler6Qk3zEfK1ZXgLSGs/iRpD7SFEj/wDoDV2cbLNCp/MVb8OW0f8Awk1jIFG5WJz/AMBNRh3++h6r8zSpU/dST7M9Nooor7A+aPkD9t7/AJGrw1/15Sf+h14h4UhuGdghVIX4ZmFe4ftu/wDI1eGf+vKT/wBDrzjwBpyXNnB9mieads7w2PLH/wBesqrtE6cKk56nZ2mlR6H4d/tNZIZbuU+XEsnLMx4AVa3tPiuPB+giTUpCjhQ8jN1JPYVf0vQ4bREvb8pK0I3IT0T6V478VfGkmvaibaFyLaE7eD1Nc3srnf7SzuxPE3i6712dkRilpuJWNT+prFeUxws3HpmsSxY7wOuetaN+5CKByqjJq+VR0RSqOUbmdbKJdRBmOEByfeu38MRpqGo74X8uzhIDuw4xXn0cTzynb3NexfDeyt0hhiki80KC5jJwHI9aWIkoRuznpqTu0d/pNyNNkgtbRo8Ou8snQg/rXeeHLuSSUwumNw4OOhrxJtSi1TWkmWF1nEgKxRDd5YBxwR29q+lfCdpBPp1vcSxgTbOg/wAK+XzHCVfbKdOR3068I0rSQ5nsdO015r6fyYFG+WZz8o9ee1fLnxl+Meo6nqFxpXhW+kt9DX5fNj+V5vX5uoX2rsf2qvGF/p8dt4bsykNtcp5s5H32GeB9K+YpJC64PrXuZfg9Paz18jy61bdIazliSxyT3puaSivYOIKKKKACiiigBV61p6VYNcuOmDWcnUV6B4O0wzyQ4U4cjBruwlJTeplWnyK5o+FvCdzeyrHBGze+OK+ofhXpOoaJpq6fcCQwH50Y9FHpT/hV4Rht7CKeRVbbzyOSa9W8tRGFAGAOlGNqQkvZpGGHlUb52zJu0LRmM7R8vejTLBbZGcjl+cHtVu4gRwS6bsdh3qC/vIbYpG52gjAwDXlxT+FHRJ9WPuVUhtvHqaZYOTGpzkZxzSQzCSTOBtK/nQDsLY9ad7OxK1NMc0EcVHA+9Ac0859aopEMoPYc1RuMKjFh0rRes+7PB44pMT1OX1VRglcV5J44QG/jZVwA65bp/EK9T10hM43Z/u15b4qlWS+ghkwqtKuPrkVrSndkun1Oh+IgkufG9+h4iidf/QRVi6u47swvHbrDDEgRVAxn1J96ueN493izUOM5Zc/98isZWblcfL2r5GtJqpOK2bf5n2UGnSg+yX5GgGimT94pO7CqEIyD7+1ZWs3VrZlVg2uVBDbu7VHcSGLc3RiMA1yutT/KSMgmtaSuc1V2ZiazemWZ9rHNclfStK+Peta+kySfxrGlGZQRiu2Ktqc27Nawt4zdREkKvl7jz3qrJhrh3Q59qLdn2SMwAO3C0scbK3TnPWsZs7KMdSdE3hTjoKtLwhLYOBUTZCjpmk37lyTznpXI1c7EyYYXlRn61Ygk3MQeO1VN3r3HNSLhSOgx0IrNxLTL6pzzzTngEuSuFYVHCwkTDHHoRU0TOrEMAfRhWWqKIpIt2A4AbpmoWbyzggqynGe1XZbiJIjvA2dya5rV9eQsy2gDP0LHpW1GE6r5UjCtVhSXNJmzLEFPmDkk5x/Sq9xcQIrL5iKx55NcfcahdXBPmTNjpgcCqbgscsST713wwEn8TPNnmUfso7aa+gkidFlTgcc1EJEf5EOQRjiuOxxxTonkjzsdl/GtfqNtmZrMXfVHYqQrOOoFQhfl3ScA5IrEtNTmjOJhvHc45rYSdLlU8s59vSuedGUHqdMMRCotGCKCwIBxU5BdflXgdTVuK2BAwBjFQXCbOlZXuzbZFC4cglV5X0FQAHJHepgjFs96ULg55zWyskZvUt202+HOPmX71ei+Bvs2qQpZ3TRBQCp3r1B7givMlYwzbgvyN1re8N3htL+LnMO8bCOo9qznGyujOSRe1SyOk6vLbGRWMb4yp7V1ehz7hG3JrJ8WxRXGopPCoQuo3gnq1WNAYjbG3Y9KuouaNzGDsz0WyYLHkkevNb/hzbJrtk4yCCePwNc3p4URj5OcV03hY/8AE3tcYxk/yNcVFWrRXmvzN6z/AHbfkz0KiiivsD54+Qf23f8AkavDP/XlJ/6HXKfDC8trHRoJZHVAMlzXVftvf8jV4Z/68pP/AEOvnRL64S2MCysIj/CDSkrm1GooN3PZ/ij8S7SfThpmgzl2cYmlHAHtXibSMzksck96jNFCSJlVcjQsid+B3q7eylYHUnjpVDTiN/NWdRI8rjvWTXvHbCX7u5Ss5nS4Tae9e0fDm0a9vTLGCZY0yGD4EQHUsO+a8WskLzqBxk16xoeojS/C94InEc7gZkB2kCs66TZNHm5D1XTLLT0e9+wW8VrqcTCaTaM+Yh6la9i8IWrx2ocMzRuAy7+SOK8D+G0kV5eQXeoTuqRofMkwdrJ3yemK+j9Emtp7GFrJla3I+Vl9K8TEyjGfIjaTfsz4y/agnuLn4o3jzH93GqxRrnOABXkJr6S/aH8PrfW+q6jHa7b2C5D7lHWPGD+NfNpr6SEFGEbdjy3K7YlFFFMQUUo60GgA7UlFFAD4zhga9M+Hd6I7m2J/vAc9q8xHWtrQ9Ue0kA3YGciu/B1VGVmY14c8bI/QTwDqds+hoPMQEEADPJrrnmRUGXUZ96+KPDXj65sxGizk45+leieFviJc6t4ggtmk3If7x4NPE4W16iehz0akk1TsfRkUyySMEIOB1FVNRgP2Z2dBI/c9MCqfh1zJpn71iOTz0NZ+r3a2cvmrcsxkb5Vzx9K8enPneh21I8ujLazpbpEWf5iQB7VKspJYHqec5rC1Bt8K/Phgu75TWlCriKJiRjHHrWlR8rXmRBNpnRWhymfWpzUFnkxqTU7mmxIjk6Vm3jhVJLce9aDnjrisTVX2qzEcDpWcp2KUb6HMa/Nvb5ckL1Iryvxk+67tiB0lU5H1r07WZG2GQELkd+leJfER7qO/s5Y5V8sTLkZ4PzCrpuyuaKF3Y9d8bqR4r1Ag/wAS/wDoIrGYfLuJxjtW941JHii+wOrL/wCgiuduZMoR0NfNV1+9l6s+jpSvTivJGTqE53EA5A9q5bWZiynPaukuEJDe1czqqglga2oROes9TlLpvnORwaqCJZJ/kzitG7j5I7VVhGyRsV1S0Qqe5KsEghdxGSoON3pTxIMKQeD29KbO+YkAbaep561Fvwo+uK5Jq53U+5ZJ3c96Xj7zLz6U1GyATxx1pDIFwdx9M1jax0IcFbOR+tSq4HYjIoUgrwQafHtAJ6k9qhvuMkhAPUZB9KW5uhawlzJwOme49Kafk+cDHrg9K5/W7vz7nywxKR8fU1dGj7WdjDE11RhzdSDUdQlvWIYkRDog/rVDbgU/AJoK17dOCgrRPnZ1JVHzSIcc9KXGelP2c05V5q7kDVj45pVjGelT5BAGMY70+OOp5gGRxHBqxaQypJuiUnHUCrtlAG4PWtrSraSKbMHBYbSMZyKxqS0Li9bofpkgkhLjjAxj0NJPEXJYDNdBp/he6T99sba/XC0alpxtsDH6V5c7KWh61Orzx1OUkiYLjAwKgVc9a1Zo13EPuP07VQZG3EDtVo0UindBjH8ucCrWjtuhMbHk8g+hpJV+QiqkMpRvlOOa2iuZWMakuV3PQEkW4gjM6fNs2k57+tXdG/4+ANu0A9M9ap6O1vJGiSk5eMbTjGDW3ZWphuowwO49c1D2sZI7DTlfYPSuo8MKP7XtiPU/yNc7p6kqOBj610vhkY1W3+p/ka46a/fw9V+ZrUf7p+h3lFFFfXHhHyB+29/yNXhr/ryk/wDQ6+aq+lf23v8AkavDX/XlJ/6HXzVQAUtJRQBcsmAccVav/uD35rPt22vWncbZLcHPNZS0Z30XzU7GXFIY5Aw7HNd7oqLrOmTwNkNtDDHcDtXn7DDGuu8EXvlzrEG5z0HGR3rPEpuHNHcnCS95wlse6/Dq3gh8Px29xHbiCZghjJ5P1r33Q2SPT44IU2KgAAxXivg6KztITPfRqtvAN6NjpnvXpGha5NJer5SrJYOAFkUcj6+lfJ1MNNVPbJ6Pc9KtNTjyW2PIviP43Ph/4l6romtwZ0W+CvvccoSOq8dM15hdfDePVPE81ppGpWMaSr58CNKD5qHn5CO/sa9O/ay8LzXNrYeJbZY2jiH2edgPmIPQn2r5kjnmhmSWKR0lQ5VlOCv0NfXZbiFOhHm1toeHXp8sm1pcsa1p76VqdxZSsGeFypIGM1Qqa7uZryd57qVpZnOWdzkk1DXRK19DNXtqLSUUUhhRRRQAU5W2nNNopp2Auw3skbhgTxXsH7Ph+2+J5bi4c5iT5VIyMnvXigGTxX0t+z9ooiso5JAI1lTc0meevIX3wKjFYiSpNN7m2Hppzv2PobQZXttNla7nUWxPyseBg/WszULLybJ181WQgyKqDJHuD/hV3xPEE0EeQpYIu8IW25x0rF8J3t5rGiRNqTIswk2oFx93NceHbhDmZNa05aGzY2ubG3BXAOMFuuK1dv71EA+7TSYzKqJgJHU9p88pNEajqVBShyRNe2/1YqRuhpqDCClbpXUzBFeUE85GBWHqjqcqmMnjnmtydsLzXP30qIrsxxz37VnyoabOO8QyhIm3LuKjv0rxLxpbma8hlnnKxLIpEY/3hXrviW4SR2ZW+VecnvXhPjjVZJ9ftLKMZiMql3x/tDitoxVrlxlK+h9CeOGC+KL899y/+giuauWBTcetdH46GfFV+Af4l/8AQRXNXEfHB4r5jEfxZerPo6P8OPovyKc65TKmub1OP52yK6qZfkA7+lc3q4wxI4NdVDY5au5yl1uiYn9DVOHqcgcmtG+GVYscmqdvGWnjA5Ga6JbCpvUhvsecqhSNq4571C5CjIHBq7qoAv2HPFVyuR0rlmd9J6BG2FwM49KcG+b+hpsZ2g5PNSIwJO7gdqwa1OgmjAJ5UD2qdEVieo/GoAc4II57VNHg/KwH4GpYEV1Iba1lfjCg9K43eWJYnknNdRr/AMmmy4zzjvXJr0r0MFH3XJnkZlO8lEmRqmWq4pynBruPNLHFNHWm7+KUMKQEq81agGSBjmqaGrtscMD3qJDRtWEGWAIxXp3w+0SO8vovMQMoIyK8501y8i56nivdvhVZMCszIQDwCe9cFZvbuaxSR6hFYWscSotvEABjG0V5n8VNDtYUSe3jEZfqFFeq9a4z4mxB9KRj2OK9DGYaEaN4qzQYab9otT55vV8tmAHseKoWMkEGq2styubZZAZABnj6VrasR5reuaw515IryUtLHqXLHi2ezudWuJNN/wCPdjleMVz0UZEnTmr+0A9KfBEJJTwK3pvl0MKqujpbFRJZQSAHjgH0rrNKcypEzsWYcGsPT4CmjImejZIroNBjH3T9QKie1yYanZaV88WQCMV03hxcajbnHc/yNYGmR7UAC4BrodByuqW49Sf5GuSn/Gh6r8y6r9xryOzooor6w8U+QP23v+Rq8Nf9eUn/AKHXzVX0r+29/wAjV4a/68pP/Q6+aqACiiigBynBrTtP3i7T0xWWOtX7J8MD1qJnThnrYr3cZilIIqzol7JYalDPEqsyt0bvVvUbcypvUEtismFvLnUt2NJNSjYdSDp1Ez6n0W+Oq+FoWswschiO4Z4H4d63PBN9JZ6ktnayIyiMM6Dqx9TXingHxC0ey2WRgkny7e3Nep+FtWayL23lwm7DbVuG+UOPr6ivBrUpx91I9JcurPYta0u38Q+H7jTb6MNBdIUkT0yOo+lfCPxB8MXHhLxTe6TcgkQufLcjG9D0Nfcfh3XLaefyWnQvGh3c8muB+LvgOw8daeZLGeOPVos+Q78bv9k98Vz4LEPBVP3nwvR+Xmc9Sj7VWW58bUlaGs6Xd6RqVxY38XlXMDFHXrz9aoYr6lNSV0eY007MSiiimIKKKKACloA5rf8ACXh251zWbG2WGXyJ5ApkCnGO/NTKSguaRUIObsja+FPhdPEOvxi7hkks0PJU4+btmvp3y9J8A6MqiZI53bKjGWBPQAVh+Evh8PDepyXOnOFt8DZnu3p71o+PrO41zWrVYIraWRVUOsjYUn6gcf1rzIz+sVuZ/Cd80qVNRW/U9J1N/wC1NC06SRv9cisxH06VRgtTaRKE4CN8rev1pEleKWzsEQELGAEH8Pr+FaNzbHYqRgqo69zmtptRjZM44XbHRG4dAYlGWbBJPQetdBpkOAM8/hWJZI24IScdq6azQpGM9cVWGp8q5mTiKik+VFjvTWbrQQfWoZHAHLED6VvcxsRXL/Ia4/WwEJdnLJ3HpXQ3srEEL+HHWuL8REiJ1kk7HgUnrqhp23OH8ZaglvayupGFHHoT6V4frU7SahbySNy8yE49dwruPEerGO/ltLhgYVGYwf615Tr2oCTXbOCJgU89Ccf7wropPS5o1y6H1v43B/4SzUPd1/8AQRWFcRMIzs5rb8bHHjDUM/3l/wDQRWPMpIPNfKYj+LL1Z9DR/hx9EZ4B2ln69BWNq0O5T2HrXRgb4SuCDWVqkJ8vAHaujDs5661OHvbcgNjmqlgh+1RgcfNWxep8xDVnROsNwr4JKnNdm6MI6Mr63AUv5Aeec1TY8DOeB1rc1rbcsJ4zwVwfrWOw2x7e9c00d1KREvzISQB9KRcgdc/Q07A2nHGaapZXARs1jY6U7kgDBcnNToCvJyT9ahVm3YYgg9qsxgFeOG74qGh3K2rJ52nygEHIz+VcmqcCu/SFWGD0Iwc1zF1prRTuqg4Bruwc94nl5hDVSMnkDFNbitGWzdByKpOmM13HmkQNOzio24pAaYizG2Kt2781nxsM8jNTpJ6VnJDWh0+lzqrKSec17V8M/EtvY30EFzMqQONuW4Cn86+fLebpg4rVg1BkABY4+tcs6d3zI1i7qzPtxGDqGQhlIyCOc1xfxO1C0i0fyXmQ3GeEByR9a+dbHxVqMKJDDezohOAoc4ArQutTknTdJIWPcsck1pXxknDklHc2w9BOXMnsQalIHkY1kSMAamuJ9x3VVY5znmuFI73oJnccgVoaVbeZOm3uapxJuwF5NdZ4esT/AKxuABWnQ55u+hu2scX2Nowvz5zWvotozkENtx0x/WqMIJX5RwTiup0ODZGCx/OsZvQqGmpftd8bLHLtGejDvXR6JzqVvj1P8jWW8aTKpYdOtX9ADR6rArHIOdp9eK5qX8aPqvzCq1KDZ2lFFFfXHinyB+29/wAjV4a/68pP/Q6+aq+lf23v+Rq8Nf8AXlJ/6HXzVQAUUVLHE8n3EZvoM0DSvsRirVsDnihLOfqYZMD/AGTV20gJPSolJHVh6TvdmrYjfEM9az9W0wqTJEp2nrWnbLtxitAKHXDKcHvXK6nI7nq/V1WhZnNaTffYSFyd2evpXrXgrUjqr263ckryo21VXAGMdTmvMNU0lkzLbrlevFWfDN/dWFz8rMj54PpTko1FzI45RlD3Ge+NpniWwns7qzV3kVyrYddrJnuK0bn+17DXAsUEsllIA6uF3BHPVSfY1y3h29nuYA8+p7dy4RGbADdq6LwPZ6xHr19qGoXSpp7KAIRLvAI79SK8/GUFVg7F0KzpS946XxX4C0zxl4bWK+ighvW+b7VHHh0P1/xr5d8b/D3VvDOqXsCRPeWluRi4jXqp6EjrX1FfeP7WLWYdHt45f3uMSBAUrporS3uz9of7I5K43Kozj3rhoVsRl8NVddiqkKeId3ofAUkbxuVkRkYdQwwRTcV9teL/AIeaF4mtzcXNrbG4Zs+eqBWJ9MjrXDaj8KvDdvdS+XpwSVIW2Ru58tz6k9jXq0s1hJXlFpnI8E72jI+XsGrFlZ3F5MkVtC8juwUBR1Jr6H+H/wAOIXlutOvNOVQ3zu8qb+M8AHsK9Dsvh5oeiSSCytVEjH5pAMYPqKmtm9OF0kXDAarmkfP/AMO/hv8A2peagmvxzQG3G1UBx856ZPpX0B8MvDaabaRW0dsqqisgcDr/ALRral0uwhtg15Geu/cOjHsT61fm1hbC2jZZUjiyFQhB/SvN562OnzN+72OyU6WGhyQWvc6Sy0i1t7GFd5cRDOCMbm9ayn2R3n7m3VQuSx4JrnofGGpTX91butubWFTmZW5PsB61l+Gb3UrvUri8uGa3sWOI4Zfvv7+1ei37ONrHnRpyqO7Z28dxtb7R8ofGFXvUkOoRl8SMTKewFYM96RLl8bicKtdJoemtMwlkGQe5rahQ5vekZVaiguVGxpVuWIcjj1NbSjA4FMgiEaBQOBUm7BOK7X2RyLuxrk9c/hVK4O4ENziprh/kPOMd6xbu8bDeWuX+mBUdSkiHUpiiHYeR2NcJ4i1KPy3DsFNbWt37rFyADjrnpXknjbW7dIn3SKz9z6VtHUlRuzzzx9e251JyWBZVJBz1rzC1lE2u2jjPM6df94Vb8U6n9t1CTZjaOM+tZuk/8hWz/wCuyf8AoQqkzeXY+3PHRP8Awl+oY/vL/wCgis6FQQNxqXx/dpH421GMt829eAP9hapW7uQCq49ya+VxH8WXqz6KjH93H0RJcJsfKtx/OoruESxAgckVZmBbG4gmliTIOTzRRlyuxFaF1c4jU7TDtkYrnbyLaTtr0HVbYYb5etchqUO0nivShK5xPQxoLgYMcg4P6VDeRMjkjp296SWJt5J4FWLciVPJmOM/dJ7VUoFwmzMGGbPOfSnKpPIOMdquS2LQyYYYPtSMhC4rmmrHbCVyvHExIPar9tCXG4DoOcVCitjIq3ArZ759jWMiy5ZW7SyBEXJzXaWnw/1DUIlnS0Y5HORjNZXhKNTqEJcDBYDj1r6YtFCW0Q9FFdOEpe1nZOx5+Mq8q5bHzB420G7sLMQ3Wkrblfuyg9a8svYgjH1r6v8AjjFA3h6N5HCybsAetfKuqELK4BzzXfyuD5Wec3dXMeQfNUZNSSnJNVy3NVYi5IGxT1kquWoD0WGi8k2Oc1Itzz1rN8zmpEO4gDqahx6lI6PR2MlxubkKK23mIUrxWZpUQhtVB+8eTVmQE9ATXn1HzSPVox5IEoJI570AZ6jNAVgKntoTJIMA4pKIpSsaWjWYldW3fUYruYUjhgWBVw2OTWFpUSWcavLgt2Udq2LFWuZwwyTmhmRu6fbjYmTyGrrbaJVjGByB1rG0i3YYQhcjkntXR2kQ2k5x7Vx1JGr0RNAg2cVd0cA6pb85wxx+RquRtUVPpOBq1qB1JJ/Q1nQ1rR9V+ZlN3izsKKKK+vPJPkD9t7/kavDX/XlJ/wCh18119Kftvf8AI1eGv+vKT/0OvmsHFADo1LuB611ehKLXaQAGrl7aVoZQ64yPUZFdHpc73Eo3Qxhu2wbQT/KsqqujvwTin5nrfhLWbc4iuVQgjnIBFaOreEtC1u2e4t0FvPn/AFkQwD9RXL6NZyW0KG4hZC3Qg5DGuwsdSKWP2cRnIwowOteXKU4M9hRjLY4u/wDh7rFkN8EIuosZBjPP5VgNbTWkvl3CPGRwVdSMV9B6Rf7bmNWQ5C4wa25dJ07V3l+22cEwPd15qXNzQ1V9m9UfOVjAJkaM459s1T1TQZFQyRcqOoFfQMnwt0q63y2Uj20meFzlR/hVI+CL2yPzKkkeMZ25BrnU6tGV7aDnOjWW+p4Fo969ncqs7NtBwB6V6honiJhYPDcTuka4K+UQM+xq1rXw8iuVaaIeTcZ7DiuRutI1TRJWWaFpE6h05z9a7VWjUS5Tz5Urbs1NVurZb+PVbZGljBxLEWxJ74x1o1K51Pzo73T7+4XSbofImCpjGOQ30rkrrxB5abQ/2WVT8wxjcfWppfF1z5MIuP8ASo8425zgetdkaSla5yOUo7Hv/g+/uV8MyW3nwz3VuAVdj9/jj6VhWfiPULi5uZNUsFMjN5YiHQN2JrkdP8WWaWOy0VGkChhnv6j8PSt7Sbmwt9NFxJL5tzO+XJ+Xn6VH1emm7oz9pPdHQ+GPEBi1B7e5gEIceYvmHk/U+vt2re/tUadLINUkj2ygtGD1xXmOpyNOJ5Z45EkPCOgzlfQCix1KW40qRdQVB5eERnfcSPUDqKyqYOhJ8xUatWx3mreI1uNOItoSscZChpMrkH2rDmuXmtY45i8jyPhAMOF9/Ye9c5bajcyaW+nIPMUtyWydgrf0CGKGPZDGIzj5pT95vxom1TXLT1Y6dJz1nojRtbABEll8vzUztVOg9z6mtG1kEpHlnc/qe9TWdm91hLdSwPB4612vh7w1FaorzJ83pinQw1/eqixGIUfdpmf4f0F55knnXgc813lvCkSBVGAKWNVRdqqAKdkY+ld19LI87Vu7FPAzUBfAJNE0oTO44+vFY2paxbWqHzJVHtnmsZTUdWy1FvRItXdyir3964/WtbitVkAfI5wTxWP4j8XuNy2cTucdegrxjxdr17cOxuLgopz8idvxrB4hN+6dtHBSkveNzxz47jijeMSg+ymvCPEviS4v5HWPKxk1p6xLGuXc72Pqa428lDyEjgeldFNt7l1KUaUSoxyc96taT/yFbL/rsn/oQqrVrSf+QrZf9dk/9CFdBwn2V8Q4gfHOpuqkvuXn/gAqnZFnADNgjsK1/HyE+MdTOcfMvH/ARWVaKUP3vmr5XEfxZerPqKD/AHUfRGmkQMf3Rn1pwiYEYwR6UkLkDDHPsKmweMcc1gpWYPXco3cHmKcL+dcprFiRlgK9FMAkhAYfN2NYeqW25ijKM13UqljinC+x5hPBliCKrNFg4xxXX6hpuGO1eM1lvYnJwvTvXbGSaMGmiCIJOgjnOD0VvSql7YvbuFP4EdDVt4CowOcU9HkXCTruj9D2qZQNYVLGITtbaw5p+75hjjFaVzZggtD8y9x3FZ7QMDx0rJ0zf2ho6dfvayCWJgrqQRXo1n8WNRSJEeKFyBjPrXlByvauo0DTLSTTWu7vO8HKgNgU4KUXeO5lUUZfEL438WXXiKL/AEthgH5QOi15LqhZZmVu1dXqcn+lTBAAgc4A7Csi+gSdDuGDjg1vCq0/eMKlBSXunLu5HQ1Ac1curZonwenrVYxkGuta6nDJNOzImNMJqfyyc8ULCT2piRCuSeK2NHszK4kYfKKhsrMyShQOK6m0tljjCKMAVhXnZWR04end3ZJEgwAOlWEjOMjmlSLAwB1rQ02yaVwDkLnkmuNQ6nZKoloRW9m0mODg1qJAlvgAgv8AyrXAtrWHEXL4xk1BDErShgM896ZnuNtIWldRzzxXb6LYbFUAfnWboOmNNcICMAmu8Wygs4wI2DSZ49hXPUmVFW3H2UICgcZ71qIoVABiqduuTkCnS3SxqcnGPeuOTuVJOT0LLNuwMdKboM2/xBCCRwxUfka5fU/FVvZKfnBcdOaxPh94pl1Dx7p9oVOGkfPt8rGqoRftYvzX5lOi+STfZnv9FFFfWnhnyB+29/yNXhr/AK8pP/Q6+fdF0DWNdaVdE0nUNSaIbpBZ2zzFB6naDivoL9t7/kavDX/XlJ/6HXGeDtYsdQ+EkXhyx8V2/hXWLXVWvZ3uHliS8iKAKd8ak7lI+6fQH6AHkEqPDK8cqMkiEqysMFSOoI7GrNldmCQZUOndW6Uaw2/V75/thvt07n7WwIM/zH94Qefm68881WiAaRQx2gnr6UmrlRk4u6Ott9fWK6L2cbpCoHAOee5zXe+H9c81bZrhDASSzzTSDDDttUZNeQ2hyJI2ulhjUFuQSGI7cU6C4/e/vZnC5z96uedFM9Clin1PqDSfEOlGZRFes5C94doz9S2a7HT7qOQK0c24k/lXyxpN/p8UBNzNCnzbl2LmVvq3YV6L4X8aabAJMaqtkMDaEkBP4k1xzo2Z286a3/E+gbC4KBxg9eta8d2vlYAzmvLdE+JOgm0aG41y3c9f3ko/nXRQ+OPDE9qrf27pUfGcGcA/j6VPI0vdOadr+8dvJHbXMIDxo2evFZWoeFrK5XCkpnoDyKzLfxr4ZKxt/wAJDpYz1H2leKu/8Jt4XJ2N4i0k9/8Aj5X/ABo9lfdGSm47M4/W/hFaagzOEiMh/iAxXFap8G5YxiGNGA6cY/UV7VD438M548Q6SAP+npP8ain8Z+Gt+Rr+lH3F0n+NP3oLRsFK71Pm3Ufhrrtpk2ttL8vQpzkVCdE8R2kagxXS4H3dh/nX0bJ4x8PbCBrelMc9rpP8akTxP4bcK39taUcnBH2qPj9aaxFTawOmtz5yJ1+7UJOs+VGMFeKt2Hh7XJNmy2l25z90gGvopNd8MScjWdHyDnP2mPn9atw+IfDYXjW9H/8AAqP/ABpqTlug57aHk+geG9beNYzBDEuecg5Neh6P4OaAg3pOTg4xW/beJ/DTKSms6SQPS6Tn9atxeKfDkhx/belkj1uk/wAa1p6PRHNVnKejJ9PsLWzQBQOK0TdxJwNxHsKzf+Eg8POvy6zpv/gSnH61Rutb0ZTlNX09/wDt5T/GipKp3M4U4t6m8b4kjYmfqcVUu9UuUOF8pB+dc23iXTzJtTULHd6+en+NU7zWrKYndqNoD0+Wdf8AGufnnLRXOiOHity7qN3K4JkuGYDsTXNX9xbmN2J3EdzzioNS1K2K/u7+3J9pl/xriPEGvRWiODfQZPP3wc0o05N3aO6EIJaMq+Kdc+yblQkjr9a8q1rVHuJWaRiPQV0upahb31tJM0ySKATkMOtedXt6k4mImSMKcKCM5rpp4dp3LnXjFaGfqd4WZlJNZDKzIZMfLnGatZt5I2E8riUMApVcrjvVacIsrCJy6A8MRjP4V3Rjyo8itVdRkVW9J/5Ctl/12T/0IVVq5pe3+1bHaT/rkzn/AHhTMT7S+IBI8Z6hk/xL/wCgisWJ23YyTWn8Rc/8JpqR54dcf98rXWaFIV0Dw3iW1Fipn+3iZkxs38ZB5J64xXzU6fta01fr+tj6KFT2dKDt2/K5yUDDaMjk1pQ/KuOoNUCImuZWtci3Dny93Xbnj9KvW+ZF4YAVxdTolsWA7ZA7eoqCa18/O4ZA7mrMSY4/WpzCCBgketaxbMXYwJbOJjtZSCO9Z1xYDPyAc11Usca8kZzVK4RCORjHcV0U6ttzCdO5x8tgE3HHNZ91bs3UcV1s1tvBYHgfrWTcWxzwODXdGakczTicywkt3DKcMO9SLNBcE+aojk/vDofrWnNabieMmqT6dlyTkVdl1FztbFK4sHZSygOvYrWfKLhF8vc+z+7W/HDJbkGNiPamXLiWX97EvA5K8Gpt2L577nLyRHByMsTVC5gIkwPxrqJ47bPzK61AthBNKAshx15FCVhOaZzD26yptZcr/KqD6Uwb5PmFegx+HFkciKdSfSt7TfCUMLrJctv74FVzqBDh7Tc8pi0C5kXKxEipl0KRQNynP0r3a0061xtWMAe4rF1mwEUhEaqB2qfbtsPYRR5Va6W8TnCk1s2mkXUoyU8tfU8VvsksUgb5Q2fSpZpml+XPTilKTZUYpaFOx0yFMeY25x6VqSRKIlRAEA7CqyKVcY61dj5xnJrNvqU0QmHKD1/nW3oukPOM+Wdo6mksbLzGBI4rpbcmKJYs4UVjUnYqMLsmVQkccYWNVTgFVxn61oxAKuePxqrY2013N5cKF/p2rS1/7DoGjPLe3ANyB8sYPesI0qla7itEaSlGFo9Spd6rHZwksQDivNvE3jBnd4rfLM3AxWbfatfa9dNDZqxH+yKgGkyafD58q/vs4IPNYu0Tuo4e2rKF9ZzF1lvZ1fK7wqngexrqPhTK7fEHRxgKm9+F6fcauUmE1xLlvujgV1fwqyPiFo4XGBI4b/v21OhK9aC81+ZvXglRm/J/kfTtFFFfWnxx8gftvf8AI1eGv+vKT/0Ovmqv081zwvoGvyxS67oel6nJEpWN7y0jmKDrgFgcCs3/AIVz4I/6E3w3/wCCuD/4mgD81aXBr9Kf+Fc+CP8AoTfDf/grg/8AiaP+Fc+CP+hO8N/+CuD/AOJoA/Naiv0p/wCFc+CP+hN8N/8Agrg/+Jo/4Vz4I/6E3w3/AOCuD/4mgD8180mTX6U/8K48Ef8AQm+G/wDwVwf/ABNH/CufBH/Qm+G//BXB/wDE0AfmuCR0pwlcDAY4+tfpN/wrnwR/0Jvhv/wVwf8AxNH/AArnwR/0Jvhv/wAFcH/xNAXPzaE0g6Ofzo8+X/no351+kv8AwrnwR/0Jvhv/AMFcH/xNH/CufBH/AEJvhv8A8FcH/wATRYLn5tefL/fNBmkPVz+dfpL/AMK58Ef9Cb4b/wDBXB/8TR/wrnwR/wBCb4b/APBXB/8AE0Dufmz5r/3zR5sn981+k3/CufBH/Qm+G/8AwVwf/E0f8K58Ef8AQm+G/wDwVwf/ABNFkF2fm158ufvml+0S/wB81+kn/CufBH/Qm+G//BXB/wDE0f8ACufBH/Qm+G//AAVwf/E0Bdn5uC6mH/LQ0ou5x/y0NfpF/wAK48Ef9Cb4b/8ABXB/8TR/wrnwR/0Jvhv/AMFcH/xNFhXPze+2T/8APT9BR9sn/v8A6V+kP/CufBH/AEJvhv8A8FcH/wATR/wrnwR/0Jvhv/wVwf8AxNFgufm59qmJ5eg3M39+v0j/AOFc+CP+hN8N/wDgrg/+Jo/4Vz4I/wChN8N/+CuD/wCJpWQ7s/NozSN1Y0wsT3r9KP8AhXPgj/oTfDf/AIK4P/iaP+Fc+CP+hN8N/wDgrg/+Jphdn5r5PrRk+tfpR/wrnwR/0Jvhv/wVwf8AxNH/AArnwR/0Jvhv/wAFcH/xNAj81sH8KSv0q/4Vz4I/6E3w3/4K4P8A4mj/AIVz4I/6E3w3/wCCuD/4mgD81at6T/yFbL/rsn/oQr9H/wDhXPgj/oTfDf8A4K4P/iaVPh34KR1ZPB/hxWU5BGmQAg/980AeZePgG8Z6mCOjr/6AtYyRhuOhr6Bn0fTLid5p9Os5Zn+87wKzN9SRTf7D0n/oF2P/AIDp/hXkVcsdSTlzbnq08yUIqPLseG2ySYwSa1IBsUAV7ANI00dNOsx/2wX/AApf7J07/nwtP+/K/wCFZ/2RL+b8Cnmaf2TyiCRmbgcCrak9+TXpo0vT16WNqPpCv+FOGnWQ6WdsP+2S/wCFNZVJfaIeYRf2TzExkryMms3ULOZyNjYU17D/AGfZf8+lv/36X/CkOnWRHNnbH/tkv+FDyqT+2EcxS+yeJwRFCV6kdqkmtxMC2zHtivZv7K0/OfsFpn/riv8AhQdL089bG1/78r/hWlPLpw+2TPHQn9k8MeyCMMqDVa5s8NkIea97/snTf+gfZ/8Aflf8KDpOmnrp9mf+2K/4V0LCS6yMHiV0R85TQHdyOaqzWvfvX0odE0onnTLE/W3T/CmnQdHPXSrA/wDbun+FX9WfcX1ldj5duLNnB4qNbQovAIJ719S/8I/o3/QI07/wGT/Cj/hHtF/6BGnf+Ayf4U/q77i9uux85aT+5OXH410MU26L27V7aNA0cdNJ08fS2T/CnjRdLAwNNsQP+uCf4VnLB36lxxSXQ8Q84hPQg1T1GYSopbqK96/sTSj10yx/8B0/wpDoWkHrpVgf+3dP8KX1J9xvFrsfNU6eZ04qERFeor6Z/wCEf0b/AKBOn/8AgMn+FH/CP6N/0CNO/wDAZP8ACj6m+4fW12Pm+KPLDjnFXYYduOK+hBoGjjppOnj/ALdk/wAKd/Yek/8AQLsf/AdP8KiWBk/tFLGRW8TxO2ICAAgYq3DPCsy/aJCsY+8Rya9i/sXS/wDoG2X/AH4T/CmtoekuMNpdiw97dD/SsZZZOX2vwNFj4pW5TyHXviFa6VZtbaLGIjjBkP3jXmzXk3iDUWbVbqaKIqSG6knsK+oG8L6Azbm0PSi3qbSPP8qfJ4c0SQ5k0fTXI/vWqH+laywVRx5VOyHSxtGnryanzbY6vBoJmj01Q4lGDkfdPtVI3lzek+a5KnnFfTn/AAi/h/8A6Aelf+Akf+FOHhrQgMDRdMH/AG6R/wCFc7ymT+3+B1LN6ad+R/efLc0irGyICz+i8mtv4Txyr8Q9I/dbU8xySTz9xq+iV8M6Cv3dE0wfS0j/AMKmttD0m1nSe20uxhmT7skduisv0IGadLKZU5qXNsxVc3jUhKPLujQooor2jwj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Sphincter atrophy- Angle closure glaucoma. B) Traumatic iris sphincter tear. c) Mydriasis due to surgical trauma. D) Pupillary distortion from congenital Reiger's syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31653=[""].join("\n");
var outline_f30_58_31653=null;
var title_f30_58_31654="Rapid detection of methicillin-resistant Staphylococcus aureus";
var content_f30_58_31654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rapid detection of methicillin-resistant Staphylococcus aureus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Joshua Freeman, MBChB, FRCPA",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Arthur Morris, MD, D(ABMM)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31654/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/58/31654/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approaches to rapid detection of methicillin-resistant Staphylococcus aureus (MRSA) include rapid culture methods and molecular techniques. A number of studies have examined the role of rapid detection methods as a component of MRSA control strategies. Molecular diagnostic methods can reduce the \"turnaround time\" for detection of MRSA colonization, leading to earlier isolation of colonized patients and lower rates of MRSA transmission. Other studies have evaluated the role of molecular and rapid culture methods as ways to rapidly detect MRSA from positive blood cultures.",
"   </p>",
"   <p>",
"    Laboratory tools for rapid detection will be discussed here; the microbiology of MRSA and clinical issues related to MRSA surveillance are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"     \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link\">",
"     \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SAMPLING SITE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior nares are the most common site for MRSA carriage; sampling multiple anatomical sites increases sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Lower sensitivities have been observed for non-nasal sample sites, perhaps due to lower colonization rates or higher quantities of competing flora at these sites. Rectal swabs are likely to contain PCR inhibitors and therefore are of limited utility when molecular methods are used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LABORATORY TOOLS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3335764\">",
"    <span class=\"h2\">",
"     Cefoxitin disk screen test",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, all methicillin-resistant S. aureus (MRSA) isolates carry the mecA gene, which confers resistance to all beta-lactam antibiotics, including cephalosporins and carbapenems. Apart from using molecular methods to detect the mecA gene directly, the most accurate phenotypic test for the presence of the mecA gene in S. aureus is the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    disk diffusion test. Cefoxitin is used because it is a more potent inducer of mecA expression than other agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    and the test results are relatively easy to interpret. The test involves incubating a lawn of the test isolate on Mueller Hinton agar +2% sodium chloride under standardized conditions with a 30 mcg cefoxitin disk. According to the Clinical and Laboratory Standards Institute (CLSI), a zone of growth inhibition around the cefoxitin disk of &ge;22 mm rules out MRSA; a zone size &lt;22 mm indicates that the mecA gene is present and the isolate should be reported as MRSA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32294801\">",
"    <span class=\"h2\">",
"     Rapid culture",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Chromogenic agar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid culture makes use of chromogenic agar, which contains media substrates that change color in the presence of S. aureus; selectivity for MRSA is achieved by incorporation of antibiotics into the agar. Use of such agar allows identification of MRSA from primary isolation plates within 24 to 48 hours, obviating the need for additional subcultures or biochemical tests [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Chromogenic media are used primarily for detection of MRSA from surveillance specimens (nasal swabs, and swabs of the throat, groin and rectum) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/1\">",
"     1",
"    </a>",
"    ]. Chromogenic media has also been evaluated for identification of MRSA in blood cultures with high sensitivity and specificity at 18 to 24 hours (97.6 and 100 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are several commercially available chromogenic media [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"     6",
"    </a>",
"    ]. The reported sensitivities of these media vary widely (50 to 100 percent) and depend on the duration of incubation and the \"gold standard\" comparator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6,8-16\">",
"     6,8-16",
"    </a>",
"    ]. However, after 24 hours of incubation the specificities of these media are consistently high (90 to 100 percent). Prolonging the incubation time to 48 hours improves sensitivity but reduces specificity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many laboratories use a combination of chromogenic agar (read at 24 hours) and conventional culture methods. This approach allows early detection of many MRSA colonized patients at 24 hours, with the remainder detected within the conventional 48 to 72 hour time-frame [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32294891\">",
"    <span class=\"h3\">",
"     Enrichment broth",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel culture method (BacLite&reg; rapid MRSA test) allows a negative result to be reported in five hours, although this assay is not available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/17\">",
"     17",
"    </a>",
"    ]. This method uses a selective enrichment broth containing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"     cefoxitin",
"    </a>",
"    and magnetic microparticle extraction of S. aureus followed by detection of adenylate kinase (a non-specific cell marker). A negative result can be reported after five hours; a positive result can typically be reported the following day. Excellent sensitivity and specificity of this assay for nasal swabs have been reported (94.6 percent and 96.9 percent, respectively), although false positive reactions with coagulase-negative staphylococci (CoNS) can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32294940\">",
"    <span class=\"h3\">",
"     Bacteriophage techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;A novel assay, the KeyPath",
"    <span class=\"nowrap\">",
"     MRSA/MSSA",
"    </span>",
"    Blood Culture Test, uses bacteriophages that replicate only in the presence of S. aureus to detect and distinguish between MRSA and MSSA in blood cultures with gram-positive cocci, in approximately five hours. In a manufacturer sponsored multicenter trial including 1116 samples, the assay had sensitivity and specificity of 91 and 98 percent, respectively (compared with culture) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/19\">",
"     19",
"    </a>",
"    ]. Among the S. aureus samples, the accuracy for identifying MRSA and MSSA was 98 and 99 percent, respectively. The assay was approved by the United States FDA in May 2011 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Molecular methods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular assays utilize target DNA sequences that include regions of the SCCmec element (which is common in S. aureus as well as coagulase-negative staphylococci), together with additional nucleic sequences specific for S. aureus. These two sequences may be either linked (ie, a single target sequence) or consist of two separate unlinked target sequences. Notably, studies have identified an SCCmec variant (SCCmec type XI) that is present in some MRSA found in the United Kingdom and Ireland. MRSA strains with this SCCmec variant may not be detected using currently available commercial molecular methods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Commercial assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of commercial and in-house methods have been described using techniques such as conventional PCR, multiplex PCR, real time PCR (RT-PCR) and gene probe hybridization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/23\">",
"     23",
"    </a>",
"    ]. These techniques allow detection of MRSA within two to six hours. However, the relatively high cost of molecular methods often necessitates batching of specimens, lengthening the turnaround time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"     6",
"    </a>",
"    ]. Given the large number of SCCmec elements and variants, the performances of the different assays vary depending on the strains of MRSA and coagulase negative staphylococci present in any given sample.",
"   </p>",
"   <p>",
"    Assays targeting a single DNA sequence linking part of SCCmec with an adjacent gene specific for S. aureus (orfX) include IDI-MRSA&reg; (GeneOhm MRSA), Genotype MRSA Direct&reg; and Gene Xpert MRSA assay&reg; (Cepheid). The sensitivity and specificity of these assays compared to conventional culture for MRSA detection in surveillance swabs ranges from 90 to 98 and 91 to 99 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/24-28\">",
"     24-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Assays detecting two unlinked target DNA sequences (eg, additional sequences specific for S. aureus that are unlinked to SCCmec) include Hyplex StaphyloResist&reg; and the LC Staphylococcus kit and LC MRSA detection kit&reg;. These assays have good sensitivity but relatively poor specificity for MRSA detection in surveillance swabs (91 to 98 and 83 to 96 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EVIGENE MRSA&reg; kit detects mecA as well as two separate sequences specific for S. aureus using three specific DNA probes. It is available in parts of Europe but not in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/32\">",
"     32",
"    </a>",
"    ]. Unlike molecular assays that use PCR, this assay does not involve an amplification step. This assay showed sensitivity and specificity rates in excess of 99 percent for detection of MRSA in blood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     \"In-house\" assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of in-house assays using real time PCR have been described. One widely studied method uses immune-mediated capture of S. aureus onto magnetic beads, followed by multiplex real time PCR to detect mecA (within SCCmec) and the S. aureus specific femA gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. This assay was used in two studies evaluating the utility of molecular surveillance techniques for universal screening of surgical patients and as part of a strategy to reduce MRSA infections in intensive care units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Compared with conventional culture, the sensitivity and specificity of this technique was 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The positive and negative and predictive values of molecular surveillance methods depend upon the prevalence of MRSA in the population. The high sensitivity of these tests results in a high negative predictive value, particularly in low prevalence settings. Therefore, negative results are useful for exclusion of MRSA in low prevalence settings. Positive results, however, require confirmation by culture before a definitive diagnosis of MRSA colonization can be made. Conversely, in high prevalence settings, assays with high specificity may be used to definitively identify MRSA carriers, because the positive predictive value will be high.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Blood cultures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Molecular assays such as the StaphSR&reg; assay and the EVIGENE MRSA&reg; detection kit can reduce the time to identification of MRSA in positive blood cultures that reveal gram positive cocci in clusters. Sensitivity and specificity of such assays have been reported to be greater than 90 percent when used in this situation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/32,37-41\">",
"     32,37-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Cepheid Xpert",
"    <span class=\"nowrap\">",
"     MRSA/SA",
"    </span>",
"    assay has excellent sensitivity and specificity for MRSA (98 and 99 percent, respectively) and MSSA (100 and 98 percent, respectively) when used on positive blood cultures with gram positive cocci in clusters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar findings have also been reported for many in-house molecular assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/43\">",
"     43",
"    </a>",
"    ]. Molecular assays that have not been validated for use on blood cultures may have unacceptable sensitivity due to potential PCR inhibitors present in blood culture media.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selection of rapid detection technique depends upon whether the assay is intended for active surveillance or rapid identification of MRSA from blood cultures. If used for active surveillance, selection depends in part on MRSA prevalence in the population screened; it is prudent to avoid molecular assays with low specificity. If used for rapid identification of MRSA from blood cultures, an assay validated for this purpose should be selected. Users of commercial methods should also be aware that MRSA strains carrying the novel SCCmec type XI may not be detected using the currently available commercial assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31654/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, selection of rapid detection technique depends on the hospital's logistical needs and capacity to batch specimens, the technical expertise of laboratory staff, and financial resources.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/53/11094?source=see_link\">",
"       Cefoxitin",
"      </a>",
"      disk diffusion testing is an accurate phenotypic method for determining whether an S. aureus isolate is methicillin-resistant S. aureus (MRSA). A zone size &lt;22 mm indicates that the mecA gene is present and the isolate should be reported as MRSA. (See",
"      <a class=\"local\" href=\"#H3335764\">",
"       'Cefoxitin disk screen test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rapid culture methods that utilize chromogenic agar allow detection of MRSA from active surveillance specimens at 24 hours with high specificity, but lower sensitivity than conventional culture (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Chromogenic agar'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A novel assay, the KeyPath",
"      <span class=\"nowrap\">",
"       MRSA/MSSA",
"      </span>",
"      Blood Culture Test, uses bacteriophages that replicate only in the presence of S. aureus to detect and distinguish between MRSA and MSSA in blood cultures with gram-positive cocci in approximately five hours. (See",
"      <a class=\"local\" href=\"#H32294940\">",
"       'Bacteriophage techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The anterior nares are the most common site for MRSA carriage; sampling multiple anatomical sites increases sensitivity (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Sampling site'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In general, molecular methods can detect MRSA with high sensitivity within several hours. Most techniques can reliably detect MRSA from active surveillance specimens. Several commercial assays have been developed for evaluation of positive blood cultures and show high sensitivity and specificity although only those assays validated for this purpose should be used. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some molecular methods may have poor specificity for MRSA when used on specimens containing mixtures of S. aureus and methicillin-resistant coagulase negative staphylococci. These assays have limited utility in definitively identifying MRSA carriage in low prevalence settings. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Molecular methods'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical issues related to MRSA surveillance are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=see_link\">",
"       \"Microbiology of methicillin-resistant Staphylococcus aureus\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=see_link\">",
"       \"Prevention and control of methicillin-resistant Staphylococcus aureus in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/1\">",
"      Reyes RC, Stoakes L, Milburn S, et al. Evaluation of a new chromogenic medium for the detection of methicillin-resistant Staphylococcus aureus carriage on nasal and perianal specimens. Diagn Microbiol Infect Dis 2008; 60:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/2\">",
"      Bishop EJ, Grabsch EA, Ballard SA, et al. Concurrent analysis of nose and groin swab specimens by the IDI-MRSA PCR assay is comparable to analysis by individual-specimen PCR and routine culture assays for detection of colonization by methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2006; 44:2904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/3\">",
"      Rohrer S, Tschierske M, Zbinden R, Berger-B&auml;chi B. Improved methods for detection of methicillin-resistant Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2001; 20:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/4\">",
"      Desjardins M, Guibord C, Lalonde B, et al. Evaluation of the IDI-MRSA assay for detection of methicillin-resistant staphylococcus aureus from nasal and rectal specimens pooled in a selective broth. J Clin Microbiol 2006; 44:1219.",
"     </a>",
"    </li>",
"    <li>",
"     Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Second Informational Supplement. Clinical and Laboratory Standards Institute, Wayne, PA 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/6\">",
"      Malhotra-Kumar S, Haccuria K, Michiels M, et al. Current trends in rapid diagnostics for methicillin-resistant Staphylococcus aureus and glycopeptide-resistant enterococcus species. J Clin Microbiol 2008; 46:1577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/7\">",
"      Pape J, Wadlin J, Nachamkin I. Use of BBL CHROMagar MRSA medium for identification of methicillin-resistant Staphylococcus aureus directly from blood cultures. J Clin Microbiol 2006; 44:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/8\">",
"      Compernolle V, Verschraegen G, Claeys G. Combined use of Pastorex Staph-Plus and either of two new chromogenic agars, MRSA ID and CHROMagar MRSA, for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007; 45:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/9\">",
"      van Hal SJ, Stark D, Lockwood B, et al. Methicillin-resistant Staphylococcus aureus (MRSA) detection: comparison of two molecular methods (IDI-MRSA PCR assay and GenoType MRSA Direct PCR assay) with three selective MRSA agars (MRSA ID, MRSASelect, and CHROMagar MRSA) for use with infection-control swabs. J Clin Microbiol 2007; 45:2486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/10\">",
"      Cherkaoui A, Renzi G, Fran&ccedil;ois P, Schrenzel J. Comparison of four chromogenic media for culture-based screening of meticillin-resistant Staphylococcus aureus. J Med Microbiol 2007; 56:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/11\">",
"      Perry JD, Davies A, Butterworth LA, et al. Development and evaluation of a chromogenic agar medium for methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2004; 42:4519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/12\">",
"      Nahimana I, Francioli P, Blanc DS. Evaluation of three chromogenic media (MRSA-ID, MRSA-Select and CHROMagar MRSA) and ORSAB for surveillance cultures of methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 2006; 12:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/13\">",
"      Louie L, Soares D, Meaney H, et al. Evaluation of a new chromogenic medium, MRSA select, for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2006; 44:4561.",
"     </a>",
"    </li>",
"    <li>",
"     Hansen, M, Silvis, W, Kaiser, P, Lehn, N. Comparison of four different MRSA-selective plates for MRSA screening, abstr. 2719. Abstr. 46th Intersci Conf Antimicrob Agents Chemother, September 27-30, 2006.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/15\">",
"      Stoakes L, Reyes R, Daniel J, et al. Prospective comparison of a new chromogenic medium, MRSASelect, to CHROMagar MRSA and mannitol-salt medium supplemented with oxacillin or cefoxitin for detection of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2006; 44:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/16\">",
"      Ben Nsira S, Dupuis M, Leclercq R. Evaluation of MRSA Select, a new chromogenic medium for the detection of nasal carriage of methicillin-resistant Staphylococcus aureus. Int J Antimicrob Agents 2006; 27:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/17\">",
"      Ohara S, Malhotra-Kumar S, Haccuria K, et al. Novel rapid culture-based detection method for methicillin-resistant Staphylococcus [corrected] aureus. J Clin Microbiol 2008; 46:3181; author reply 381.",
"     </a>",
"    </li>",
"    <li>",
"     O'Hara, S, Gregory, S, Taylor, D et al. 2007 Evaluation of the 3M BacLite rapid MRSA test for the direct detection of MRSA from nasal and groin surveillance specimens, abstr 540, p. 162-163. Abstr. Annu. Meet. Infect. Dis. Soc. Am. Infectious Diseases Society of America, Arlington, VA.",
"    </li>",
"    <li>",
"     file://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=9fbfe494-6945-4d38-9ccb-1599f6c8cdaa&amp;cKey=0188c349-3ec7-483d-aa67-0ff29c684149&amp;mKey={93AEED6A-54D4-4EF6-99BD-A9B3CE9FACD9} (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm254512.htm (Accessed on June 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/21\">",
"      Garc&iacute;a-&Aacute;lvarez L, Holden MT, Lindsay H, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis 2011; 11:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/22\">",
"      Shore AC, Deasy EC, Slickers P, et al. Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55:3765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/23\">",
"      Carroll KC. Rapid diagnostics for methicillin-resistant Staphylococcus aureus: current status. Mol Diagn Ther 2008; 12:15.",
"     </a>",
"    </li>",
"    <li>",
"     Eigner, U, Holfelder, M, Wild, U, et al. Evaluation of a rapid molecular dipstick assay for the direct detection of methicillin-resistant Staphylococcus aureus in clinical specimens, abstr. O-21. 17th Eur Congr Clin Microbiol Infect Dis., 30 March to 3 April 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/25\">",
"      Holfelder M, Eigner U, Turnwald AM, et al. Direct detection of methicillin-resistant Staphylococcus aureus in clinical specimens by a nucleic acid-based hybridisation assay. Clin Microbiol Infect 2006; 12:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/26\">",
"      Paule SM, Hacek DM, Kufner B, et al. Performance of the BD GeneOhm methicillin-resistant Staphylococcus aureus test before and during high-volume clinical use. J Clin Microbiol 2007; 45:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/27\">",
"      Rossney AS, Herra CM, Fitzgibbon MM, et al. Evaluation of the IDI-MRSA assay on the SmartCycler real-time PCR platform for rapid detection of MRSA from screening specimens. Eur J Clin Microbiol Infect Dis 2007; 26:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/28\">",
"      Wolk DM, Picton E, Johnson D, et al. Multicenter evaluation of the Cepheid Xpert methicillin-resistant Staphylococcus aureus (MRSA) test as a rapid screening method for detection of MRSA in nares. J Clin Microbiol 2009; 47:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/29\">",
"      Levi K, Towner KJ. Rapid detection of methicillin-resistant Staphylococcus aureus from screening enrichment broths by real-time PCR. Eur J Clin Microbiol Infect Dis 2005; 24:423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/30\">",
"      Daeschlein G, Assadian O, Daxboeck F, Kramer A. Multiplex PCR-ELISA for direct detection of MRSA in nasal swabs advantageous for rapid identification of non-MRSA carriers. Eur J Clin Microbiol Infect Dis 2006; 25:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/31\">",
"      Wagenvoort JH, van de Cruijs MF, Meuwissen CT, et al. Comparison of an enrichment broth-enhanced commercial PCR procedure versus bacteriological culture for separating non-colonized from suspected or colonized MRSA individuals. Eur J Clin Microbiol Infect Dis 2007; 26:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/32\">",
"      Levi K, Towner KJ. Detection of methicillin-resistant Staphylococcus aureus (MRSA) in blood with the EVIGENE MRSA detection kit. J Clin Microbiol 2003; 41:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/33\">",
"      Francois P, Pittet D, Bento M, et al. Rapid detection of methicillin-resistant Staphylococcus aureus directly from sterile or nonsterile clinical samples by a new molecular assay. J Clin Microbiol 2003; 41:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/34\">",
"      Harbarth S, Masuet-Aumatell C, Schrenzel J, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care 2006; 10:R25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/35\">",
"      Harbarth S, Fankhauser C, Schrenzel J, et al. Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 2008; 299:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/36\">",
"      Francois P, Bento M, Renzi G, et al. Evaluation of three molecular assays for rapid identification of methicillin-resistant Staphylococcus aureus. J Clin Microbiol 2007; 45:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/37\">",
"      Stamper PD, Cai M, Howard T, et al. Clinical validation of the molecular BD GeneOhm StaphSR assay for direct detection of Staphylococcus aureus and methicillin-resistant Staphylococcus aureus in positive blood cultures. J Clin Microbiol 2007; 45:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/38\">",
"      Hogg GM, McKenna JP, Ong G. Rapid detection of methicillin-susceptible and methicillin-resistant Staphylococcus aureus directly from positive BacT/Alert blood culture bottles using real-time polymerase chain reaction: evaluation and comparison of 4 DNA extraction methods. Diagn Microbiol Infect Dis 2008; 61:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/39\">",
"      Misawa Y, Yoshida A, Saito R, et al. Application of loop-mediated isothermal amplification technique to rapid and direct detection of methicillin-resistant Staphylococcus aureus (MRSA) in blood cultures. J Infect Chemother 2007; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/40\">",
"      Gr&ouml;bner S, Kempf VA. Rapid detection of methicillin-resistant staphylococci by real-time PCR directly from positive blood culture bottles. Eur J Clin Microbiol Infect Dis 2007; 26:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/41\">",
"      Thomas LC, Gidding HF, Ginn AN, et al. Development of a real-time Staphylococcus aureus and MRSA (SAM-) PCR for routine blood culture. J Microbiol Methods 2007; 68:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/42\">",
"      Wolk DM, Struelens MJ, Pancholi P, et al. Rapid detection of Staphylococcus aureus and methicillin-resistant S. aureus (MRSA) in wound specimens and blood cultures: multicenter preclinical evaluation of the Cepheid Xpert MRSA/SA skin and soft tissue and blood culture assays. J Clin Microbiol 2009; 47:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31654/abstract/43\">",
"      Stratidis J, Bia FJ, Edberg SC. Use of real-time polymerase chain reaction for identification of methicillin-resistant Staphylococcus aureus directly from positive blood culture bottles. Diagn Microbiol Infect Dis 2007; 58:199.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3166 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31654=[""].join("\n");
var outline_f30_58_31654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SAMPLING SITE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LABORATORY TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3335764\">",
"      Cefoxitin disk screen test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32294801\">",
"      Rapid culture",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Chromogenic agar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32294891\">",
"      - Enrichment broth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32294940\">",
"      - Bacteriophage techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Molecular methods",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Commercial assays",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - \"In-house\" assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Blood cultures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/13/15575?source=related_link\">",
"      Microbiology of methicillin-resistant Staphylococcus aureus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/59/17338?source=related_link\">",
"      Prevention and control of methicillin-resistant Staphylococcus aureus in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_58_31655="Periodontal destruction";
var content_f30_58_31655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F54957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F54957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Necrotizing periodontal disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    HIV-positive individual. Pre-treatment and after treatment showing the sequela of severe periodontal destruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31655=[""].join("\n");
var outline_f30_58_31655=null;
var title_f30_58_31656="Neurologic complications of bacterial meningitis in children";
var content_f30_58_31656=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurologic complications of bacterial meningitis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31656/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/58/31656/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacterial meningitis continues to result in substantial morbidity and mortality despite the availability of effective antimicrobial therapy. The risk of dying or of developing complications is related to the age and underlying condition of the patient, the causative pathogen, the severity and duration of illness at the time of presentation, and, occasionally, to delays in the initiation of antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neurologic complications of bacterial meningitis in children will be discussed here. The neurologic complications of bacterial meningitis in neonates and adults, and the prevention of neurologic complications in children, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in the neonate\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18280?source=see_link\">",
"     \"Neurologic complications of bacterial meningitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=see_link\">",
"     \"Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications of bacterial meningitis can be divided into systemic and neurologic. Systemic complications, such as septic shock, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and septic or reactive arthritis are usually the consequence of the bacteremia that frequently accompanies meningitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neurologic complications of meningitis may be sudden or gradual in onset and can appear at any time after the onset of symptoms, including after the completion of therapy. Although many neurologic complications are severe and readily apparent, others, such as hearing loss, may be subtle or inapparent during the early phases of infection. The neurologic complications of meningitis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Impaired mental status",
"     </li>",
"     <li>",
"      Cerebral edema and increased intracranial pressure",
"     </li>",
"     <li>",
"      Seizures",
"     </li>",
"     <li>",
"      Focal deficits (eg, hearing loss, cranial nerve palsies, hemiparesis or quadriparesis)",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"     <li>",
"      Cerebrovascular abnormalities",
"     </li>",
"     <li>",
"      Neuropsychologic impairment, developmental disability",
"     </li>",
"     <li>",
"      Subdural effusion or empyema",
"     </li>",
"     <li>",
"      Hydrocephalus",
"     </li>",
"     <li>",
"      Hypothalamic dysfunction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neurologic complications can develop at any time during the course of bacterial meningitis. Impaired mental status is seen in most patients at presentation, and seizures are more often seen during the acute episode. Although also occurring early, sensorineural hearing loss is typically not appreciated until the patient has recovered from the acute illness or, in young children, when a hearing assessment is performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H45#H45\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Hearing evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of the incidence of neurologic complications of bacterial meningitis have been undertaken in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The incidence of complications in these studies has varied widely depending upon the time of the study and the duration of follow-up. In a meta-analysis of 45 prospective studies (1955 to 1993) including 4920 children, neurologic sequelae that persisted or developed after hospital discharge occurred in 16 percent of survivors in developed countries and 26 percent in developing countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2\">",
"     2",
"    </a>",
"    ]. Among the 19 reports of prospective studies from developed countries, the most common sequelae were:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deafness &mdash; 11 percent, including bilateral severe or profound deafness in 5 percent",
"     </li>",
"     <li>",
"      Intellectual disability (mental retardation) &mdash; 4 percent",
"     </li>",
"     <li>",
"      Spasticity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresis &mdash; 4 percent",
"     </li>",
"     <li>",
"      Seizure disorder &mdash; 4 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a literature review of published reports (1970 to 2010), approximately one-half of 1433 survivors of pediatric meningitis (1 month to &lt;18 years) had at least one sequela at &ge;five years of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/3\">",
"     3",
"    </a>",
"    ]. Among children with sequelae, the distribution of bacterial etiologies (when specified) was as follows: H. influenzae (37 percent), tuberculosis (12 percent), S. pneumoniae (4 percent), and N. meningitidis (3 percent). Among the 1012 reported sequelae,",
"    <span class=\"nowrap\">",
"     intellectual/behavioral",
"    </span>",
"    deficits (eg, cognitive impairment, academic limitations, attention deficit hyperactivity disorder) accounted for 78 percent, neurologic deficits (seizures, motor deficits, cerebral palsy) for 14 percent; hearing loss for 7 percent; and vision deficits for 3 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Prediction of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors related to the outcome of bacterial meningitis in children include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The age of the patient (the younger the child, the worse the prognosis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/5-7\">",
"       5-7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The etiologic agent (Streptococcus pneumoniae is associated with worse outcome compared with other pathogens) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2,8-11\">",
"       2,8-11",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=see_link&amp;anchor=H31#H31\">",
"       \"Pneumococcal meningitis in children\", section on 'Outcome'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The duration",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progression of illness before effective antibiotic therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The number of organisms or the quantity of polysaccharide material present in the cerebrospinal fluid at the time of diagnosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The rapidity with which the CSF is sterilized [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/14\">",
"       14",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The adequacy of the host response to infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of studies have attempted to identify predictors of adverse outcome in children with bacterial meningitis. Clinical features that have been associated with increased risk of neurologic complications or sequelae include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Prolonged or complicated seizures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/15\">",
"       15",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Low cerebrospinal fluid (CSF) glucose concentration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/5,8\">",
"       5,8",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ge;2 days of symptoms before admission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8,16\">",
"       8,16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Ataxia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8,17,18\">",
"       8,17,18",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      &ge;10(7) colony forming units",
"      <span class=\"nowrap\">",
"       (CFU)/mL",
"      </span>",
"      of CSF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/12,13,19\">",
"       12,13,19",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Focal neurologic deficits in patients who are not postictal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/20\">",
"       20",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      S. pneumoniae infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2,8-11\">",
"       2,8-11",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among the subset of children requiring mechanical ventilation, a Pediatric Risk of Mortality (PRISM) score &ge;20 within the first 24 hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/21\">",
"       21",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The increased risk of adverse outcome with pneumococcal meningitis may result in part from the persistence of potent biologic activity in the debris of killed bacteria. The debris may stimulate the host inflammatory response, which in turn contributes to tissue damage. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=see_link\">",
"     \"Pathogenesis and pathophysiology of bacterial meningitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ALTERED MENTAL STATUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Altered mental status is a common presenting feature of bacterial meningitis. Among children, alterations in the level of consciousness are highly variable. In developed countries, most children are described as irritable or lethargic; only about 15 percent are considered comatose on admission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4\">",
"     4",
"    </a>",
"    ]. The major cause of severely diminished consciousness and coma is increased intracranial pressure (ICP). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=see_link&amp;anchor=H9#H9\">",
"     \"Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age\", section on 'Neurologic findings'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     INCREASED INTRACRANIAL PRESSURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with bacterial meningitis develop increased ICP, which can produce a number of clinical signs or problems. Mild to moderate increases in ICP typically cause headache, confusion, irritability, nausea, and vomiting. More severe increases can produce one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Altered mental status that can include coma",
"     </li>",
"     <li>",
"      Bradycardia with hypertension (the Cushing reflex)",
"     </li>",
"     <li>",
"      Papilledema, which takes several days to become apparent (uncommon in children) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/22\">",
"       22",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cranial nerve palsy, particularly involving the abducens (VI) nerve",
"     </li>",
"     <li>",
"      Herniation of the cerebellar tonsils, leading to death",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Elevated ICP in patients with meningitis is primarily due to cerebral edema. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=see_link&amp;anchor=H9#H9\">",
"     \"Elevated intracranial pressure in children\", section on 'Presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cerebral edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possibility of cerebral edema should be considered in all critically ill patients with meningitis. Treatment of severe intracranial hypertension can be initiated if the diagnosis is confirmed by neuroimaging studies or earlier if strongly suspected on clinical grounds (eg, papilledema, fixed dilated pupil). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=see_link&amp;anchor=H20#H20\">",
"     \"Elevated intracranial pressure in children\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cerebral edema can be caused by vasogenic, cytotoxic, or interstitial mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/23\">",
"     23",
"    </a>",
"    ]. The net effect of these processes is an increase in the total fluid volume of the brain, leading to a rise in intracranial pressure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vasogenic cerebral edema usually results from increased permeability of the blood-brain barrier, especially in the choroid plexus endothelium and the endothelium of the cerebral microvasculature",
"     </li>",
"     <li>",
"      Cytotoxic factors released from neutrophils, microglia, and astrocytes can directly produce cerebral edema",
"     </li>",
"     <li>",
"      The inflammation produced by the infection can impede the normal absorption of CSF from the subarachnoid space via the arachnoid villi",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cerebral perfusion pressure, normally maintained by an autoregulatory mechanism, becomes dependent upon peripheral blood pressure during meningitis because autoregulation is impaired [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Cerebral edema itself can increase the intracranial pressure and secondarily reduce cerebral blood flow.",
"   </p>",
"   <p>",
"    Fluid management in children with bacterial meningitis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=see_link&amp;anchor=H11#H11\">",
"     \"Treatment and prognosis of acute bacterial meningitis in children older than one month of age\", section on 'Fluid management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SEIZURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures occur in 20 to 30 percent of children with acute bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,10\">",
"     4,10",
"    </a>",
"    ]. The pathogenesis of seizures in meningitis is not well understood. Although fever may be a cofactor in very young children, cerebrovascular inflammation or secondary neurochemical changes are presumably the cause of most seizures. In one study, as an example, the occurrence of seizures correlated with bacterial counts of greater than 10(7)",
"    <span class=\"nowrap\">",
"     CFU/mL",
"    </span>",
"    in the CSF sample prior to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The two most common types of seizures in children with bacterial meningitis are partial, generalized seizures with focal predominance, and partial seizures with secondary generalization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/20\">",
"     20",
"    </a>",
"    ]. Seizures occurring before or at the time of presentation are usually generalized, whereas seizures occurring &ge;72 hours after admission are usually focal.",
"   </p>",
"   <p>",
"    Seizures that occur early in the course of bacterial meningitis and that are easily controlled are rarely associated with permanent neurologic sequelae. In contrast, seizures that are prolonged, difficult to control, or begin more than 72 hours after hospitalization are more likely to be associated with neurologic sequelae, suggesting that a cerebrovascular complication may have occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/10,20,22\">",
"     10,20,22",
"    </a>",
"    ]. Persistent neurologic deficits are the major independent predictor of late afebrile seizures in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Cerebrovascular complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     FOCAL DEFICITS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal neurologic deficits are a common complication of meningitis. These include hearing loss, cranial nerve palsy, paresis (monoparesis, hemiparesis, quadriparesis), visual field defects, aphasia, and ataxia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,22\">",
"     4,22",
"    </a>",
"    ]. Most focal deficits resolve with successful treatment of the meningitis, but long-term disability can occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2-4,20\">",
"     2-4,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate at which focal neurologic deficits occur in meningitis depends upon the duration of illness before treatment, the age of the patient, and the causative organism. In one review, for example, 34 percent of children with pneumococcal meningitis had one or more focal neurologic deficits compared with 15 percent in children with H. influenzae meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hearing loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss after bacterial meningitis may be transient or permanent. Transient hearing loss may be secondary to a conductive disturbance in many affected patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/26\">",
"     26",
"    </a>",
"    ]. However, sensorineural hearing loss (transient or permanent) can result from damage to the eighth cranial nerve, cochlea, or labyrinth, induced by direct bacterial invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the inflammatory response elicited by the infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/26-30\">",
"     26-30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Permanent sensorineural hearing loss occurs in as many as 11 percent of children with bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the largest cohort since the 1980s, hearing loss developed in 7 percent of cases, one-quarter of which were detected after the routine follow-up period had ended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8\">",
"     8",
"    </a>",
"    ]. All of the children with hearing loss had one or more of the following risk factors at presentation:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms for &ge;2 days before admission",
"     </li>",
"     <li>",
"      Absence of petechiae",
"     </li>",
"     <li>",
"      CSF glucose concentration &le;10.8",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (0.6",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      S. pneumoniae infection",
"     </li>",
"     <li>",
"      Ataxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hearing loss is two to three times more common in children with pneumococcal meningitis than with other forms of bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8,27\">",
"     8,27",
"    </a>",
"    ]. Ataxia is commonly associated with hearing loss in children, since both are related to bacterial labyrinthitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8,17,18\">",
"     8,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Cranial nerve palsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial nerve palsies can result from compression due to brain swelling or perineuritis due to the adjacent meningeal inflammatory reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/31\">",
"     31",
"    </a>",
"    ]. The abducens (VI) nerve is the cranial nerve most commonly affected in meningitis, probably because its long intracranial segment adjacent to the brainstem is highly vulnerable to elevated intracranial pressure and the inflammatory reaction that can occur with meningitis. Cranial nerves III, IV, and VII also may be affected. Cranial nerve deficits related to meningitis are usually transient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=see_link\">",
"     \"Third cranial nerve (oculomotor nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/12999?source=see_link\">",
"     \"Fourth cranial nerve (trochlear nerve) palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=see_link\">",
"     \"Facial nerve palsy in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=see_link&amp;anchor=H3#H3\">",
"     \"Sixth cranial nerve (abducens nerve) palsy in children\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Bacterial meningitis can induce arachnoiditis around the optic nerve, which can lead to transient or permanent visual loss. Optic atrophy that results in irreversible total blindness is a rare complication of severe meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Paresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemiparesis or quadriparesis is another focal neurologic complication of bacterial meningitis. Paresis typically results from an intracranial abnormality (eg, cortical vein or sagittal vein thrombosis, cerebral artery spasm, subdural effusion or empyema, hydrocephalus, cerebral infarct or abscess, cerebral edema).",
"   </p>",
"   <p>",
"    Paresis resulting from meningitis generally improves with time. In a review of 235 children with bacterial meningitis, hemiparesis or quadriparesis was noted in 30 patients (12 percent) shortly after discharge, but persisted in only 5 (2 percent) one year after discharge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CEREBROVASCULAR COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis, vasculitis, acute cerebral hemorrhage or infarction, and aneurysm formation of cerebral vessels are potential complications of bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/15,33-36\">",
"     15,33-36",
"    </a>",
"    ]. These diverse processes can manifest similarly as a focal abnormality, such as hemiparesis or focal seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEUROPSYCHOLOGIC IMPAIRMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cognitive impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to severe intellectual disability (mental retardation) is a well-recognized complication of bacterial meningitis in children. However, few studies have utilized appropriate controls and sufficient follow-up to assess the risk. In a meta-analysis of 19 prospective studies of bacterial meningitis in children from developed countries, intellectual disability (defined by IQ &le;70) occurred in 4 percent of survivors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have evaluated the intelligence quotient (IQ) of survivors of bacterial meningitis compared with their siblings or other control children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,37-39\">",
"     4,37-39",
"    </a>",
"    ]. Although not all of the studies found a difference in the mean IQ compared with controls (usually siblings) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,39\">",
"     4,39",
"    </a>",
"    ], a greater proportion of children who had meningitis had IQ less than 70 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,40\">",
"     4,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other sequelae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional neuropsychologic outcomes in survivors of bacterial meningitis have been evaluated in several prospective studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/7,40-48\">",
"     7,40-48",
"    </a>",
"    ]. Intellectual and behavioral deficits, (eg, cognitive impairment, academic limitations, and attention deficit hyperactivity disorder) are the most common long-term sequelae [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A cohort of 130 children were evaluated 7 and 12 years after meningitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/7,40\">",
"       7,40",
"      </a>",
"      ]. After adjustment for sociodemographic variables, scores on measures of intelligence, learning, and neuropsychologic skills were consistently below those of age- and grade-matched controls, even though meningitis survivors achieved scores in the average range [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/49\">",
"       49",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Onset of meningitis before 12 months of age was significantly associated with decreased performance on tests requiring language and executive skills [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/7\">",
"       7",
"      </a>",
"      ]. The occurrence of acute neurologic complications and duration of symptoms before diagnosis were not predictors of outcome at 12 years.",
"     </li>",
"     <li>",
"      The effects of meningitis in infancy on academic achievement at age 16 years were evaluated in a case-control study of a British cohort of 461 teenagers who had bacterial meningitis in infancy and 289 matched controls (recruited when the cases were five years old) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/41,47\">",
"       41,47",
"      </a>",
"      ]. The groups had been previously compared at age 5 and 13 years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/42,48\">",
"       42,48",
"      </a>",
"      ]. The following results were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      8 percent of cases attended special schools (compared with none of the controls); this rate is more than four times the national average",
"     </li>",
"     <li>",
"      25 percent of cases did not pass any General Certificate of Secondary Education (GCSE) compared with 7 percent of controls",
"     </li>",
"     <li>",
"      Twice as many cases as controls failed to achieve the national standard of passing GCSE in five key subjects (English language, English literature, mathematics, science, modern foreign language)",
"     </li>",
"     <li>",
"      Cases who were not identified as having meningitis-associated disability at age five years did no better than those who were identified to have meningitis-associated disability at age five years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survivors of childhood bacterial meningitis may have increased behavior problems over time (eg, somatic complaints, mood problems, social problems, thought problems, attention problems, and delinquent behavior) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/3,42-45\">",
"       3,42-45",
"      </a>",
"      ]. Whether the frequency of behavior problems varies according to pathogen is not clear; one retrospective review found the prevalence of behavior problems among survivors of non-Hib meningitis to be similar to that in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, these observations indicate that survivors of childhood meningitis are at increased risk for developmental problems associated with learning and behavioral difficulties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/3,49,51\">",
"     3,49,51",
"    </a>",
"    ]. This is true even for those who do not have acute neurologic complications or physical sequelae. Caregivers and schoolteachers should be aware of possible language deficits and problems understanding language-based material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/4,38\">",
"     4,38",
"    </a>",
"    ]. Early identification and intervention may help to minimize the long-term impact of these problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUBDURAL EFFUSIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subdural effusions occur in 10 to 33 percent of children with acute bacterial meningitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Clinical manifestations of subdural effusions are often subtle or absent. In very young children, bulging fontanelles may be a sign of this complication, while in older children, subdural effusions can rarely produce increased intracranial pressure and a shift of intracranial structures. In most children, subdural effusions produce few symptoms and require no treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/54\">",
"     54",
"    </a>",
"    ]. However, development of subdural empyema requires drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     UNUSUAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of unusual neurologic complications can occur in children with meningitis. These unusual complications are rare and include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Spinal cord complications, such as transverse myelitis or infarction, presumably as a direct result of local vascular changes with secondary cord ischemia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/55-57\">",
"       55-57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Brain abscesses. Brain abscesses are rare in patients with meningitis due to S. pneumoniae, H. influenzae, and N. meningitidis, but occur with higher frequency with certain rare pathogens, such as Enterobacter sakazakii (also known as Cronobacter [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/58\">",
"       58",
"      </a>",
"      ]) or Citrobacter sp. [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Severe permanent hydrocephalus",
"     </li>",
"     <li>",
"      Aneurysm formation of focal intracranial vessels, presumably secondary to inflammatory changes in the blood vessel wall [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Cortical visual impairment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31656/abstract/34,60-62\">",
"       34,60-62",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=see_link\">",
"       \"Patient information: Bacterial meningitis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Permanent neurologic sequelae occur in up to one-half of children with bacterial meningitis. The most common sequelae include",
"      <span class=\"nowrap\">",
"       intellectual/behavioral",
"      </span>",
"      deficits, neurologic deficits (including spasticity",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      paresis and seizures), hearing loss, and intellectual disability (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Incidence'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Clinical features that have been associated with increased risk of neurologic sequelae include prolonged or complicated seizures, low cerebrospinal fluid (CSF) glucose concentration, &ge;10(7) colony forming",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      of CSF, and focal neurologic deficits. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prediction of risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Seizures that are prolonged, difficult to control, or begin more than 72 hours after hospitalization are more likely to be associated with neurologic sequelae. Persistent neurologic deficits are the major predictor of late afebrile seizures in children. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Seizures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hemiparesis or quadriparesis resulting from meningitis often improves with time. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Paresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Permanent sensorineural hearing loss occurs in as many as 11 percent of children with bacterial meningitis. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Hearing loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of childhood meningitis are at increased risk of developmental, learning, and behavioral difficulties, even if they did not have acute neurologic complications or physical sequelae. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Neuropsychologic impairment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/1\">",
"      Kaplan SL, Catlin FI, Weaver T, Feigin RD. Onset of hearing loss in children with bacterial meningitis. Pediatrics 1984; 73:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/2\">",
"      Baraff LJ, Lee SI, Schriger DL. Outcomes of bacterial meningitis in children: a meta-analysis. Pediatr Infect Dis J 1993; 12:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/3\">",
"      Chandran A, Herbert H, Misurski D, Santosham M. Long-term sequelae of childhood bacterial meningitis: an underappreciated problem. Pediatr Infect Dis J 2011; 30:3.",
"     </a>",
"    </li>",
"    <li>",
"     Feigin  RD, Cutrer W. Bacterial meningitis beyond the neonatal period. In: Textbook of Pediatric Infectious Diseases, 6th, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/5\">",
"      Herson VC, Todd JK. Prediction of morbidity in Hemophilus influenzae meningitis. Pediatrics 1977; 59:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/6\">",
"      Anderson V, Bond L, Catroppa C, et al. Childhood bacterial meningitis: impact of age at illness and acute medical complications on long term outcome. J Int Neuropsychol Soc 1997; 3:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/7\">",
"      Anderson V, Anderson P, Grimwood K, Nolan T. Cognitive and executive function 12 years after childhood bacterial meningitis: effect of acute neurologic complications and age of onset. J Pediatr Psychol 2004; 29:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/8\">",
"      Koomen I, Grobbee DE, Roord JJ, et al. Hearing loss at school age in survivors of bacterial meningitis: assessment, incidence, and prediction. Pediatrics 2003; 112:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/9\">",
"      Kornelisse RF, Westerbeek CM, Spoor AB, et al. Pneumococcal meningitis in children: prognostic indicators and outcome. Clin Infect Dis 1995; 21:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/10\">",
"      Arditi M, Mason EO Jr, Bradley JS, et al. Three-year multicenter surveillance of pneumococcal meningitis in children: clinical characteristics, and outcome related to penicillin susceptibility and dexamethasone use. Pediatrics 1998; 102:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/11\">",
"      Oostenbrink R, Maas M, Moons KG, Moll HA. Sequelae after bacterial meningitis in childhood. Scand J Infect Dis 2002; 34:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/12\">",
"      Feldman WE. Concentrations of bacteria in cerebrospinal fluid of patients with bacterial meningitis. J Pediatr 1976; 88:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/13\">",
"      Feldman WE, Ginsburg CM, McCracken GH Jr, et al. Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis. J Pediatr 1982; 100:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/14\">",
"      Lebel MH, McCracken GH Jr. Delayed cerebrospinal fluid sterilization and adverse outcome of bacterial meningitis in infants and children. Pediatrics 1989; 83:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/15\">",
"      Taft TA, Chusid MJ, Sty JR. Cerebral infarction in Hemophilus influenzae type B meningitis. Clin Pediatr (Phila) 1986; 25:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/16\">",
"      Kaaresen PI, Flaegstad T. Prognostic factors in childhood bacterial meningitis. Acta Paediatr 1995; 84:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/17\">",
"      Kaplan SL, Goddard J, Van Kleeck M, et al. Ataxia and deafness in children due to bacterial meningitis. Pediatrics 1981; 68:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/18\">",
"      Schwartz JF. Ataxia in bacterial meningitis. Neurology 1972; 22:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/19\">",
"      Feldman WE. Relation of concentrations of bacteria and bacterial antigen in cerebrospinal fluid to prognosis in patients with bacterial meningitis. N Engl J Med 1977; 296:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/20\">",
"      Pomeroy SL, Holmes SJ, Dodge PR, Feigin RD. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med 1990; 323:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/21\">",
"      Madagame ET, Havens PL, Bresnahan JM, et al. Survival and functional outcome of children requiring mechanical ventilation during therapy for acute bacterial meningitis. Crit Care Med 1995; 23:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/22\">",
"      Feigin RD, McCracken GH Jr, Klein JO. Diagnosis and management of meningitis. Pediatr Infect Dis J 1992; 11:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/23\">",
"      Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin Microbiol Rev 1993; 6:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/24\">",
"      Tureen JH, Dworkin RJ, Kennedy SL, et al. Loss of cerebrovascular autoregulation in experimental meningitis in rabbits. J Clin Invest 1990; 85:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/25\">",
"      Goitein KJ, Tamir I. Cerebral perfusion pressure in central nervous system infections of infancy and childhood. J Pediatr 1983; 103:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/26\">",
"      Dodge PR, Davis H, Feigin RD, et al. Prospective evaluation of hearing impairment as a sequela of acute bacterial meningitis. N Engl J Med 1984; 311:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/27\">",
"      Kaplan SL, Woods CR. Neurologic complications of bacterial meningitis in children. Curr Clin Top Infect Dis 1992; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/28\">",
"      Bhatt SM, Lauretano A, Cabellos C, et al. Progression of hearing loss in experimental pneumococcal meningitis: correlation with cerebrospinal fluid cytochemistry. J Infect Dis 1993; 167:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/29\">",
"      Merchant SN, Gopen Q. A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol 1996; 17:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/30\">",
"      Klein M, Schmidt C, Kastenbauer S, et al. MyD88-dependent immune response contributes to hearing loss in experimental pneumococcal meningitis. J Infect Dis 2007; 195:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/31\">",
"      Durand ML, Calderwood SB, Weber DJ, et al. Acute bacterial meningitis in adults. A review of 493 episodes. N Engl J Med 1993; 328:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/32\">",
"      Ellsworth J, Marks MI, Vose A. Meningococcal meningitis in children. Can Med Assoc J 1979; 120:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/33\">",
"      Dunn DW, Daum RS, Weisberg L, Vargas R. Ischemic cerebrovascular complications of Haemophilus influenzae meningitis. The value of computed tomography. Arch Neurol 1982; 39:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/34\">",
"      Mankhambo LA, Makwana NV, Carrol ED, et al. Persistent visual loss as a complication of meningococcal meningitis. Pediatr Infect Dis J 2006; 25:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/35\">",
"      Chang CJ, Chang WN, Huang LT, et al. Cerebral infarction in perinatal and childhood bacterial meningitis. QJM 2003; 96:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/36\">",
"      Kaplan SL, Fishman MA. Update on bacterial meningitis. J Child Neurol 1988; 3:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/37\">",
"      Taylor HG, Mills EL, Ciampi A, et al. The sequelae of Haemophilus influenzae meningitis in school-age children. N Engl J Med 1990; 323:1657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/38\">",
"      Sell SH. Long term sequelae of bacterial meningitis in children. Pediatr Infect Dis 1983; 2:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/39\">",
"      Tejani A, Dobias B, Sambursky J. Long-term prognosis after H. influenzae meningitis: prospective evaluation. Dev Med Child Neurol 1982; 24:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/40\">",
"      Grimwood K, Anderson VA, Bond L, et al. Adverse outcomes of bacterial meningitis in school-age survivors. Pediatrics 1995; 95:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/41\">",
"      de Louvois J, Halket S, Harvey D. Effect of meningitis in infancy on school-leaving examination results. Arch Dis Child 2007; 92:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/42\">",
"      Halket S, de Louvois J, Holt DE, Harvey D. Long term follow up after meningitis in infancy: behaviour of teenagers. Arch Dis Child 2003; 88:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/43\">",
"      Grimwood K, Anderson P, Anderson V, et al. Twelve year outcomes following bacterial meningitis: further evidence for persisting effects. Arch Dis Child 2000; 83:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/44\">",
"      Fellick JM, Sills JA, Marzouk O, et al. Neurodevelopmental outcome in meningococcal disease: a case-control study. Arch Dis Child 2001; 85:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/45\">",
"      Berg S, Trollfors B, Hugosson S, et al. Long-term follow-up of children with bacterial meningitis with emphasis on behavioural characteristics. Eur J Pediatr 2002; 161:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/46\">",
"      Feldman HM, Michaels RH. Academic achievement in children ten to 12 years after Haemophilus influenzae meningitis. Pediatrics 1988; 81:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/47\">",
"      de Louvois J, Blackbourn J, Hurley R, Harvey D. Infantile meningitis in England and Wales: a two year study. Arch Dis Child 1991; 66:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/48\">",
"      Bedford H, de Louvois J, Halket S, et al. Meningitis in infancy in England and Wales: follow up at age 5 years. BMJ 2001; 323:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/49\">",
"      Grimwood K. Legacy of bacterial meningitis in infancy. Many children continue to suffer functionally important deficits. BMJ 2001; 323:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/50\">",
"      Ritchi L, Jennekens-Schinkel A, van Schooneveld M, et al. Behaviour is not really at risk after surviving meningitis in childhood. Acta Paediatr 2008; 97:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/51\">",
"      Marlow N, Johnson S. What the teacher needs to know. Arch Dis Child 2007; 92:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/52\">",
"      Taylor HG, Schatschneider C, Minich NM. Longitudinal outcomes of Haemophilus influenzae meningitis in school-age children. Neuropsychology 2000; 14:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/53\">",
"      DODGE PR, SWARTZ MN. BACTERIAL MENINGITIS--A REVIEW OF SELECTED ASPECTS. II. SPECIAL NEUROLOGIC PROBLEMS, POSTMENINGITIC COMPLACATIONS AND CLINICOPATHOLOGICAL CORRELATIONS. N Engl J Med 1965; 272:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/54\">",
"      Snedeker JD, Kaplan SL, Dodge PR, et al. Subdural effusion and its relationship with neurologic sequelae of bacterial meningitis in infancy: a prospective study. Pediatrics 1990; 86:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/55\">",
"      Seay AR. Spinal cord dysfunction complicating bacterial meningitis. Arch Neurol 1984; 41:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/56\">",
"      Almasanu BP, Owensby JR, Pavlakis SG, Edwards JH. Spinal cord infarction in meningitis: polygenic risk factors. Pediatr Neurol 2005; 32:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/57\">",
"      Haupt HM, Kurlinski JP, Barnett NK, Epstein M. Infarction of the spinal cord as a complication of pneumococcal meningitis. Case report. J Neurosurg 1981; 55:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/58\">",
"      Iversen C, Lehner A, Mullane N, et al. Identification of \"Cronobacter\" spp. (Enterobacter sakazakii). J Clin Microbiol 2007; 45:3814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/59\">",
"      Perry JR, Bilbao JM, Gray T. Fatal basilar vasculopathy complicating bacterial meningitis. Stroke 1992; 23:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/60\">",
"      Newton NL Jr, Reynolds JD, Woody RC. Cortical blindness following Hemophilus influenzae meningitis. Ann Ophthalmol 1985; 17:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/61\">",
"      Ackroyd RS. Cortical blindness following bacterial meningitis: a case report with reassessment of prognosis and aetiology. Dev Med Child Neurol 1984; 26:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31656/abstract/62\">",
"      Tepperberg J, Nussbaum D, Feldman F. Cortical blindness following meningitis due to hemophilus influenzae type B. J Pediatr 1977; 91:434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6000 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-382E3F64B8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31656=[""].join("\n");
var outline_f30_58_31656=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Prediction of risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ALTERED MENTAL STATUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      INCREASED INTRACRANIAL PRESSURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SEIZURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      FOCAL DEFICITS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Cranial nerve palsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Paresis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CEREBROVASCULAR COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEUROPSYCHOLOGIC IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cognitive impairment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other sequelae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUBDURAL EFFUSIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      UNUSUAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/8/28810?source=related_link\">",
"      Clinical features and diagnosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/21/4442?source=related_link\">",
"      Dexamethasone and other measures to prevent neurologic complications of bacterial meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/37/44633?source=related_link\">",
"      Elevated intracranial pressure in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25257?source=related_link\">",
"      Facial nerve palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/44/12999?source=related_link\">",
"      Fourth cranial nerve (trochlear nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/54/18280?source=related_link\">",
"      Neurologic complications of bacterial meningitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/43/24246?source=related_link\">",
"      Neurologic complications of bacterial meningitis in the neonate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/41/38549?source=related_link\">",
"      Pathogenesis and pathophysiology of bacterial meningitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/1/31762?source=related_link\">",
"      Patient information: Bacterial meningitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/42/12970?source=related_link\">",
"      Pneumococcal meningitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43046?source=related_link\">",
"      Sixth cranial nerve (abducens nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/34/40487?source=related_link\">",
"      Third cranial nerve (oculomotor nerve) palsy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/35/38458?source=related_link\">",
"      Treatment and prognosis of acute bacterial meningitis in children older than one month of age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_58_31657="Treatment of osteoporosis in men";
var content_f30_58_31657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of osteoporosis in men",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Joel S Finkelstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?30/58/31657/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?30/58/31657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 6, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis is a leading cause of morbidity and mortality in elderly people. While less common in men than women, over 8 million men in the United States have low bone mass or osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The mortality rate associated with hip fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], as well as vertebral and other major fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/5\">",
"     5",
"    </a>",
"    ], is higher in men than in women. In addition, men are even less likely than women to be evaluated or receive antiresorptive therapy after a hip fracture (4.5 versus 49.5 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of osteoporosis in men consists of lifestyle measures and drug or hormonal therapy. An overview of the approach to therapy of osteoporosis in men will be presented here. The diagnosis, evaluation, and epidemiology of osteoporosis in men are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and evaluation of osteoporosis in men\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link\">",
"     \"Epidemiology and etiology of osteoporosis in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LIFESTYLE MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lifestyle modifications should be encouraged for all men with osteoporosis. A weight-bearing exercise regimen may be modestly beneficial given the association of reduced physical activity with bone loss and fracture in older men and the positive effect of exercise in women with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=see_link&amp;anchor=H16#H16\">",
"     \"Epidemiology and etiology of osteoporosis in men\", section on 'Physical activity and strength'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Exercise'",
"    </a>",
"    .) In addition, smoking and excessive alcohol intake should be avoided.",
"   </p>",
"   <p>",
"    As a general rule, men with osteoporosis should receive adequate calcium (1000",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in younger men, 1000 to 1200 mg daily in older men, total diet plus supplement) and vitamin D (600 to 800 international",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    supplementation. Older persons confined indoors and other high risk groups may have low serum 25-hydroxyvitamin D concentrations at this intake level and may require higher intakes of vitamin D. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=see_link&amp;anchor=H5541302#H5541302\">",
"     \"Treatment of vitamin D deficiency in adults\", section on 'Groups at high risk for suboptimal intake'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some trials, calcium and vitamin D have been shown to reduce fracture risk in men and women when administered at a dose of at least 700 international",
"    <span class=\"nowrap\">",
"     units/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"     \"Calcium and vitamin D supplementation in osteoporosis\"",
"    </a>",
"    .) However, in most cases, the addition of pharmacologic or hormonal therapy is necessary for the treatment of osteoporosis in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT OF SECONDARY CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a cause of osteoporosis is identified, it should be treated. As an example, potential offending agents (eg, glucocorticoids, alcohol, tobacco, etc) should be eliminated whenever possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Testosterone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism is among the most commonly identified causes of osteoporosis in men. Several studies have demonstrated that testosterone replacement increases bone mineral density in young men with hypogonadism associated with a clear etiology (eg, pituitary tumors, Klinefelter syndrome, GnRH deficiency etc). For example, in one report of 36 men with previously-untreated, acquired hypogonadism, most of whom had pituitary tumors, spinal bone mineral density increased (5 percent by DXA and 14 percent by computed tomography) during 12 to 18 months of intramuscular testosterone replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/10\">",
"     10",
"    </a>",
"    ]. Serum bone-specific alkaline phosphatase concentrations and urinary excretion of deoxypyridinoline, markers of bone formation and resorption, respectively, both decreased significantly, suggesting that the beneficial effects of testosterone replacement were due to its ability to suppress bone turnover.",
"   </p>",
"   <p>",
"    Similar results were reported in a larger group of 72 men with hypogonadism, many of whom had GnRH deficiency (idiopathic hypogonadotropic hypogonadism) (",
"    <a class=\"graphic graphic_figure graphicRef50233 \" href=\"mobipreview.htm?4/60/5057\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/11\">",
"     11",
"    </a>",
"    ]. The mean bone mineral density increased from 95 to 120",
"    <span class=\"nowrap\">",
"     mg/cm3",
"    </span>",
"    in the first year of testosterone replacement and in some men it eventually normalized. The response was greatest in previously untreated men with the lowest bone mineral density at baseline. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Testosterone replacement also increases bone mineral density, primarily cortical bone mineral density, in men with hyperprolactinemic hypogonadism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/12\">",
"     12",
"    </a>",
"    ] or idiopathic hypogonadotropic hypogonadism (",
"    <a class=\"graphic graphic_figure graphicRef65580 \" href=\"mobipreview.htm?40/22/41326\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/13\">",
"     13",
"    </a>",
"    ]. The effect is most marked in men with hypogonadotropic hypogonadism who are still skeletally immature when treatment is initiated although, even with prolonged therapy, bone mineral density remains low in these men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few studies have examined the effects of testosterone on bone mineral density in older men. In one study of 108 men over age 65 years whose baseline mean serum testosterone concentration was approximately 367",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (12.7",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    and whose initial lumbar spine bone mineral density was below the mean of young men, topical testosterone supplementation failed to increase lumbar spine or hip bone mineral density more than placebo (",
"    <a class=\"graphic graphic_figure graphicRef73732 \" href=\"mobipreview.htm?40/27/41406\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/14\">",
"     14",
"    </a>",
"    ]. A post-hoc analysis predicted a testosterone treatment effect of 5.9 percent above placebo in men whose pretreatment serum testosterone concentration was &lt;200",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (6.9",
"    <span class=\"nowrap\">",
"     nmol/L).",
"    </span>",
"   </p>",
"   <p>",
"    In contrast, intramuscular testosterone administration did increase spine and hip bone mineral density significantly in 70 men aged 65 years or older whose baseline testosterone levels were &lt;350",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    (12.1",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    on two occasions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/15\">",
"     15",
"    </a>",
"    ]. Differences in the results from these two studies may be due to the selection of men whose serum testosterone concentrations were too high to benefit from the therapy in the first study or to differences in the methods",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    doses of testosterone supplementation.",
"   </p>",
"   <p>",
"    Because testosterone therapy has beneficial effects on bone mineral density and other consequences of hypogonadism, we recommend testosterone replacement therapy for symptomatic hypogonadal men or men who have an unequivocal cause for hypogonadism (eg, pituitary tumor, Klinefelter syndrome, GnRH deficiency, etc) and who do not have contraindications to testosterone therapy. The diagnosis of hypogonadism and details of testosterone therapy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=see_link\">",
"     \"Clinical features and diagnosis of male hypogonadism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=see_link\">",
"     \"Testosterone treatment of male hypogonadism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20461678\">",
"    <span class=\"h2\">",
"     Glucocorticoid-induced osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoid therapy is associated with an appreciable risk of bone loss, which is most pronounced in the first few months of use. In addition, glucocorticoids increase fracture risk, and fractures occur at higher bone mineral density (BMD) values than occur in postmenopausal osteoporosis. The increased risk of fracture has been reported with doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent as low as 2.5 to 7.5 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/16\">",
"     16",
"    </a>",
"    ]. Thus, glucocorticoid-induced bone loss should be treated aggressively, particularly in those already at high risk for fracture (elderly, prior fragility fracture). In other individuals, clinical risk factor and BMD assessment may help guide therapy. The prevention and treatment of glucocorticoid-induced bone loss in men and women is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3195499\">",
"    <span class=\"h2\">",
"     Androgen deprivation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Androgen deprivation therapy (bilateral orchiectomy or GnRH agonist administration) in men with prostate cancer increases the risk of clinical fractures. Bisphosphonates, selective estrogen receptor modulators, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    have been shown to increase BMD. Denosumab has also been shown to reduce vertebral fractures in such men. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PHARMACOLOGIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Candidates for therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with the highest risk of fracture are the ones most likely to benefit from drug therapy; therefore, selection of patients based upon fracture risk, as determined by a combination of BMD and clinical risk factors, is desirable (",
"    <a class=\"graphic graphic_table graphicRef52512 \" href=\"mobipreview.htm?6/49/6939\">",
"     table 1",
"    </a>",
"    ). For the treatment of men with osteoporosis (T-score below -2.5 or fragility fracture) who do not have symptomatic hypogonadism, or in hypogonadal men in whom testosterone therapy is contraindicated, we recommend pharmacologic therapy. (See",
"    <a class=\"local\" href=\"#H20048148\">",
"     'Choice of therapy'",
"    </a>",
"    below.) For the treatment of high risk men with T-scores between -1.0 and -2.5, we also suggest pharmacologic therapy. A reasonable cut point that may be cost-effective in some settings is a 10-year probability of hip fracture or combined major osteoporotic fracture of &ge;3.0 or &ge;20 percent, respectively. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Fracture risk assessment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    One area of uncertainty is the selection of hypogonadal men, who are already treated with testosterone therapy, for additional pharmacologic therapy. There are no clinical trial data that address this question, and in particular, the effect of testosterone on fracture risk has not been evaluated. We agree with guidelines from the Endocrine Society for management of men with osteoporosis that suggest adding a pharmacologic agent with proven anti-fracture efficacy (eg, a bisphosphonate or teriparatide) in hypogonadal men whose risk of fracture is felt to be high [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/2\">",
"     2",
"    </a>",
"    ]. In the absence of definitive data upon which to objectively classify fracture risk in men, high risk groups might include men on high-dose glucocorticoids; men with frequent falls; men who have a had a recent fragility fracture, particularly if they have a BMD T-score below -2.5 at any skeletal site; or men with T-scores below -3.5 or even below -3 if they have other risk factors for fracture. Adding an established osteoporosis therapy to testosterone should also be considered in hypogonadal men whose BMD T-score is &lt;-2.5 even after receiving adequate testosterone replacement therapy for two years. The latter suggestion is based upon clinical trial data in men showing that testosterone continues to improve BMD for at least two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Fracture risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, a WHO task force introduced a Fracture Risk Assessment Tool (FRAX), which estimates the 10-year probability of hip fracture or major osteoporotic fractures combined (hip, spine, shoulder, or wrist) for an untreated patient using femoral neck BMD and easily obtainable clinical risk factors for fracture (",
"    <a class=\"graphic graphic_table graphicRef76445 \" href=\"mobipreview.htm?2/21/2395\">",
"     table 2",
"    </a>",
"    ). The technical aspects of FRAX are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H4#H4\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Fracture risk assessment tool'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The National Osteoporosis Foundation (NOF) released revised osteoporosis treatment and prevention guidelines based upon the WHO fracture prediction algorithm in conjunction with an updated US-specific economic analysis (",
"    <a class=\"graphic graphic_table graphicRef52512 \" href=\"mobipreview.htm?6/49/6939\">",
"     table 1",
"    </a>",
"    ). The guidelines provide treatment recommendations for postmenopausal women and men age 50 and older. Guidelines from the Endocrine Society for the management of osteoporosis in men are similarly based upon the WHO fracture prediction algorithm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These guidelines recommend treatment of men &ge;50 years with a history of hip or vertebral fracture or with osteoporosis based upon BMD measurement (T-score &le;-2.5). These recommendations are widely accepted, and clinical trial data support the use of bisphosphonates to prevent fracture in such individuals. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Bisphosphonates'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The guidelines also provide treatment recommendations for men with osteopenia on BMD (T-score between -1.0 and -2.5). In these individuals, the model suggests that treatment is cost-effective when the 10-year probability of hip fracture reaches 3 percent or the 10-year probability of osteoporotic fractures combined is &ge;20 percent (",
"    <a class=\"graphic graphic_table graphicRef52512 \" href=\"mobipreview.htm?6/49/6939\">",
"     table 1",
"    </a>",
"    ). These criteria were chosen on the basis of a US-specific economic analysis and they have not been assessed in clinical trials.",
"   </p>",
"   <p>",
"    Intervention thresholds have been estimated for other countries based upon assessment of absolute fracture risk and country-specific analyses. The 2010 Osteoporosis Canada guidelines recommend pharmacologic therapy to patients at high absolute risk (&gt;20 percent probability for major osteoporotic fracture over 10 years) and to individuals over age 50 who have a fragility fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/17\">",
"     17",
"    </a>",
"    ]. For those at moderate risk (10 to 20 percent), the decision to treat should be based upon the presence of additional risk factors not considered in the risk assessment system and upon individual preference.",
"   </p>",
"   <p>",
"    In the UK, pharmacologic treatment was cost effective at all ages when the 10-year probability of major osteoporotic fracture exceeded 7 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/18\">",
"     18",
"    </a>",
"    ]. The UK National Osteoporosis Guideline Group recommends an age-dependent intervention threshold, which ranges from 7.5 to 30 percent for ages 50 to 80 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/19\">",
"     19",
"    </a>",
"    ]. For clinicians in the UK, intervention thresholds may be accessed directly from the",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX",
"    </a>",
"    website.",
"   </p>",
"   <p>",
"    The 10-year probability of fracture can be calculated using the",
"    <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"     FRAX algorithm",
"    </a>",
"    (click on Calculation Tool and select country). It should be noted that the FRAX algorithm uses femoral neck BMD",
"    <span class=\"nowrap\">",
"     (g/cm2)",
"    </span>",
"    for calculation of fracture probability. BMD from non-hip sites has not been validated and is therefore not recommended for use in the algorithm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We largely agree with the NOF and Endocrine Society guidelines described above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/2,20\">",
"     2,20",
"    </a>",
"    ]. However, the NOF economic analysis estimated drug costs based upon use of generic bisphosphonates. The use of more expensive drugs increases the 10-year fracture probability at which intervention is cost effective. In addition, these guidelines should not be applied to individuals living in different countries as the guidelines are based upon a US-specific economic analysis. Intervention thresholds have been estimated for other countries and country-specific guidelines are available or are in development. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Fracture risk assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=see_link&amp;anchor=H5#H5\">",
"     \"Osteoporotic fracture risk assessment\", section on 'Clinical application of fracture risk assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some high-risk patients, such as men receiving high-dose glucocorticoids, GnRH agonists, or who have undergone organ transplantation, should often be treated even if they fail to meet the criteria listed above. Although these guidelines are useful, osteoporosis treatment should remain individualized through shared decision-making between patient and clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20048148\">",
"    <span class=\"h2\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men seem to respond to available therapies in the same way that women respond so that, for the most part (notable exceptions being male hypogonadism), the approach to treating men and women with osteoporosis is quite similar. In the absence of high quality head-to-head drug comparison trials to determine the relative efficacy of the individual drugs, choice of therapy should be based upon efficacy, safety, cost, convenience, and other patient-related factors. Bisphosphonates are considered the treatment of choice for most men with osteoporosis requiring pharmacologic therapy. We and others suggest weekly",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    as initial therapy for most men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/2,17,21\">",
"     2,17,21",
"    </a>",
"    ]. We prefer oral bisphosphonates as initial therapy because of their efficacy, favorable cost, and the availability of long-term safety data.",
"   </p>",
"   <p>",
"    For men who cannot tolerate oral bisphosphonates or who have difficulty with the dosing requirements, including an inability to sit upright for 30 to 60 minutes, we suggest an intravenous bisphosphonate formulation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    is the only intravenous bisphosphonate that has demonstrated efficacy for fracture prevention in men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], and is therefore our agent of choice.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    is an alternative option for men who cannot tolerate oral or intravenous bisphosphonates or who have difficulty with the dosing requirements and have impaired renal function. However, denosumab has not yet been shown to prevent fracture in men, except for men with prostate cancer receiving androgen deprivation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Teriparatide, an anabolic agent, is also available and is generally reserved for men with severe osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture), or men who have failed previous therapy (eg, continue to fracture after one year of bisphosphonate therapy).",
"   </p>",
"   <p>",
"    All of these medications reduce fracture in postmenopausal women with osteoporosis. There are few trials evaluating the effect of pharmacologic agents to reduce fracture risk in men. In systematic reviews of trials that included men,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    was shown to reduce the risk of vertebral and nonvertebral (including hip) fracture and teriparatide was shown to reduce the risk of total fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. Some of the individual trials are discussed below. (See",
"    <a class=\"local\" href=\"#H20048947\">",
"     'Efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20048947\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bisphosphonates, one of the first-line drugs for the treatment of osteoporosis in women, are effective in men as well. Both oral and intravenous preparations have been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h4\">",
"     Oral bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the oral bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    have been best studied and are approved in many countries, including the United States, for the treatment of men with osteoporosis. For patient convenience, we suggest weekly alendronate or risedronate in men who do not have hypogonadism or in hypogonadal men in whom testosterone therapy is contraindicated. The addition of a bisphosphonate to testosterone replacement therapy should be considered in hypogonadal men at high risk for fracture (eg, who experience a fragility fracture or have a BMD T-score &lt;-2.5 even after receiving adequate testosterone replacement therapy for two years). (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Candidates for therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    improves BMD and reduces the risk of fracture in men with osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. A meta-analysis of two trials assessing fracture prevention efficacy of alendronate versus comparators (placebo, calcium, vitamin D) in 375 men with primary osteoporosis or osteoporosis secondary to hypogonadism showed a reduction in vertebral fracture in alendronate-treated men (odds ratio [OR] 0.44, 95% CI 0.23-0.83) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/29\">",
"     29",
"    </a>",
"    ]. The reduction in non-vertebral fracture appeared to be of a similar magnitude but did not achieve statistical significance (OR 0.60, 95% CI 0.29-1.44). The meta-analysis was limited by a paucity of anti-fracture efficacy data in men and the small number of non-vertebral fractures.",
"   </p>",
"   <p>",
"    Cost-effectiveness analyses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    for the treatment of osteoporosis in men are favorable if treatment is reserved for men &gt;65 to 70 years with low BMD and prior fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], men &gt;70 years with low BMD and treatment with androgen deprivation therapy for prostate cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/32\">",
"     32",
"    </a>",
"    ], or men &ge;80 years without prior fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     Risedronate",
"    </a>",
"    is also effective in men with osteoporosis, as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a one year open label trial of 316 men with osteoporosis who were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      (5 mg daily) or a comparator group (alfacalcidiol or vitamin D), treatment with risedronate significantly improved BMD in the lumbar spine (4.7 versus 1.0 percent with control), total hip (2.7 versus 0.4 percent), and femoral neck (1.8 versus 0.2 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/33\">",
"       33",
"      </a>",
"      ]. The incidence of vertebral fractures, a secondary endpoint, was lower in the risedronate group (5.1 versus 12.7 percent with control).",
"     </li>",
"     <li>",
"      In a two year trial of standard dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      (35 mg weekly) versus placebo in 284 men with osteoporosis, treatment with risedronate significantly increased lumbar spine BMD (6.0 versus 1.4 percent with placebo) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/34\">",
"       34",
"      </a>",
"      ]. There were also significant but smaller increases (1 to 2 percent) in total hip and femoral neck BMD. New vertebral or nonvertebral fractures (secondary endpoints) occurred infrequently with no difference between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    are also beneficial in high risk groups, including elderly men with hemiplegic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/35\">",
"     35",
"    </a>",
"    ], and in men with secondary causes of osteoporosis, such as glucocorticoid excess, androgen deprivation therapy, and gastrointestinal disorders. Management of the different causes of secondary osteoporosis is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=see_link\">",
"     \"Metabolic bone disease in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     IV bisphosphonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other bisphosphonates are available but are used less often for the treatment of osteoporosis in men. Intravenous bisphosphonates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    , offer an alternative option for individuals who cannot tolerate oral bisphosphonates or who find the dosing regimen more convenient. In the absence of direct fracture efficacy data for IV ibandronate, we prefer zoledronic acid based upon the following trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the HORIZON Recurrent Fracture Trial, 2127 men and women with hip fracture were randomly assigned to receive yearly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (5 mg) or placebo within three months of surgical repair [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/22\">",
"       22",
"      </a>",
"      ]. Subjects also received vitamin D (50,000 to 125,000 international units 14 days prior to infusion, if 25OHD concentration was &lt;15",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or unknown, and 800 to 1200 international units daily thereafter) and calcium. After a median follow-up of 1.9 years, new fractures occurred in 8.6 and 13.9 percent of individuals in the ZA and placebo groups, respectively, representing a relative risk reduction of 35 percent (HR 0.65, 95% CI 0.5-0.8). All-cause mortality, a secondary safety endpoint, was lower in the ZA compared with placebo group (HR 0.72, 95% CI 0.56-0.93).",
"     </li>",
"     <li>",
"      In a separate trial, 1199 men with primary or hypogonadism-associated osteoporosis (mean T-score femoral neck -2.23, approximately 30 percent with prevalent vertebral fractures) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (5 mg intravenously) or placebo at baseline and 12 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/23\">",
"       23",
"      </a>",
"      ]. All patients received calcium and vitamin D supplementation. After two years, there were fewer morphometric vertebral fractures in the zoledronic acid group (1.6 versus 4.9 percent in the placebo group, RR 0.33, 95% CI 0.16-0.70).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    prevent bone loss due to androgen deprivation therapy in men with prostate cancer. It is not clear, however, whether they offer any advantage over the use of oral bisphosphonates in these subjects. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h4\">",
"     Adverse effects and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of bisphosphonates and the prescribing instructions designed to minimize gastrointestinal side effects are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with kidney disease and estimated glomerular filtration rate (eGFR) &gt;30 to 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    are managed similarly, as long as there are no accompanying biochemical abnormalities (eg, hyperparathyroidism, hyperphosphatemia) that indicate the co-existence of renal osteodystrophy. Bisphosphonates are generally not recommended for those with eGFR below 30 to 35",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/19/37178?source=see_link\">",
"     \"Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20461645\">",
"    <span class=\"h4\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no consensus on how long to continue bisphosphonate therapy. In postmenopausal women with osteoporosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"     alendronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    have demonstrated efficacy for 10, 7, and 6 years, respectively. Stopping therapy after three to five years (a \"drug holiday\") may be reasonable for some men, as there appears to be residual BMD and fracture benefit when bisphosphonates are stopped in postmenopausal women. For men taking alendronate for five years or who received zoledronic acid once yearly for three years, who have a stable BMD, no previous fragility fractures, and who are at low risk for fracture in the near future, we suggest discontinuing the drug. BMD should be monitored every two years after suspending therapy, and therapy should generally be resumed if BMD declines significantly or if the patient develops a new fragility fracture.",
"   </p>",
"   <p>",
"    This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=see_link&amp;anchor=H11271424#H11271424\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Duration of therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Parathyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most men with unexplained osteoporosis appear to have decreased bone formation and therefore an anabolic agent like parathyroid hormone (PTH) may be an ideal form of therapy. The mechanism of action and fracture reduction efficacy of PTH is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the largest trial to date, 437 men with osteoporosis were randomly assigned to receive recombinant human PTH 1-34 (20 or 40",
"    <span class=\"nowrap\">",
"     mcg/day)",
"    </span>",
"    or placebo. The study was stopped after a median duration of only 11 months (because of occurrence of osteosarcoma in rats, see below). However, spine and femoral neck bone density increased, as compared with placebo (5.9 and 9 percent in the low- and high-dose groups at the spine; 1.5 and 2.9 percent in the low- and high-dose groups at the femoral neck) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/36\">",
"     36",
"    </a>",
"    ]. Although early termination of the study prevented the assessment of fracture reduction efficacy in these men, PTH 1-34 treatment markedly reduces the risk of spine and nonvertebral fractures in postmenopausal women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"     \"Parathyroid hormone therapy for osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    PTH 1-34 (teriparatide) is available for use in women and men at \"high-risk\" for fracture, including those with a previous osteoporotic fracture, multiple risk factors for fracture, or failed previous treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/37\">",
"     37",
"    </a>",
"    ]. Treatment should be reserved for these high-risk patients because of the need for daily injection, high cost, and concern about the risk of osteosarcoma, which occurred in rats receiving teriparatide for at least 18 months, but has rarely been seen in humans. Contraindications to and adverse effects of parathyroid hormone therapy are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H40#H40\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Management issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H27#H27\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'Adverse events'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because teriparatide stimulates bone formation and bisphosphonates reduce bone resorption, it has been hypothesized that combining the two therapies would increase bone mineral density more than either therapy alone. However, several trials have reported that adding a bisphosphonate to PTH 1-34 or PTH 1-84 (either started concurrently or prior to PTH) offers no additional benefit, and may even impair the ability of PTH monotherapy to increase spine and hip BMD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H18#H18\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'PTH plus bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these trials, we do not recommend concurrent use of bisphosphonates with teriparatide for the management of osteoporosis. However, the immediate use of bisphosphonates after teriparatide is withdrawn appears to help optimize gains in BMD at the lumbar spine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link&amp;anchor=H22#H22\">",
"     \"Parathyroid hormone therapy for osteoporosis\", section on 'After PTH'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20461764\">",
"    <span class=\"h3\">",
"     Denosumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    prevents bone loss and reduces vertebral fracture risk in men with nonmetastatic prostate cancer receiving androgen deprivation therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=see_link&amp;anchor=H7#H7\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Osteoporosis and bone fractures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has also been shown to improve BMD in men with low bone mass unrelated to androgen deprivation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/39\">",
"     39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     Denosumab",
"    </a>",
"    may reduce fracture in such men, but until such data are available, we do not suggest denosumab for the initial treatment of men with osteoporosis who are not undergoing androgen deprivation therapy. However, denosumab may have a role in men who are intolerant of or unresponsive to other therapies and in those with impaired renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link&amp;anchor=H3#H3\">",
"     \"Denosumab for osteoporosis\", section on 'Effect on BMD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4968342\">",
"    <span class=\"h3\">",
"     Strontium ranelate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strontium ranelate is an orally active drug consisting of two atoms of stable strontium and an organic moiety (ranelic acid). In animal studies, strontium appears to inhibit bone resorption and, in one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/40\">",
"     40",
"    </a>",
"    ] but not other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/41-43\">",
"     41-43",
"    </a>",
"    ] studies, increases bone formation. Its mechanism of action in humans is less certain. Based upon changes in markers of bone formation and resorption in postmenopausal women with osteoporosis, it appears to have a modest anti-resorptive effect, with little effect on bone formation. It is available for use in Europe for the treatment of osteoporosis in postmenopausal women to reduce the risk of vertebral and hip fractures and in men at increased risk of fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/44\">",
"     44",
"    </a>",
"    ]. Strontium ranelate is not available in the United States. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H14246434#H14246434\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Strontium ranelate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Strontium has been shown to increase bone mineral density in men with osteoporosis. As an example, in a two year trial, 261 men with osteoporosis (mean BMD T-score lumbar spine -2.7, femoral neck -2.3) were randomly assigned to strontium ranelate (2 g daily) or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/45\">",
"     45",
"    </a>",
"    ]. There were greater increases in lumbar spine, femoral neck, and total hip BMD in the strontium group (between group difference 7.7, 2.8, and 3.1 percent, respectively). However, studies reporting effects of strontium ranelate on BMD should be interpreted cautiously. Because strontium is a cation (like calcium), but has a higher molecular weight than calcium, when it is substituted for calcium in bone mineral it will attenuate x-rays more effectively than calcium does, leading to a larger apparent increase in BMD. Correction factors can (and should) be applied to bone density data in patients treated with strontium to account for this artifact that affects DXA results. The magnitude of change in uncorrected BMD after strontium therapy is not indicative of greater fracture risk reduction. In this trial, radiographic vertebral fracture occurred in a similar proportion of men in each group (5.8 versus 7.8 percent of men receiving placebo).",
"   </p>",
"   <p>",
"    Because strontium ranelate is a weak antiresorptive agent, and there are more effective osteoporosis agents in the United States and most countries, we do not use strontium ranelate in men with osteoporosis. Some experts might consider strontium ranelate (where it is available) if other osteoporosis drugs (oral and intravenous bisphosphonates, teriparatide,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    ) cannot be used, are unavailable, or are not tolerated. Strontium should not be prescribed to patients with current or history of venous thromboembolism, or in patients who are temporarily or permanently immobilized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?30/58/31657/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, it should be discontinued if a skin reaction develops, and treatment should not be restarted. Adverse reactions and precautions are reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H14246434#H14246434\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Strontium ranelate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other agents, including growth hormone and insulin-like growth factor-I, are in evaluation for the treatment of men with osteoporosis. Growth hormone is effective in men with growth hormone deficiency who have osteoporosis. The effects of growth hormone on BMD are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=see_link&amp;anchor=H7#H7\">",
"     \"Growth hormone deficiency in adults\", section on 'Bone mineral density'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MONITORING THE RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring the response to therapy is important for identifying patients who may require a change in therapy. While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. Patients can be monitored with BMD measurements, as recommended for postmenopausal women, although there may be limitations to the use of spine DXA in aging men due to interference from osteophytes and vascular calcifications on the spine measurement. For patients starting on therapy, we typically obtain a follow-up DXA of hip and spine after two years, and if BMD is stable or improved, less frequent monitoring thereafter. The use of biochemical markers of bone turnover to monitor response to therapy is not well studied in men and is not routinely recommended. Monitoring is reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=see_link\">",
"       \"Patient information: Osteoporosis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       \"Patient information: Osteoporosis prevention and treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=see_link\">",
"       \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of osteoporosis in men includes lifestyle measures, calcium and vitamin D supplementation, and hormonal or pharmacologic therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Important lifestyle measures include exercise, smoking cessation, counseling on fall prevention, and avoidance of heavy alcohol use for all men with osteoporosis. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Lifestyle measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In men with osteoporosis (T-score below -2.5), we suggest calcium and vitamin D supplementation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Although the optimal intake (diet plus supplement) has not been clearly established in men with osteoporosis, approximately 1000 to 1200 mg of calcium (total diet plus supplement) and 600 to 800 international units of vitamin D daily are generally suggested. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The dose of calcium and vitamin D may vary in individuals with coexisting medical conditions. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=see_link&amp;anchor=H16#H16\">",
"       \"Calcium and vitamin D supplementation in osteoporosis\", section on 'Coexisting medical problems'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For men with osteoporosis and symptomatic hypogonadism (or a clear etiology for hypogonadism) and who do not have any contraindications to testosterone therapy, we recommend testosterone replacement therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Testosterone therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=see_link\">",
"       \"Clinical features and diagnosis of male hypogonadism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=see_link\">",
"       \"Testosterone treatment of male hypogonadism\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For hypogonadal men who are at high risk for fracture, we suggest the addition of pharmacologic therapy to testosterone therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). High risk groups might include hypogonadal men whose BMD T-score is &lt;-2.5 even after receiving adequate testosterone replacement therapy for two years; men on high-dose glucocorticoids; men with frequent falls; men who have a had a recent fragility fracture, particularly if they have a BMD T-score below -2.5 at any skeletal site; or men with T-scores below -3.5 or even below -3 if they have other risk factors for fracture. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Candidates for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of men with osteoporosis (T-score below -2.5 or fragility fracture) who do not have symptomatic hypogonadism or in hypogonadal men in whom testosterone therapy is contraindicated, we recommend pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Candidates for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For the treatment of high risk men with T-scores between -1.0 and -2.5, we also suggest pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). A reasonable cut point that may be cost-effective in some settings is a 10-year probability of hip fracture or combined major osteoporotic fracture of &ge;3.0 or &ge;20 percent, respectively. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Candidates for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For pharmacologic therapy in men, we suggest bisphosphonates as first-line therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We favor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/10/24743?source=see_link\">",
"       alendronate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/41/17047?source=see_link\">",
"       risedronate",
"      </a>",
"      over other available bisphosphonates because of clinical trial data demonstrating efficacy in men with osteoporosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Bisphosphonates'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Intravenous bisphosphonate formulations are available for patients who cannot tolerate oral bisphosphonates or who have difficulty with dosing requirements, including an inability to sit upright for 30 to 60 minutes.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/1/9241?source=see_link\">",
"       Zoledronic acid",
"      </a>",
"      is the only intravenous bisphosphonate that has demonstrated efficacy for fracture prevention in men, and is therefore our agent of choice. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'IV bisphosphonates'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"       Denosumab",
"      </a>",
"      may have a role in men who are intolerant of or unresponsive to other therapies and in those with impaired renal function. However, denosumab has not yet been shown to prevent fracture in men. (See",
"      <a class=\"local\" href=\"#H20461764\">",
"       'Denosumab'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=see_link\">",
"       \"Denosumab for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest PTH therapy for men with",
"      <strong>",
"       severe",
"      </strong>",
"      osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who are unable to tolerate any of the available bisphosphonates (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"       \"Parathyroid hormone therapy for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In men with",
"      <strong>",
"       severe",
"      </strong>",
"      osteoporosis (low bone mineral density [T score &lt;-2.5] and at least one fragility fracture) who continue to fracture after one year of bisphosphonate therapy, we suggest discontinuing the bisphosphonate and switching to human recombinant PTH therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=see_link\">",
"       \"Parathyroid hormone therapy for osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While there are a number of approaches to monitoring therapy, there is no consensus on the optimal approach. Patients can be monitored with BMD measurements, as recommended for postmenopausal women. For patients starting on therapy, we typically obtain a follow-up DXA of hip and spine after two years and, if BMD is stable or improved, less frequent monitoring thereafter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=see_link&amp;anchor=H31#H31\">",
"       \"Overview of the management of osteoporosis in postmenopausal women\", section on 'Monitoring the response to therapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/1\">",
"      Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/2\">",
"      Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97:1802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/3\">",
"      Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003; 32:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/4\">",
"      Haentjens P, Magaziner J, Col&oacute;n-Emeric CS, et al. Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/5\">",
"      Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/6\">",
"      Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/7\">",
"      Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: a gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163:2165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/8\">",
"      Feldstein AC, Nichols G, Orwoll E, et al. The near absence of osteoporosis treatment in older men with fractures. Osteoporos Int 2005; 16:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/9\">",
"      Ebeling PR, Wark JD, Yeung S, et al. Effects of calcitriol or calcium on bone mineral density, bone turnover, and fractures in men with primary osteoporosis: a two-year randomized, double blind, double placebo study. J Clin Endocrinol Metab 2001; 86:4098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/10\">",
"      Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. J Clin Endocrinol Metab 1996; 81:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/11\">",
"      Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82:2386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/12\">",
"      Greenspan SL, Oppenheim DS, Klibanski A. Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 1989; 110:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/13\">",
"      Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 1989; 69:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/14\">",
"      Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 1999; 84:1966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/15\">",
"      Amory JK, Watts NB, Easley KA, et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J Clin Endocrinol Metab 2004; 89:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/16\">",
"      van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/17\">",
"      Papaioannou A, Morin S, Cheung AM, et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010; 182:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/18\">",
"      Kanis JA, McCloskey EV, Johansson H, et al. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 2008; 19:1395.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.shef.ac.uk/NOGG/index.html (Accessed on March 10, 2011).",
"    </li>",
"    <li>",
"     file://nof.org/files/nof/public/content/file/344/upload/159.pdf (Accessed on December 10, 2012).",
"    </li>",
"    <li>",
"     file://www.shef.ac.uk/NOGG/NOGG_Pocket_Guide_for_Healthcare_Professionals.pdf (Accessed on June 21, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/22\">",
"      Lyles KW, Col&oacute;n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/23\">",
"      Boonen S, Reginster JY, Kaufman JM, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med 2012; 367:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/24\">",
"      MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008; 148:197.",
"     </a>",
"    </li>",
"    <li>",
"     Crandall CJ, Newberry SJ, Diamant A, et al. Treatment to prevent fractures in men and women with low bone density or osteoporosis: Update of a 2007 report, AHRQ March 2012. file://www.ncbi.nlm.nih.gov/books/NBK92566/pdf/TOC.pdf (Accessed on September 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/26\">",
"      Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/27\">",
"      Ringe JD, Faber H, Dorst A. Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study. J Clin Endocrinol Metab 2001; 86:5252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/28\">",
"      Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int 2004; 24:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/29\">",
"      Sawka AM, Papaioannou A, Adachi JD, et al. Does alendronate reduce the risk of fracture in men? A meta-analysis incorporating prior knowledge of anti-fracture efficacy in women. BMC Musculoskelet Disord 2005; 6:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/30\">",
"      Borgstr&ouml;m F, Johnell O, J&ouml;nsson B, et al. Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden. Bone 2004; 34:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/31\">",
"      Schousboe JT, Taylor BC, Fink HA, et al. Cost-effectiveness of bone densitometry followed by treatment of osteoporosis in older men. JAMA 2007; 298:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/32\">",
"      Ito K, Elkin EB, Girotra M, Morris MJ. Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 2010; 152:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/33\">",
"      Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int 2006; 26:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/34\">",
"      Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/35\">",
"      Sato Y, Iwamoto J, Kanoko T, Satoh K. Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke. Arch Intern Med 2005; 165:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/36\">",
"      Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 2003; 18:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/37\">",
"      \"The Pink Sheet\". 2002; 64:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/38\">",
"      Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004; 15:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/39\">",
"      Orwoll E, Teglbj&aelig;rg CS, Langdahl BL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab 2012; 97:3161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/40\">",
"      Delannoy P, Bazot D, Marie PJ. Long-term treatment with strontium ranelate increases vertebral bone mass without deleterious effect in mice. Metabolism 2002; 51:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/41\">",
"      Buehler J, Chappuis P, Saffar JL, et al. Strontium ranelate inhibits bone resorption while maintaining bone formation in alveolar bone in monkeys (Macaca fascicularis). Bone 2001; 29:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/42\">",
"      Marie PJ, Hott M, Modrowski D, et al. An uncoupling agent containing strontium prevents bone loss by depressing bone resorption and maintaining bone formation in estrogen-deficient rats. J Bone Miner Res 1993; 8:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/43\">",
"      Grynpas MD, Hamilton E, Cheung R, et al. Strontium increases vertebral bone volume in rats at a low dose that does not induce detectable mineralization defect. Bone 1996; 18:253.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion/human/000560/WC500127765.pdf (Accessed on February 11, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?30/58/31657/abstract/45\">",
"      Kaufman JM, Audran M, Bianchi G, et al. Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men. J Clin Endocrinol Metab 2013; 98:592.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.prescriber.org.uk/2012/03/new-contraindications-for-strontium-ranelate/ (Accessed on February 11, 2013).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2059 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-189.2.19.178-294E67EF58-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31657=[""].join("\n");
var outline_f30_58_31657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LIFESTYLE MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT OF SECONDARY CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Testosterone therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20461678\">",
"      Glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3195499\">",
"      Androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Candidates for therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Limitations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20048148\">",
"      Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20048947\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Oral bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IV bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Adverse effects and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20461645\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Parathyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20461764\">",
"      - Denosumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4968342\">",
"      - Strontium ranelate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MONITORING THE RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/2059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2059|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/60/5057\" title=\"figure 1\">",
"      Spinal BMD with testosterone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/22/41326\" title=\"figure 2\">",
"      Cortical trabecular BMD IHH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/27/41406\" title=\"figure 3\">",
"      Mean BMD testosterone placebo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/2059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/49/6939\" title=\"table 1\">",
"      Treatment guidelines osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/21/2395\" title=\"table 2\">",
"      Risk factors for osteoporosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/56/12170?source=related_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/23/36213?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22040?source=related_link\">",
"      Denosumab for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/45/32473?source=related_link\">",
"      Epidemiology and etiology of osteoporosis in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/50/1833?source=related_link\">",
"      Growth hormone deficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/54/30569?source=related_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/19/37178?source=related_link\">",
"      Osteoporosis in patients with chronic kidney disease: Diagnosis, evaluation, and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/42/29354?source=related_link\">",
"      Osteoporotic fracture risk assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/52/39754?source=related_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/26/15786?source=related_link\">",
"      Parathyroid hormone therapy for osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?22/60/23491?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/12/36034?source=related_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/58/35746?source=related_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/32/1545?source=related_link\">",
"      Testosterone treatment of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/21/3417?source=related_link\">",
"      Treatment of vitamin D deficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f30_58_31658="Iron overload liver Light";
var content_f30_58_31658=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F70985%7EGAST%2F50096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F70985%7EGAST%2F50096&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Liver biopsy in hereditary hemochromatosis (H and E staining)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 437px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a liver biopsy from a patient with hereditary hemochromatosis showing brown pigmentation of hepatocytes due to iron deposition (hematoxylin and eosin stain). The presence of iron can be confirmed by Perls' Prussian blue stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Liver biopsy in hereditary hemochromatosis (iron stain)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 237px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Perls' Prussian blue stain of a liver biopsy from a patient with hereditary hemochromatosis. Left panel: Low power view shows intense iron staining of hepatocytes. The blue-stained iron deposits typically start at the periphery of the liver lobule and extend centrally. Right panel: High power view shows intense iron staining (in blue) of hepatocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31658=[""].join("\n");
var outline_f30_58_31658=null;
var title_f30_58_31659="Types of bronchoscopy";
var content_f30_58_31659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Relative attributes of rigid, flexible and virtual bronchoscopy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Rigid",
"       </td>",
"       <td class=\"subtitle1\">",
"        Flexible",
"       </td>",
"       <td class=\"subtitle1\">",
"        Virtual",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Invasiveness",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination of upper lobe airways",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tissue sampling",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Level of anesthesia/sedation",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Airway stent placement",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        ++",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endobronchial tumor debulking",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Technology availability",
"       </td>",
"       <td>",
"        +",
"       </td>",
"       <td>",
"        +++",
"       </td>",
"       <td>",
"        +",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31659=[""].join("\n");
var outline_f30_58_31659=null;
var title_f30_58_31660="Paraneoplastic syndromes of the nervous system";
var content_f30_58_31660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F50304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F50304&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Paraneoplastic syndromes of the nervous system",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Paraneoplastic syndromes of the central nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Encephalomyelitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myelitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Limbic encephalitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Brainstem encephalitis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cerebellar degeneration*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opsoclonus myoclonus ataxia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Visual syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Cancer associated retinopathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Melanoma associated retinopathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Optic neuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Necrotizing myelopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Motor neuron syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Subacute motor neuronopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Other syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stiff-person syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subacute sensory neuronopathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Paraneoplastic syndromes of the peripheral nervous system",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Chronic sensorimotor neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Association with plasma cell dyscrasias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Acute sensorimotor neuropathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Guillain-Barr&eacute; syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Plexitis (eg, brachial neuritis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autonomic neuropathy*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasculitis of nerve and muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Paraneoplastic syndromes of the neuromuscular junction and muscle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Myasthenia gravis*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lambert-Eaton myasthenic syndrome*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dermatomyositis /polymyositis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neuromyotonia*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute necrotizing myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cachectic myopathy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Syndromes in which specific paraneoplastic markers have been identified in more than three patients. However, the absence of antibodies does not exclude a paraneoplastic etiology.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31660=[""].join("\n");
var outline_f30_58_31660=null;
var title_f30_58_31661="Baseline FHR by gestational age";
var content_f30_58_31661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Graph of baseline FHR according to gestational age, weeks",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 215px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Bpm: beats per minute; FHR: fetal heart rate.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Park, MI, Hwang, JG, Cha, KJ, et al. Int J Gynaecol Obstet 2001; 74:157.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31661=[""].join("\n");
var outline_f30_58_31661=null;
var title_f30_58_31662="Intussusception lymphoma BE";
var content_f30_58_31662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F64048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F64048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intussusception of ileal lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 238px; height: 344px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Barium enema shows a large soft tissue mass in the cecum (arrows) caused by intussusception of a lymphoma arising in the terminal ileum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31662=[""].join("\n");
var outline_f30_58_31662=null;
var title_f30_58_31663="Dosage and pharmacology of antipsychotics";
var content_f30_58_31663=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F60624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F60624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pharmacology of antipsychotics: Dosing (adult), formulations, kinetics and drug interactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"8%\">",
"     </colgroup>",
"     <colgroup width=\"36%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual oral dose range",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Initial oral dose",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Usual maximum oral dose",
"        <br/>",
"        (mg/day)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Formulations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Generic available in US",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time to peak",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Half-life",
"        <br/>",
"        (hours)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Metabolism and selected drug interactions",
"        <br/>",
"        (see NOTE*)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        First generation agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chlorpromazine",
"       </td>",
"       <td>",
"        400-600",
"       </td>",
"       <td>",
"        25-200",
"       </td>",
"       <td>",
"        2000",
"       </td>",
"       <td>",
"        Tab, IM",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        2-4 oral",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 2D6 transformation and active metabolites. Interacts with lithium, potent inhibitors of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) and potent CYP inducers (eg, carbamazepine). Low oral bioavailability relative to IM injection due to first-pass metabolism. Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluphenazine",
"       </td>",
"       <td>",
"        2-15",
"       </td>",
"       <td>",
"        2-10",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Tab, IM, LA-depot, oral solution",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        Rapid",
"       </td>",
"       <td>",
"        33",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 2D6 and other transformations. Interacts with potent inhibitors of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) and potent CYP inducers (eg, carbamazepine).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Haloperidol",
"       </td>",
"       <td>",
"        2-20",
"       </td>",
"       <td>",
"        2-10",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Tab, IM, LA-depot, oral solution",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        <p>",
"         2-6 oral",
"        </p>",
"        0.5 IM",
"       </td>",
"       <td>",
"        20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 3A4 and CYP 2D6 transformations. Interacts with potent inhibitors of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) and potent CYP inducers (eg, carbamazepine). Additive QTc prolongation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loxapine",
"       </td>",
"       <td>",
"        20-80",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        Capsule",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1.5-3",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Rapid hepatic metabolism includes direct glucuronidation (UGT1A4) and active metabolites. Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Perphenazine",
"       </td>",
"       <td>",
"        12-48",
"       </td>",
"       <td>",
"        8-16",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        Tab",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        9-12",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 2D6, CYP 3A4 transformations and active metabolites. Interacts with lithium and potent CYP inducers (eg, carbamazepine).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pimozide",
"       </td>",
"       <td>",
"        8-16",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        6-8",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 3A4 and other transformations. Due to concentration dependent risk of QTc prolongation and cardiac arrhythmias, concurrent use of inhibitors of CYP3A4 (eg, clarithromycin, itraconazole) is contraindicated. Use with other drugs known also to cause QTc prolongation is contraindicated. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thiothixene (tiotixene)",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Capsule",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 1A2 and other transformations. Interacts with potent inhibitors of CYP 1A2 (eg, fluvoxamine). Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Thioridazine",
"       </td>",
"       <td>",
"        200-600",
"       </td>",
"       <td>",
"        150",
"       </td>",
"       <td>",
"        800",
"       </td>",
"       <td>",
"        Tablet",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        21-25",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP2D6 transformations and active metabolites (mesoridazine, sulforidazine). Due to concentration dependent risk of QTc prolongation and cardiac arrhythmias, concurrent use of inhibitors of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) is contraindicated. Use with other drugs known also to cause QTc prolongation is contraindicated. Alpha-1 antagonism. Not a first-line agent.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trifluoperazine",
"       </td>",
"       <td>",
"        15-30",
"       </td>",
"       <td>",
"        4-10",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Tab",
"       </td>",
"       <td>",
"        Yes",
"       </td>",
"       <td>",
"        1.5-6",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 1A2 and other transformations. Interacts with potent inhibitors of CYP 1A2 (eg, fluvoxamine). Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"9\">",
"        Second generation agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aripiprazole",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        10-15",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        Tab, ODT, IM, oral solution",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        <p>",
"         3-5 oral",
"        </p>",
"        1-3 IM",
"       </td>",
"       <td>",
"        75-94",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP2 D6 and CYP 3A4 transformations and an active metabolite (dehydro-aripiprazole). 50 percent dose reduction recommended if concurrently taking potent inhibitor of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) or CYP 3A4 (eg, clarithromycin). Dose increase recommended if concurrently taking potent inducer of CYP (eg, carbamazepine). Half-life prolonged in CYP 2D6 slow metabolizers. Unpredictable effect in combination with other antipsychotics.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asenapine",
"       </td>",
"       <td>",
"        10-20",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        Sublingual tab",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        0.5-1.5",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        Hepatically metabolized by CYP 1A2 and glucuronidation (UGT1A4). Additive QTc prolongation. Alpha-1 antagonism. Limited experience.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clozapine",
"       </td>",
"       <td>",
"        150-600",
"       </td>",
"       <td>",
"        25-50",
"       </td>",
"       <td>",
"        600",
"       </td>",
"       <td>",
"        Tab, ODT",
"       </td>",
"       <td>",
"        <p>",
"         Yes tab",
"        </p>",
"        No ODT",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 1A2 transformation and active metabolite (nor-clozapine). Interacts with potent inhibitors of CYP 1A2 (eg, fluvoxamine), lithium, and potent CYP inducers (eg, carbamazepine). Avoid combination with other myelosuppressive agents. Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iloperidone",
"       </td>",
"       <td>",
"        12-24",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        Tab",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        2-4",
"       </td>",
"       <td>",
"        18-26",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 2D6 and CYP 3A4 transformations and active metabolites. Prolonged half-life up to 37 hours in CYP2D6 slow metabolizers. 50 percent dose reduction if concurrently taking potent inhibitor of CYP 2D6 (eg, fluoxetine, paroxetine, bupropion) or CYP 3A4 (eg, clarithromycin). Additive QTc prolongation. Alpha-1 antagonism. Limited experience.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lurasidone",
"       </td>",
"       <td>",
"        40-120",
"       </td>",
"       <td>",
"        <p>",
"         40",
"        </p>",
"        20 (renal or hepatic insufficiency)",
"       </td>",
"       <td>",
"        <p>",
"         160",
"        </p>",
"        <p>",
"         80 (moderate or severe renal insufficiency, moderate hepatic insufficiency)",
"        </p>",
"        40 (severe hepatic insufficiency)",
"       </td>",
"       <td>",
"        Tab",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        <p>",
"         18 (single dose)",
"        </p>",
"        29-37 (steady state following 7 days of daily use)",
"       </td>",
"       <td>",
"        To ensure adequate oral absorption, dose should be taken with a meal. Hepatic metabolism includes CYP 3A4 transformation and active metabolites. Coadministration with strong CYP 3A4 inhibitors (eg, oral ketoconazole) or inducers (eg, rifampin) is contraindicated. Maximum recommended dose with moderate CYP 3A4 inhibitors (eg, diltiazem) is 80 mg per day. A list of inhibitors and inducers of CYP 3A4 is provided as a separate table. Dose reduction required for patients with renal or hepatic insufficiency. Does not cause significant orthostatic hypotension or QTc prolongation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olanzapine",
"       </td>",
"       <td>",
"        10-30",
"       </td>",
"       <td>",
"        5-10",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        Tab, ODT, IM, ER-IM",
"       </td>",
"       <td>",
"        <p>",
"         Yes (tab)",
"        </p>",
"        No (IM, IM-ER)",
"       </td>",
"       <td>",
"        <p>",
"         5-8 oral",
"        </p>",
"        0.25-0.75 IM",
"       </td>",
"       <td>",
"        30-38",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 1A2 transformation and direct glucuronidation. Interacts with potent inhibitors of CYP 1A2 (eg, fluvoxamine) and CYP inducers (eg, cigarettes, carbamazepine). Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paliperidone",
"       </td>",
"       <td>",
"        6-12",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        ER tab, ER-IM",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        24 oral",
"       </td>",
"       <td>",
"        23 oral",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Minimal hepatic metabolism. Paliperidone is excreted primarily unchanged in urine necessitating dose reduction in renal insufficiency. Additive QTc prolongation. Alpha-1 antagonism. Limited experience.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Quetiapine",
"       </td>",
"       <td>",
"        300-750",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        1200",
"       </td>",
"       <td>",
"        Tab, ER tab",
"       </td>",
"       <td>",
"        <p>",
"         Yes (tab)",
"        </p>",
"        No (extended release tab)",
"       </td>",
"       <td>",
"        <p>",
"         1.5",
"        </p>",
"        6 ER tab",
"       </td>",
"       <td>",
"        6-12",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 3A4 transformation and active hydroxy- metabolite. Interacts with potent inhibitors of CYP 3A4 (eg, clarithromycin) and CYP inducers (eg, carbamazepine). Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Risperidone",
"       </td>",
"       <td>",
"        2-6",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        Tab, ODT, LA-depot, oral solution",
"       </td>",
"       <td>",
"        <p>",
"         Yes (tab, ODT)",
"        </p>",
"        No (LA-depot)",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"       <td>",
"        20",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Hepatic metabolism includes CYP 2D6 and CYP 3A4 transformations and active hydroxy-metabolite. Interacts with potent inhibitors of CYP 2D6 (eg, paroxetine, fluoxetine, bupropion) and potent CYP inducers (eg, carbamazepine). Prolonged half-life in CYP 2D6 slow metabolizers. Additive QTc prolongation. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ziprasidone",
"       </td>",
"       <td>",
"        120-160",
"       </td>",
"       <td>",
"        40-80",
"       </td>",
"       <td>",
"        240",
"       </td>",
"       <td>",
"        Capsule, IM",
"       </td>",
"       <td>",
"        <p>",
"         Yes (capsule)",
"        </p>",
"        No (IM)",
"       </td>",
"       <td>",
"        <p>",
"         6-8 oral",
"        </p>",
"        &le;1 IM",
"       </td>",
"       <td>",
"        <p>",
"         7 oral",
"        </p>",
"        2-5 IM",
"       </td>",
"       <td>",
"        To ensure adequate oral absorption, dose should be taken with a meal. Hepatic metabolism includes CYP 3A4 and other transformations. Use with other drugs known also to cause QTc prolongation is contraindicated. Alpha-1 antagonism.",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Doses shown are total daily dose, oral administration, for maintenance treatment of schizophrenia in healthy adults. Total daily doses are generally divided two or three times daily or, for certain drugs, may be administered as a single bedtime dose. Dose reduction needed for older adults and debilitated persons. Doses for IM and IV administration are not shown in this table. See Lexicomp drug information database for additional information.",
"    <br/>",
"    Data on drug metabolism and activity of metabolite(s) are included for assessment of potential for drug interactions, polymorphic metabolism, and risk of accumulation or prolonged clearance upon discontinuation. Refer to topic \"Acquired long QT syndrome\" for further information about risk associated with concurrent use of medications that prolong the QTc interval.",
"    <div class=\"footnotes\">",
"     ODT: orally dissolving tablet; IM: short acting intramuscular injection; LA-depot: long acting depot (eg, decanoate) injection; ER-IM: extended release intramuscular injection; ER tab: extended release tablet; CYP: cytochrome P-450.",
"     <br/>",
"     *",
"     <strong>",
"      NOTE:",
"     </strong>",
"     Not all drug interactions are listed. For additional interactions refer to Lexi-Interact drug interactions program included with UpToDate. Applies to all: avoid or minimize combination with other agents strongly associated with dystonic reactions or neuroleptic malignant syndrome (eg, metoclopramide). Smoking may decrease blood concentrations of antipsychotics primarily metabolized by CYP 1A2.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Can enhance effect of antihypertensive agents and negate effect of pressors due to significant alpha-1 antagonism.",
"     <br/>",
"     &Delta; Half-life of long-acting depot and extended release injection is considerably longer than shown for oral or short acting intramuscular injection.",
"    </div>",
"    <div class=\"reference\">",
"     Data courtesy of authors with additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"      </li>",
"      <li>",
"       Wynn GH, et al (eds) Clinical Manual of Drug Interaction Principles for Medical Practice APA publishing, Washington DC. Copyright &copy; 2009.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f30_58_31663=[""].join("\n");
var outline_f30_58_31663=null;
